

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

## Prevalence and distribution of hypertension and related risk factors in Jilin Province, China 2015

| Journal:                             | BMJ Open  |
|--------------------------------------|---|
| Manuscript ID                        | bmjopen-2017-020126   |
| Article Type:                        | Research  |
| Date Submitted by the Author:        | 17-Oct-2017   |
| Complete List of Authors:            | <ul> <li>Wu, Junduo; the Second Hospital of Jilin University, cardiology</li> <li>Li, Tianyi; the Second Hospital of Jilin University, cardiology</li> <li>Song, Xianjing; the Second Hospital of Jilin University, cardiology</li> <li>Sun, Wei; the Second Hospital of Jilin University, cardiology</li> <li>Zhang, Yangyu</li> <li>Liu, Yingyu</li> <li>Li, Longbo; the Second Hospital of Jilin University, cardiology</li> <li>Yu, Yunpeng; the Second Hospital of Jilin University, cardiology</li> <li>Liu, Yihang; the Second Hospital of Jilin University, cardiology</li> <li>Qi, Chao; the Second Hospital of Jilin University, cardiology</li> <li>Liu, Bin; The Second Hospital of Jilin University, Department of Cardiology</li> </ul> |
| <b>Primary Subject<br/>Heading</b> : | Epidemiology  |
| Secondary Subject Heading:           | Public health   |
| Keywords:                            | prevalence, Hypertension < CARDIOLOGY, EPIDEMIOLOGY, China, Jilin province  |
|                                      |   |

SCHOLARONE<sup>™</sup> Manuscripts



BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

| 1<br>ว   |    |   |
|----------|----|---|
| 2<br>3   |    |   |
| 4        | 1  | Prevalence and distribution of hypertension and related risk  |
| 5        |    |   |
| 6<br>7   | 2  | factors in Jilin Province, China 2015   |
| 8        | 3  |   |
| 9        | 5  |   |
| 10       | 4  | Junduo Wu <sup>1</sup> , Tianyi Li <sup>1</sup> , Xianjing Song <sup>1</sup> , Wei Sun <sup>1</sup> , Yangyu Zhang <sup>2</sup> , Yingyu Liu <sup>2</sup> , |
| 11<br>12 | 5  | Longbo Li <sup>1</sup> , Yunpeng Yu <sup>1</sup> , Yihang Liu <sup>1</sup> , Chao Qi <sup>1</sup> , Bin Liu <sup>1*</sup>                                   |
| 12       | 5  | Longoo Er, Tunpong Tu, Tinung Eru, Onuo Qi, Din Eru   |
| 14       | 6  |   |
| 15       |    |   |
| 16       | 7  |   |
| 17<br>18 |    |   |
| 19       | 8  | 1 Department of Cardiology, The Second Hospital of Jilin University, Changchun,   |
| 20       |    |   |
| 21       | 9  | Jilin, China  |
| 22<br>23 |    |   |
| 24       | 10 | 2 Department of Epidemiology and Biostatistics, School of Public Health, Jilin  |
| 25       |    |   |
| 26       | 11 | University, No.1163 Xinmin Street, Changchun, Jilin,130021, China   |
| 27<br>28 |    |   |
| 29       | 12 |   |
| 30       |    |   |
| 31       | 13 |   |
| 32       |    |   |
| 33<br>34 | 14 |   |
| 35       |    |   |
| 36       | 15 |   |
| 37       |    |   |
| 38<br>39 | 16 | *Corresponding author   |
| 40       |    |   |
| 41       | 17 | E-mail address: liubin3333@vip.sina.com   |
| 42       |    |   |
| 43<br>44 |    |   |
| 45       |    |   |
| 46       |    |   |
| 47<br>48 |    |   |
| 40<br>49 |    |   |
| 50       |    |   |
| 51       |    |   |
| 52<br>53 |    |   |
| 53<br>54 |    |   |
| 55       |    |   |
| 56       |    |   |
| 57       |    | 1   |
| 58<br>59 |    |   |

| 18 | Abstract  |
|----|---|
| 19 | Objective: To investigate the prevalence and distribution of hypertension and its         |
| 20 | associated factors in Jilin province in China.  |
| 21 | Design: a cross-sectional study in four cities and four rural counties in the province as |
| 22 | part of a national China study.   |
| 23 | Participants and setting: A total of 15206 participants aged 15 years old or older        |
| 24 | selected using a stratified multistage random sampling method.                            |
| 25 | Main outcome measures: prevalence of hypertension.  |
| 26 | Results: The prevalence of hypertension in Jilin province was found to be 24.7%.          |
| 27 | Moreover, the prevalence of hypertension increased with age in both sexes, and was        |
| 28 | higher in males than in females. Body mass index, smoking and alcohol drinking were       |
| 29 | associated with the prevalence of hypertension. All these risk factors above are similar  |
| 30 | compared with southern China, except smoking, which has no association with               |
| 31 | hypertension prevalence in the South.   |
| 32 | Conclusions: Age, sex, body mass index, smoking, and alcohol drinking are risk            |
| 33 | factors of hypertension. Control of these related risk factors, especially smoking, may   |
| 34 | be helpful in the treatment and management of hypertension in Jilin province.             |
| 35 |   |
| 36 | Strength and limitations of this study  |
| 37 | This is a cross-sectional population-based study performed in four cities and four        |
| 38 | rural counties in Jilin province.   |
| 39 | A large sample of participants allowed for the subgroups of related factors for           |
|    | 2   |

statistical analysis.

| 1<br>2         |    |
|----------------|----|
| 3<br>4         | 40 |
| 5<br>6<br>7    | 41 |
| 8<br>9         | 42 |
| 10<br>11<br>12 | 43 |
| 13<br>14       | 44 |
| 15<br>16       | 45 |
| 17<br>18<br>19 | 46 |
| 20<br>21       | 47 |
| 22<br>23<br>24 | 48 |
| 25<br>26       | 49 |
| 27<br>28<br>29 | 50 |
| 30<br>31       | 51 |
| 32<br>33<br>34 | 52 |
| 35<br>36       | 53 |
| 37<br>38<br>39 | 54 |
| 40<br>41       | 55 |
| 42<br>43<br>44 | 56 |
| 44<br>45<br>46 | 57 |
| 47<br>48       | 58 |
| 49<br>50<br>51 | 59 |
| 52<br>53       | 60 |
| 54<br>55<br>56 | 61 |
| 57<br>58       |    |
| 59<br>60       |    |

The causality cannot be assumed between the risk factors and hypertension. Data relevant to physical activity, salt intake and blood lipids were not collected. Key words Prevalence, hypertension, epidemiology, China, Jilin province Introduction As highlighted in the recent World Health Organization report, cardiovascular disease (CVD) is at the top of the list of the four prioritized non-communicable diseases worldwide that require immediate global action plans for prevention and control[1]. Hypertension is among the leading cause of cardiovascular disease and deaths worldwide [2, 3]. It is estimated that the global economic burden related to hypertension could be as high as US\$ 370 billion [4]. In the People's Republic of China, the prevalence of hypertension has been increasing dramatically from 5.1% in 1959, 7.7% in 1979, 13.6% in 1991 to 18.8% in 2002 [5, 6]. Further, there is a disproportionately higher hypertension rate reported among people living in the northern region of China[7, 8]. The province of Jilin is located in the northeast of China, with a population of approximately 27.5 million according to the National Bureau of Statistics. As for other northern provinces, Jilin has a longer winter season in comparison with the southern China, and, limited by this environment, the lifestyle of the people is different from the other parts of the country. 3

An in-depth analysis of the survey results from Jilin province related to risk factors for hypertension will provide an opportunity to understand the differential reasons for hypertension in the North, and will assist in the development of effective intervention and control strategies for this preventable disease. The objectives of this study were: to estimate the prevalence of hypertension in Jilin province and to explore potential risk factors associated with hypertension in the province. This will provide information for making recommendations on the prevention and control of hypertension in the northern region of China. 

#### 71 Methods

#### 72 Study population

This cross-sectional study was conducted between July 2014 and December 2015. A 4-stage, stratified sampling method was used to select a representative sample of the general population age 15 years and older in Jilin province, China. First, four cities from the urban areas and four counties from rural areas were selected using probability proportional to size (PPS). Then two districts or two townships were selected in each city or county using simple random sampling (SRS). Next, in each district and township, three communities or villages were chosen respectively using SRS. Finally, participants stratified by sex (50% men and 50% women) and age (aged 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 65-74, 275 years) were chosen using SRS according to the national population composition. Participants were chosen from the list provided by the local government registers of households [9]. 

#### BMJ Open

Considering a design effect of 2.5 and assuming a prevalence of hypertension of 17.7% among the population aged 15 years and older, an estimated sample size of 15,200 participants was needed to ensure that the bound on the error of estimation (i.e. width of the 95% confidence interval (CI)) for the prevalence in the entire population and subpopulation defined by age and sex were less than 0.4% and 1.8%, respectively [9]. As a result, a total of 15,206 participants living in Jilin province over 6 months and aged 15 years and older were randomly selected to participate in the survey.

92 Measurement

A questionnaire interview and physical examination were conducted in the survey. The standardized questionnaire was developed by the national coordinating center of the Fuwai Hospital (Beijing, China) and included questions on demographic, health behaviors and physical activities. The questionnaire was completed by the participants in a face-to-face interview with trained staff.

The physical examination included blood pressure (BP), body weight and height. BP was measured on the right arm supported at the heart level after participants rested for five minutes, using the Omron HBP-1300 Professional Portable Blood Pressure Monitor (OMRON, Japan). BP was measured three times, with 30 seconds between each measurement. The average of three readings was used for further analysis [10]. Body weight without heavy clothing, basal metabolism (BM), body fat percentage (BFP) and visceral fat index (VFI) were measured using an OMRON body fat and weight measurement device (Vbody HBF-371, OMRON, Japan). Height was 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

measured without shoes using a standard right-angle device and a fixed measurementtape (to the nearest 0.5 cm).

#### **Definitions**

Hypertension was defined as systolic BP (SBP) $\geq$ 140mmHg or diastolic BP (DBP) $\geq$ 90mmHg, or self-reported use of antihypertensive medication [11]. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Overweight was defined as BMI 25-30kg/m<sup>2</sup>, and obesity was defined as BMI $\geq$ 30kg/m<sup>2</sup>.

#### 116 Statistical analysis

Data was entered and validated using Epidata<sup>®</sup> 3.0 software[12]. All estimates and analyses were weighted to represent the population in Jilin Province aged 15 years or older. The weights were calculated based on the 2010 Jilin province population census data, and the sampling age, sex and geographic subgroups were taken into account. Continuous data were presented as mean  $\pm$  standard deviation (SD) or mean with 95% confidence intervals (CI), and differences between groups were compared using the t-est. Categorical data were presented as frequency, rate and 95% CI, and the prevalence between different groups was compared using the corrected Rao-Scott chi-square test. Logistic regression analysis was conducted assessing the relationship of age, sex, obesity, smoking, and alcohol drinking for hypertension adjusted for demographic factors, that have been included in similar studies, including 

#### **BMJ** Open

| Enseignement Superieur (ABES) .<br>Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. | BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de |
|---|--|
| l tra   | njope  |

sex, region, age, education level, employment status, marital status, BMI, and family history of hypertension. All analyses were conducted using SPSS<sup>®</sup> 18.0 software[13]. Results **Distribution of participants** A total of 14,956 participants from 15,206 eligible participants (6,946 males and 8,010 females; aged 15–97 years) completed the survey and were included in the statistical analysis. The non-responders (1.6%) were mainly young people with nonresponse likely related to their busy work schedule. The average age of the participants was 45.5 years, with the average age for males being 45.6±19.6 years and for females 45.5±18.9 years. There was no statistically significant difference in age between the sexes (p=0.92). The distribution of participants by age and sex are shown in Table 1 and Figure 1. **Characteristics of participants** The BMI of the participants was  $24.01\pm3.67$  kg/m<sup>2</sup>, BM was (1397.47 $\pm244.15$ ), BFP was 26.20±8.4 and VFI was 8.54±4.99. The SBP of the participants was 128.92±17.97) mmHg, and the DBP was 76.81±10.36 mmHg. These physical characteristics by age and sex are shown in Supplementary Table 1. All these characters were statistically significantly different between males and females (p<0.01). In particular, BM and VFI for males was higher than for females in all age groups (Figure 2A and 2B), while BFP for females was higher than males in all age 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

groups (Figure 2C). BMI reached its highest value for males in the 35-44 year age
group and for females in the 55-66 year age group (Figure 2D). The SBP was similar
between males and females in all age groups (Figure 2E), yet the DBP of males was
higher than for female in all age groups (Figure 2F).

#### 155 Lifestyle risk factors - obesity, smoking and alcohol drinking

The prevalence of overweight and obesity of participants was 29.8% and 6.2%, respectively. The prevalence of overweight for the male participants was 30.9%, higher than for the female participants at 28.7% (p=0.013). On the other hand, there was no statistical difference between the prevalence of obesity of male participants (6.3%) and female participants (6.2%) (p=0.78). The percentage of current smoking and ever smoking was 22.7% and 1.4%, respectively. When stratified by sex, the percentage of current smoking in males (36.9%) was higher than in females (8.2%) (p<0.001). Similarly, the percentage of ever smoking in males (2.3%) was higher than that in females (0.5%) (p<0.001). The percentage of alcohol drinking was 17.6%. The percentage in males (32.0%) was significantly higher than in females (2.9%) (p<0.001). The risk factors BMI, smoking and alcohol drinking, summarized by age and sex, are shown in Table 2.

#### **Prevalence of hypertension stratified by age and sex**

170 Of the 14,956 participants, 4,332 were diagnosed with hypertension, and the 171 prevalence of hypertension was 24.7% (95% CI: 23.9%, 25.5%). The prevalence of

hypertension was larger for the older age groups, and was higher in males (25.6%) than in females (23.8%) (p=0.03). For each age group less than 45 years, the prevalence of hypertension in males was higher than in females (p<0.001); while for the 65-74 year age group, the prevalence of hypertension in females was higher than in males (p=0.04); and in the other age groups, the prevalence of hypertension in males and females showed no statistical difference (p>0.05). The prevalence of hypertension stratified by age and sex is shown in Table 3.

#### 180 Prevalence of hypertension stratified by obesity, smoking and alcohol drinking

The prevalence of hypertension was statistically different across BMI categories (p<0.001); the highest prevalence being reported was 48.1% in the obese group, followed by the overweight group at 35.7%. When stratified by smoking, the prevalence of hypertension also showed statistical differences between the current smoking, ever smoking, and never smoking groups (p<0.001); with the highest prevalence of 53.1% in the ever smoking group, followed by 32.2% in the current smoking group and 22.0% in the never smoking group. The prevalence of hypertension in the alcohol drinking group was 34.6%, higher than 22.6% in the no-alcohol drinking group (p < 0.001). The prevalence of hypertension stratified by BMI, smoking and alcohol drinking are shown in Table 4.

192 Factors associated with hypertension

Several factors, including age, sex, obesity, smoking, and alcohol drinking, are

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Page 10 of 32

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### BMJ Open

| 194 | associated with the prevalence of hypertension, both in the crude model and adjusted   |
|-----|--|
| 195 | logistic model. In particular, in the absence of adjusting for other factors, the      |
| 196 | univariate logistic model indicated that the risk of hypertension was greater in males |
| 197 | with an OR=1.1 (95% CI: 1.01, 1.2) than in females, overweight partipants with an      |
| 198 | OR=2.52 (95% CI: 2.3, 2.77) than in normal participants, obese participants with an    |
| 199 | OR=4.21 (95% CI: 3.56, 4.96) than in normal participants, smokers with OR=1.64         |
| 200 | (95% CI: 1.48, 1.81) than in non-smokers, and alcohol drinkers with OR=1.81 (95%       |
| 201 | CI: 1.62, 2.02) than in non-alcohol drinkers. All the difference were statistically    |
| 202 | significant (p<0.05). A multivariable logistic regression model was used to adjust for |
| 203 | potential influencing factors. After adjustment for age, sex, region, education level, |
| 204 | employment status, BMI, family history of hypertension, and marital status that may    |
| 205 | affect hypertension, the risk of hypertension was greater in males with an adjusted    |
| 206 | OR=1.26 (95% CI:1.13, 1.39) than in females, in overweigh participants with an         |
| 207 | adjusted OR=2.3 (95% CI: 2.06, 2.58) than in normal participants, in obese             |
| 208 | participants with an adjusted OR=5.11 (95% CI: 4.16, 6.27) than in normal              |
| 209 | participants, in smokers with an adjusted OR=1.28 (95% CI: 1.13, 1.46) than in         |
| 210 | non-smokers, and in alcohol drinkers with an adjusted OR=1.49 (95% CI: 1.28, 1.73).    |
| 211 | These results are shown in Table 5.  |

213 Discussion

With the estimated prevalence of hypertension in Jilin province of 24.7%, a population of approximately 6.8 million in the province are hypertensive. At the

| 216 | national level, the prevalence of hypertension in Jilin is comparable to that in          |
|-----|---|
| 217 | Zhejiang province [12]; while the prevalence is lower than in other regions in China,     |
| 218 | including Jiangxi [13], Inner Mongolia [14], and Macau [15], as well as, lower than       |
| 219 | the overall prevalence in China [16]. Worldwide, this prevalence is lower than that in    |
| 220 | the US, the UK, but is higher than that in Canada [4]. However, there are some            |
| 221 | limitations in terms of the direct comparisons among these studies, given the varying     |
| 222 | methods and environments and variations of population genetics.                           |
| 223 | Although the prevalence of 24.7% is lower than 30.8% that was found in 2012               |
| 224 | [17], it is still not acceptable in terms of optimal hypertension health in the province. |
| 225 | Our study found that the prevalence of overweight and obesity was 29.8% and 6.2%,         |
| 226 | respectively, which is higher than that reported at the national level of 17.7% and       |
| 227 | 5.6%, respectively[18]. Several studies have shown that obesity is a risk factor for the  |
| 228 | development of hypertension[19-21]. Obesity can increase hypertension through             |
| 229 | multiple mechanisms, including insulin resistance, activation of sympathetic nervous      |
| 230 | system, sodium retention leading to increase in renal reabsorption, and activation of     |
| 231 | the renin-angiotensin system[22]. The growing number of people with obesity and           |
| 232 | being overweight in the province of Jilin presents a strong indicator of the potential    |
| 233 | risk of future increasing incidence of hypertension. Unfortunately, this modifiable risk  |
| 234 | factor has exhibited no change in between the report in 2012 and now[17], not to          |
| 235 | mention that the population of overweight and obesity may have been underestimated,       |
| 236 | since the standard definition of overweight and obesity used in our research may be       |
| 237 | set too high for asian people[23, 24]. Moreover, some people may be abdominal obese       |
|     |   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1<br>2<br>3<br>4     |  |
|----------------------|--|
| 5<br>6<br>7<br>8     |  |
| 8<br>9<br>10<br>11   |  |
| 12<br>13<br>14       |  |
| 15<br>16<br>17<br>18 |  |
| 19<br>20<br>21       |  |
| 22<br>23<br>24<br>25 |  |
| 26<br>27<br>28       |  |
| 29<br>30<br>31<br>32 |  |
| 33<br>34<br>35       |  |
| 36<br>37<br>38<br>39 |  |
| 40<br>41<br>42       |  |
| 43<br>44<br>45<br>46 |  |
| 47<br>48<br>49       |  |
| 50<br>51<br>52<br>53 |  |
| 54<br>55<br>56       |  |
| 57<br>58<br>59       |  |

60

with a normal BMI value (18.5-24.9kg/m<sup>2</sup>). Studies have reported that despite the normal BMI value, abdominal obesity is also a risk factor for hypertension worldwide[25, 26]. This modifiable risk factor deserves attention and requires an effective proactive intervention program to slow and ultimately reduce the number of individuals with obesity becoming hypertensive.

Our study found that the overall prevalence of hypertension increases with age in 243 244 both males and females, especially in the range of 35-74 years of age. This result supports the hypothesis that age is one of the risk factors of hypertension [27-30]. An 245 246 increasing lifespan among the population in Jilin requires that a practical and effective hypertension management strategy of intervention and control targeting the aging 247 population be devloped. The overall prevalence of hypertension is higher in males 248 249 than in females. However, the prevalence in females increased more rapidly than in 250 males aged 65-74 years. This may be partially explained by hormonal changes in post-menopausal women and the difference in lifespan between males and females [4, 251 31]. However, the exact mechanisms need to be explored. 252

253 Consistent with previous studies [32, 33], our study also showed that smoking, 254 both current and ever smoking, is associated with an increased risk of hypertension. 255 Smoking can increase blood viscosity, stimulate the adrenergic nervous system, and 256 contribute to the development of both micro- and macro-vascular diseases[34]. 257 Although some studies reported weak associations between smoking and hypertension 258 [13, 20], smoking is considered a major risk factor worldwide [13, 20, 35-37], 259 Additionally, drinking of alcohol is also a factor associated with increasing the risk of

Page 13 of 32

#### **BMJ** Open

| 260 | hypertension in our study, which is consistent with previous studies [4, 38-40]. These  |
|-----|---|
| 261 | results indicate that changes in living habits, including quitting smoking and alcohol  |
| 262 | drinking, should help to reduce the prevalence of hypertension.                         |
| 263 | National studies reported that the prevalence of hypertension is higher in northern     |
| 264 | China than that in southern China[7, 16]. When comparing the associations between       |
| 265 | risk factors and hypertension with Zhejiang province located in the South[12], we       |
| 266 | found that the risk of hypertension with demographic factors, such as age, sex, and     |
| 267 | region, and clinical factors, such as family history of hypertension and abdominal      |
| 268 | waist circumference, were similar in Jilin province and in southern China. When it      |
| 269 | comes to the lifestyle factors, the risk of hypertension with obesity and alcohol       |
| 270 | drinking were similar, however, there was a marked difference in the modifiable risk    |
| 271 | factor smoking; in particular, in Jilin province there was a strong association with an |
| 272 | adjusted OR=1.28 (95% CI: 1.13, 1.46), whereas no association between smoking and       |
| 273 | hypertension in southern China was found, with an adjusted OR=1.0 (95% CI: 0.9,         |
| 274 | 1.1). These findings indicate that programs aimed at reducing smoking would be an       |
| 275 | important step to mitigate the prevalence of hypertension in Jilin province. Some       |
| 276 | social factors including retirement status, marital status, and educationan level were  |
| 277 | also different between the North and the South. Of interest, there was a difference on  |
| 278 | BFP categories. In particular, for category 10-19 for males and 20-29 for females,      |
| 279 | there was no association between BFP and hypertension in Jilin province with an         |
| 280 | adjusted OR=0.95 (95%CI: 0.71, 1.27), whereas in this category BFP is protective        |
| 281 | againt hypertension in south China with an adjusted OR=0.6 (95% CI: 0.5, 0.8). In the   |
|     |   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 282 | range of over 25 for males and over 35 for females, BFP is strongly associated with      |
|-----|--|
| 283 | hypertension in Jilin province with an adjusted OR=1.45 (95% CI: 1.07, 1.96),            |
| 284 | whereas no association was found in the South with an adjusted OR=1.3 (95%CI: 1.0,       |
| 285 | 1.5). These results indicate that BFP tends to be more of a risk for hypertension in the |
| 286 | North compared to the South. Studies have reported that high BFP increase blood          |
| 287 | pressure[41, 42]. There are also studies reporting that the relationship between BFP     |
| 288 | and BMI may be different in different ethnic groups[43], and the latter is already       |
| 289 | known to be a risk factor for hypertension. These studies provide inside of the          |
| 290 | different role BFP has on hypertension in the northern and southern China. Further       |
| 291 | studies on the relationship between BFP and hypertension need to be done.                |
| 292 | A survey in 2012 found a prevalence of hypertension of 30.8% [17]. The                   |
| 293 | prevalence of hypertension in our study was lower. This reduction may be related to      |
| 294 | the following two factors. First, the government of Jilin province is aware of the       |
| 295 | damage and burdern of hypertension and is dedicated to increase the funding of           |
| 296 | medical insurance, especially for rural residents, from RMB ¥3.9 billion in 2012 to      |
| 297 | RMB ¥6.4 billion, according to the statistical bureau of Jilin province. Second, new     |
| 298 | hypertension guidelines on grass-roots management of hypertension[44] and patient        |
| 299 | education[45] have been published in China since 2012. However, some key                 |
| 300 | modifiable risk factors have exhibited slight negative changes, in particular, the trend |
| 301 | towards obesity, drinking and smoking. This can be due in part to the evolving           |
| 302 | economy of Jilin province with the gross domestic product increasing from RMB            |
| 303 | ¥361.5 billion in 2015, to RMB ¥857.8 billion in 2010, to RMB ¥1.4 trillion in 2015,     |
|     | **   |

according to the statistical bureau of Jilin province. To reverse these trends will require an effective and workable intervention program to control hypertension by incorporating best practices identified in theory and practice. For example, rates of hypertension awareness have greatly improved from 24.4% to 42.6%, treatment from 20.0% to 24.2% based on national surveys [16]. However, the control rate is only 9.3% in comparison with 53% in the USA[4]. One of the challenges is to improve adherence to anti-hypertension drugs. There are some limitations in this study. First, this is a cross-sectional study design, thus the causality cannot be assumed between the risk factors and hypertension. Second, due to limited financial resource, data relevant to physical activity, salt intake and blood lipids were not collected. Third, the decrease of prevalence of hypertension in our study compared with that in 2012 may be related with sampling factor. In summary, the prevalence of hypertension in Jilin province decreased compared with that in 2012, and is lower than the overall prevalence in China. In addition, the study showed that hypertension is associated with age, sex, obesity, smoking and alcohol drinking. In particular, smoking seemed to be responsible for the different prevalence of hypertension in northern and southern China. These factors above, especially smoking, might be important points to control and manage hypertension in Jilin province. 

**Reference** 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Page 16 of 32

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

| 1        |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4<br>5   |  |
| 5<br>6   |  |
| 6<br>7   |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24<br>25 |  |
| 25<br>26 |  |
| 26<br>27 |  |
| 27       |  |
| 20<br>29 |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48<br>40 |  |
| 49<br>50 |  |
| 50<br>51 |  |
| 51<br>52 |  |
| 52<br>53 |  |
| 55<br>54 |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |
| 60       |  |

60

1

327 1. Organization WH: Global action plan for the prevention and control of noncommunicable 328 diseases 2013-2020. 2013. 329 2. Cifkova R, Fodor G, Wohlfahrt P: Changes in Hypertension Prevalence, Awareness, 330 Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update. Current 331 hypertension reports 2016, 18(8):62. 332 3. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U: Hypertension prevalence, 333 awareness, treatment and control in Germany 1998 and 2008-11. Journal of human 334 hypertension 2015, 29(4):247-253. 335 4. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, McAlister FA, Johansen 336 H, Baclic O, Campbell N: Hypertension prevalence, awareness, treatment and control in 337 national surveys from England, the USA and Canada, and correlation with stroke and 338 ischaemic heart disease mortality: a cross-sectional study. BMJ open 2013, 3(8):e003423. 339 5. Wu X, Duan X, Gu D, Hao J, Tao S, Fan D: Prevalence of hypertension and its trends in 340 Chinese populations. International journal of cardiology 1995, 52(1):39-44. 341 6. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li X, Chalmers J, Gao R et al: 342 Prevalence, awareness, treatment, and control of hypertension in China: data from the 343 China National Nutrition and Health Survey 2002. Circulation 2008, 118(25):2679-2686. 344 7. Reynolds K, Gu D, Muntner P, Wu X, Chen J, Huang G, Duan X, Whelton PK, He J, Inter ACG: 345 Geographic variations in the prevalence, awareness, treatment and control of hypertension 346 in China. J Hypertens 2003, 21(7):1273-1281. 347 8. Wang X, Bots ML, Yang F, Hoes AW, Vaartjes I: Prevalence of hypertension in China: a 348 systematic review and meta-regression analysis of trends and regional differences. J 349 Hypertens 2014, 32(10):1919-1927; discussion 1927. 350 9. Wang Z, Zhang L, Chen Z, Wang X, Shao L, Guo M, Zhu M, Gao R, China Hypertension Survey 351 G: Survey on prevalence of hypertension in China: background, aim, method and design. 352 International journal of cardiology 2014, **174**(3):721-723. 353 10. Fodor JG, Leenen FH, Helis E, Turton P: 2006 Ontario Survey on the Prevalence and Control 354 of Hypertension (ON-BP): Rationale and design of a community-based cross-sectional 355 survey. Canadian Journal of Cardiology 2008, 24(6):503-505. 356 11. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the joint national 357 committee on the prevention, detection, evaluation, and treatment of high blood pressure 358 (JNC 7). Hypertension 2003, 41(6):1178-1179. 359 12. Yang L, Yan J, Tang X, Xu X, Yu W, Wu H: Prevalence, Awareness, Treatment, Control and Risk 360 Factors Associated with Hypertension among Adults in Southern China, 2013. PloS one 2016, 361 **11**(1):e0146181. 362 13. Hu L, Huang X, You C, Li J, Hong K, Li P, Wu Y, Wu Q, Bao H, Cheng X: Prevalence and Risk 363 Factors of Prehypertension and Hypertension in Southern China. PloS one 2017, 364 12(1):e0170238. 365 14. Li G, Wang H, Wang K, Wang W, Dong F, Qian Y, Gong H, Xu G, Li Y, Pan L: Prevalence, 366 awareness, treatment, control and risk factors related to hypertension among urban adults 367 in Inner Mongolia 2014: differences between Mongolian and Han populations. BMC public 368 health 2016, 16(1):294. 369 15. Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Li Y, Feng X, Van F, Lau W, Brock KE: Prevalence, 370 awareness, treatment and control of hypertension in Macau: results from a cross-sectional

#### BMJ Open

| 1        |            |     |  |
|----------|------------|-----|--|
| 2        | 0.74       |     |  |
| 3        | 371        |     | epidemiological study in Macau, China. Am J Hypertens 2015, 28(2):159-165.                               |
| 4<br>5   | 372        | 16. | Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease                  |
| 6        | 373        |     | Working G: Prevalence, awareness, treatment, and control of hypertension in China: results               |
| 7        | 374        |     | from a national survey. Am J Hypertens 2014, 27(11):1355-1361.   |
| 8        | 375        | 17. | Yang G, Ma Y, Wang S, Su Y, Rao W, Fu Y, Yu Y, Kou C: Prevalence and Correlates of                       |
| 9        | 376        |     | Prehypertension and Hypertension among Adults in Northeastern China: A Cross-Sectional                   |
| 10       | 377        |     | <b>Study</b> . International journal of environmental research and public health 2015, <b>13</b> (1):82. |
| 11       | 378        | 18. | Li L, Rao K, Kong L, Yao C, Xiang H, Zhai F, Ma G, Yang X: A description on the Chinese                  |
| 12<br>13 | 379        |     | national nutrition and health survey in 2002. Zhonghua liu xing bing xue za zhi= Zhonghua                |
| 14       | 380        |     | liuxingbingxue zazhi 2005, <b>26</b> (7):478-484.  |
| 15       | 381        | 19. | Crump C, Sundquist J, Winkleby MA, Sundquist K: Interactive Effects of Physical Fitness and              |
| 16       | 382        | 19. | Body Mass Index on the Risk of Hypertension. JAMA internal medicine 2016,                                |
| 17       |            |     |  |
| 18       | 383        |     | <b>176</b> (2):210-216.  |
| 19       | 384        | 20. | Papathanasiou G, Zerva E, Zacharis I, Papandreou M, Papageorgiou E, Tzima C,                             |
| 20       | 385        |     | Georgakopoulos D, Evangelou A: Association of high blood pressure with body mass index,                  |
| 21<br>22 | 386        |     | smoking and physical activity in healthy young adults. The open cardiovascular medicine                  |
| 23       | 387        |     | journal 2015, <b>9</b> :5.   |
| 24       | 388        | 21. | Tyson CC, Appel LJ, Vollmer WM, Jerome GJ, Brantley PJ, Hollis JF, Stevens VJ, Ard JD, Patel UD,         |
| 25       | 389        |     | Svetkey LP: Impact of 5 - year weight change on blood pressure: results from the Weight                  |
| 26       | 390        |     | Loss Maintenance trial. The Journal of Clinical Hypertension 2013, 15(7):458-464.                        |
| 27       | 391        | 22. | Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new                         |
| 28       | 392        |     | insights into mechanisms. Hypertension 2005, 45(1):9-14.   |
| 29<br>30 | 393        | 23. | Organization WH: The Asia-Pacific perspective: redefining obesity and its treatment. In.:                |
| 31       | 394        | -   | Sydney: Health Communications Australia; 2000.   |
| 32       | 395        | 24. | Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, Shimono K, Yamane Y: The new BMI                    |
| 33       | 396        | 27. | criteria for asians by the regional office for the western pacific region of WHO are suitable            |
| 34       | 390<br>397 |     |  |
| 35       |            |     | for screening of overweight to prevent metabolic syndrome in elder Japanese workers.                     |
| 36<br>37 | 398        |     | Journal of occupational health 2003, <b>45</b> (6):335-343.  |
| 38       | 399        | 25. | Okosun IS, Prewitt TE, Cooper RS: Abdominal obesity in the United States: prevalence and                 |
| 39       | 400        |     | attributable risk of hypertension. Journal of human hypertension 1999, <b>13</b> (7):425-430.            |
| 40       | 401        | 26. | Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M: Abdominal                  |
| 41       | 402        |     | obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. The                   |
| 42       | 403        |     | American journal of medicine 2007, <b>120</b> (2):S3-S8.   |
| 43       | 404        | 27. | Yang L, Xu X, Yan J, Yu W, Tang X, Wu H, Parkin CL: Analysis on associated factors of                    |
| 44<br>45 | 405        |     | uncontrolled hypertension among elderly hypertensive patients in Southern China: a                       |
| 46       | 406        |     | community-based, cross-sectional survey. BMC public health 2014, 14(1):903.                              |
| 47       | 407        | 28. | Yip W, Wong TY, Jonas JB, Zheng Y, Lamoureux EL, Nangia V, Sabanayagam C: Prevalence,                    |
| 48       | 408        |     | awareness, and control of hypertension among Asian Indians living in urban Singapore and                 |
| 49       | 409        |     | rural India. Journal of hypertension 2013, <b>31</b> (8):1539-1546.                                      |
| 50       | 410        | 29. | Doulougou B, Gomez F, Alvarado B, Guerra RO, Ylli A, Guralnik J, Zunzunegui MV: Factors                  |
| 51<br>52 | 410        |     | associated with hypertension prevalence, awareness, treatment and control among                          |
| 52<br>53 | 411        |     | participants in the International Mobility in Aging Study (IMIAS). Journal of human                      |
| 55<br>54 |            |     |  |
| 55       | 413        | 20  | hypertension 2016, <b>30</b> (2):112-119.  |
| 56       | 414        | 30. | Cheng S, Xanthakis V, Sullivan LM, Vasan RS: Blood pressure tracking over the adult life                 |
| 57       |            |     | 17   |
| 58       |            |     |  |
| 59       |            |     |  |

Page 18 of 32

**BMJ** Open

| 59<br>60 |     |     | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                          |
|----------|-----|-----|--|
| 58       |     |     | 18   |
| 56<br>57 |     |     |  |
| 55<br>56 | 458 | 44. | Wang W: Guidelines for the management of hypertension in China Chinese Journal of                  |
| 54       | 457 |     | <b>363</b> (9403):157.   |
| 53       | 456 |     | populations and its implications for policy and intervention strategies. The lancet 2004,          |
| 51<br>52 | 455 | 43. | Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I: Appropriate body-mass index for Asian         |
| 50<br>51 | 454 |     | 1985, <b>7</b> (4):578-585.  |
| 49       | 453 |     | The relative contribution of body fat and fat pattern to blood pressure level. Hypertension        |
| 48       | 452 | 42. | Weinsier RL, Norris DJ, Birch R, Bernstein RS, Wang J, Yang M-U, Pierson RN, Van Itallie TB:       |
| 47       | 451 |     | Metabolism and Cardiovascular Diseases 2012, <b>22</b> (9):741-747.                                |
| 45       | 450 |     | cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutrition,                    |
| 44<br>45 | 449 | 41. | Shea JL, King MTC, Yi Y, Gulliver W, Sun G: Body fat percentage is associated with                 |
| 43<br>44 | 448 |     | biochemistry and molecular biology 2014, <b>144</b> :152-155.                                      |
| 42       | 447 |     | hypertension in a large representative population from Macau. The Journal of steroid               |
| 41       | 446 |     | factors including sunlight exposure and fish consumption are associated with risk of               |
| 40       | 445 | 40. | Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Feng X, Van F, Leong S, Lau W, Lueng P: Modifiable risk    |
| 39       | 444 |     | 2010, <b>67</b> (12):1301-1308.  |
| 38       | 443 |     | between alcoholism risk and obesity in the United States. Archives of general psychiatry           |
| 36<br>37 |     | 39. | Grucza RA, Krueger RF, Racette SB, Norberg KE, Hipp PR, Bierut LJ: <b>The emerging link</b>        |
| 35<br>36 | 441 | 20  |  |
| 34       | 440 |     | population-based study. Hypertension 2004, 44(6):813-819.  |
| 33       | 440 |     | Trevisan M: Relationship of alcohol drinking pattern to risk of hypertension: a                    |
| 32       | 439 | 38. | Stranges S, Wu T, Dorn JM, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH,            |
| 31       | 438 |     | <b>50</b> (21):2085-2092.  |
| 30       | 437 |     | risk of incident hypertension in women. Journal of the American College of Cardiology 2007,        |
| 28<br>29 | 436 | 37. | Bowman TS, Gaziano JM, Buring JE, Sesso HD: A prospective study of cigarette smoking and           |
| 27<br>28 | 435 |     | hypertension 2009, <b>27</b> (5):963-975.  |
| 26<br>27 | 434 |     | and control of hypertension between developing and developed countries. Journal of                 |
| 25       | 433 | 36. | Pereira M, Lunet N, Azevedo A, Barros H: Differences in prevalence, awareness, treatment           |
| 24       | 432 |     | <b>29</b> (7):1303-1310.   |
| 23       | 431 |     | adults from 33 communities of China: the CHPSNE study. J Hypertens 2011,                           |
| 22       | 430 |     | awareness, treatment, control, and risk factors associated with hypertension in urban              |
| 20<br>21 | 429 | 35. | Meng XJ, Dong GH, Wang D, Liu MM, Lin Q, Tian S, Xu LX, Hou H, Ren YF, Lee YL: <b>Prevalence</b> , |
| 19<br>20 |     | 25  |  |
| 18       | 427 |     | <b>107</b> (6):1019-1026.  |
| 17       | 420 | υт. | measurements: a new insight on the endothelium. Thromb Haemost 2012,                               |
| 16       | 426 | 34. | Heitmar R, Summers RJ: Assessing vascular function using dynamic retinal diameter                  |
| 15       | 425 |     | in a large cohort of Iranian adult population. Journal of hypertension 2013, <b>31</b> (7):1364.   |
| 13       | 424 |     | Poustchi H, Navabakhsh B, Naemi M: Prevalence, awareness and risk factors of hypertension          |
| 12       | 423 | 33. | Malekzadeh MM, Etemadi A, Kamangar F, Khademi H, Golozar A, Islami F, Pourshams A,                 |
| 11<br>12 | 422 |     | community medicine 2014, <b>21</b> (1):29.   |
| 10<br>11 | 421 |     | hypertension and associated cardiovascular risk factors in Central India. Journal of family $\&$   |
| 9        | 420 | 32. | Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V: Prevalence of               |
| 8        | 419 |     | <b>172</b> (2):223-230.  |
| 7        | 418 |     | Northeast China: a cross-sectional study. European journal of pediatrics 2013,                     |
| 5<br>6   | 417 |     | and associated risk factors of prehypertension among rural children and adolescents in             |
| 4<br>5   | 416 | 31. | Guo X, Zheng L, Li Y, Yu S, Zhou X, Wang R, Zhang X, Sun Z, Sun Y: Gender-specific prevalence      |
| 3        | 415 |     | course. Hypertension 2012:HYPERTENSIONAHA. 112.201780.   |
| 2        |     |     |  |

60

#### **BMJ** Open

| 1        |     |  |
|----------|-----|--|
| 2<br>3   | 459 | Hypertension 2015, <b>23</b> (1):24-43.  |
| 4        | 460 | 45. Wu Z, Yong H, Wang W, Zhao L, Zhu D: Guidelines for Hypertension Education in China. |
| 5        | 461 | <i>Chinese Journal of Hypertension</i> 2014(3):78-110.                                   |
| 6        |     |  |
| 7        | 462 |  |
| 8<br>9   | 463 |  |
| 10       | 464 | Footnotes  |
| 11       | 464 | Footnotes  |
| 12<br>13 | 465 | Contributors   |
| 14       | 466 | BL is involved in the design, JW, XS, LL, YY, YL, and CQ collected the data, YZ          |
| 15       | 400 |  |
| 16<br>17 | 467 | and YL performed the statistical analysis, TL, WS, and BL wrote the paper. All           |
| 18       | 468 | authors reviewed and approved the final version of the paper.                            |
| 19       |     |  |
| 20       | 469 |  |
| 21<br>22 | 470 | Ethics approval  |
| 22       |     |  |
| 24       | 471 | This study was approved by the Fuwai Hospital Ethics Review Board.                       |
| 25       | 472 |  |
| 26<br>27 | 470 | End the s  |
| 28       | 473 | Funding  |
| 29       | 474 | This work was supported by the National Key R&D Program in the Twelfth                   |
| 30<br>31 | 475 | Five-year Plan (No. 2011BAI11B01) from the Chinese Ministry of Science and               |
| 32       | 476 | Technology and the National Clinical Key Specialty Project.                              |
| 33<br>34 | 470 | reemology and the National Chinear Rey Specialty Hojeet.                                 |
| 35       | 477 |  |
| 36       | 478 | Competing interests  |
| 37       |     |  |
| 38<br>39 | 479 | None declared.   |
| 40       | 480 | Data sharing statement   |
| 41       | 404 | Data shaving statement   |
| 42<br>43 | 481 | Data sharing statement   |
| 44       | 482 | No additional data are available.  |
| 45       |     |  |
| 46       |     |  |
| 47       |     |  |
| 48<br>49 |     |  |
| 50       |     |  |
| 51       |     |  |
| 52       |     |  |
| 53<br>54 |     |  |
| 54<br>55 |     |  |
| 56       |     |  |
| 57       |     | 19   |
| 58       |     | 19   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 

### 483 Figure Captions

**Figure 1:** Population pyramid by age and sex of participants in Jilin province

486 Figure 2: Trends of physical characteristics by age and sex. (A) basal metabolism BM

487 (B) body fat percentage - BFP (C) visceral fat index - VFI (D) body mass index - BMI

488 (E) systolic blood pressure - SBP (F) diastolic blood pressure - DBP

**Table 1:** Distribution of participants by age and sex in Jilin province (N, %)

| 1 99  | Mal  | le    | Fen  | nale  | Total |       |  |
|-------|------|-------|------|-------|-------|-------|--|
| Age   | N    | %     | Ν    | %     | Ν     | %     |  |
| 15-24 | 1120 | 9.07  | 1146 | 8.51  | 2266  | 17.59 |  |
| 25-34 | 1316 | 8.91  | 1520 | 8.52  | 2836  | 17.43 |  |
| 35-44 | 1084 | 11.95 | 1359 | 11.40 | 2443  | 23.35 |  |
| 45-54 | 1043 | 10.02 | 1333 | 9.68  | 2376  | 19.70 |  |
| 55-64 | 950  | 6.36  | 1121 | 6.47  | 2071  | 12.83 |  |
| 65-74 | 755  | 3.01  | 823  | 3.23  | 1578  | 6.24  |  |
| 75+   | 678  | 1.31  | 708  | 1.55  | 1386  | 2.86  |  |
| Total | 6946 | 50.63 | 8010 | 49.37 | 14956 | 100.0 |  |
|       |      |       |      |       |       |       |  |
|       |      |       |      |       |       |       |  |
|       |      |       |      |       |       |       |  |

Page 21 of 32

1

**BMJ** Open

| י<br>ר                           |   |
|----------------------------------|---|
| 2                                |   |
| 3                                |   |
| 4                                |   |
| 5                                |   |
| 6                                |   |
| 7                                |   |
| 8                                |   |
| 9                                |   |
| 10                               |   |
| 11                               |   |
| 12                               |   |
| 13                               |   |
| 14                               |   |
| 15                               |   |
| 11<br>12<br>13<br>14<br>15<br>16 |   |
| 17                               |   |
| 18                               |   |
| 19                               |   |
| 20                               |   |
| 21                               |   |
| 22                               |   |
| 23                               |   |
| 24<br>25<br>26                   |   |
| 25                               |   |
| 26                               |   |
| 27                               |   |
| 28                               |   |
| 29                               |   |
| 30                               |   |
| 31                               |   |
| 32                               |   |
| 33                               |   |
| 34                               |   |
| 35<br>36                         |   |
| 36                               |   |
| 37                               |   |
| 38                               |   |
| 39                               |   |
| 40                               |   |
| 41                               |   |
| 42                               |   |
| 43                               |   |
| 44                               |   |
| 45                               |   |
| 46                               | Т |

47

|        |               | BN            | ΛI            |              |               | Smoking     |               | Alcohol Drinkin |
|--------|---------------|---------------|---------------|--------------|---------------|-------------|---------------|-----------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0        | Current       | Ever        | Never         |                 |
| Male   |               |               |               |              |               |             |               |                 |
| 15-24  | 13.33         | 67.57         | 14.85         | 4.25         | 6.95          | 0.36        | 92.69         | 5.80            |
|        | (11.11,15.91) | (64.24,70.73) | (12.58,17.46) | (3.03,5.93)  | (5.47,8.80)   | (0.10,1.22) | (90.79,94.22) | (4.62, 7.26)    |
| 25-34  | 2.80          | 57.76         | 31.36         | 8.08         | 39.19         | 0.64        | 60.17         | 29.70           |
|        | (1.98,3.93)   | (54.70,60.77) | (28.57,34.30) | (6.52,9.96)  | (36.20,42.26) | (0.30,1.37) | (57.09,63.17) | (26.96, 32.60)  |
| 35-44  | 1.89          | 54.86         | 35.26         | 7.99         | 46.92         | 1.32        | 51.76         | 39.90           |
|        | (0.18,3.01)   | (51.49,58.18) | (32.10,38.55) | (6.35,10.02) | (43.57,50.30) | (0.79,2.18) | (48.39,55.12) | (36.62, 43.26)  |
| 45-54  | 1.56          | 55.63         | 36.25         | 6.56         | 48.42         | 3.19        | 48.38         | 44.70           |
|        | (0.93,2.60)   | (52.33,58.88) | (33.14,39.47) | (5.11,8.39)  | (45.13,51.73) | (2.25,4.52) | (45.10,51.68) | (41.44, 48.00)  |
| 55-64  | 0.79          | 59.10         | 35.17         | 4.94         | 44.79         | 5.19        | 50.02         | 39.30           |
|        | (0.39,1.60)   | (55.67,62.44) | (31.96,38.52) | (3.65,6.66)  | (41.38,48.25) | (3.88,6.91) | (46.57,53.47) | (35.99, 42.71)  |
| 65-74  | 2.16          | 60.45         | 33.51         | 3.88         | 32.13         | 6.99        | 60.88         | 34.30           |
|        | (1.26,3.69)   | (56.54,64.22) | (29.91,37.33) | (2.66,5.62)  | (28.57,35.91) | (5.22,9.30) | (56.97,64.65) | (30.65, 38.14)  |
| 75+    | 3.71          | 62.83         | 30.22         | 3.23         | 22.06         | 5.58        | 72.35         | 18.74           |
|        | (2.53,5.42)   | (58.82,66.68) | (26.61,34.10) | (2.01,5.15)  | (18.85,25.64) | (3.96,7.82) | (68.54,75.87) | (15.72, 22.19)  |
| Female |               |               |               |              |               |             |               |                 |
| 15-24  | 13.46         | 70.77         | 12.55         | 3.22         | 0.36          | 0.00        | 99.64         | 0.76            |
|        | (11.24,16.03) | (67.48,73.85) | (10.34,15.16) | (2.34,4.43)  | (0.11,1.16)   |             | (98.84,99.89) | (0.43,1.35)     |
| 25-34  | 6.46          | 66.10         | 22.33         | 5.11         | 2.90          | 0.06        | 97.04         | 3.50            |
|        | (5.25,7.94)   | (63.37,68.72) | (20.06,24.79) | (3.97,6.55)  | (2.05,4.08)   | (0.01,0.44) | (95.85,97.89) | (2.65,4.62)     |
| 35-44  | 1.81          | 61.59         | 29.86         | 6.74         | 8.00          | 0.07        | 91.93         | 4.40            |
|        | (1.16,2.81)   | (58.64,64.45) | (27.18,32.67) | (5.38,8.41)  | (6.45,9.88)   | (0.01,0.50) | (90.05,93.49) | (3.37,5.73)     |

Table 2: Distribution of participants by age and sex stratified by body mass index, smoking and alcoholic drinking in Jilin province (%, 95%CI) 492

21

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright,אַשָּפּוּקוּשָׁאָשָׁאַפּאַלפּשַלַסְנָפּאַלָּפָאַלָּפָאַלָסָנפּאַלפּאַלָּאָאָשָאַמָלָפָאַ

| 45-54 | 1.99         | 54.20         | 36.38         | 7.44         | 10.36         | 0.52        | 89.12         | 3.08        |
|-------|--------------|---------------|---------------|--------------|---------------|-------------|---------------|-------------|
|       | (1.29,3.04)  | (51.27,57.09) | (33.62,39.24) | (6.05,9.11)  | (8.69,12.31)  | (0.23,1.17) | (87.14,90.83) | (2.23,4.25) |
| 55-64 | 2.53         | 48.89         | 40.24         | 8.34         | 16.81         | 1.46        | 81.73         | 2.53        |
|       | (1.72,3.71)  | (45.72,52.08) | (37.17,43.39) | (6.72,10.30) | (14.58,19.30) | (0.85,2.49) | (79.16,84.05) | (1.68,3.81) |
| 65-74 | 4.89         | 50.05         | 38.50         | 6.57         | 17.61         | 1.68        | 80.71         | 1.81        |
|       | (3.53,6.72)  | (46.31,53.78) | (34.91,42.22) | (4.94,8.67)  | (14.97,20.60) | (0.93,2.99) | (77.62,83.47) | (1.03,3.16) |
| 75+   | 10.17        | 57.46         | 26.17         | 6.20         | 12.82         | 1.27        | 85.91         | 2.48        |
|       | (7.87,13.04) | (53.37,61.45) | (22.77,29.89) | (4.50,8.50)  | (10.29,15.87) | (0.64,2.50) | (82.77,88.55) | (1.45,4.23) |
|       |              |               |               |              |               |             |               |             |

Protected by copyright, includes telefted to text and lease set and lease within or the training and alminer technologies.

BMJ Open: first published as 10.1136/mjopen-20126 on 28 March 2018. Downloaded from http://pmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (SBBA)

|     | Age       |           | Male               |     | Female             |      | Total            |
|-----|-----------|-----------|--------------------|-----|--------------------|------|------------------|
|     | group     | n         | CR(95%CI)          | n   | CR(95%CI)          | n    | CR(95%CI)        |
| -   | 15-24     | 80        | 6.86(5.27,8.87)    | 23  | 1.88(1.19,2.96)    | 103  | 4.45(3.53,5.59)  |
|     | 25-34     | 106       | 8.47(6.89,10.36)   | 50  | 4.28(3.20,5.69)    | 156  | 6.42(5.43,7.58)  |
|     | 35-44     | 221       | 21.00(18.36,23.91) | 195 | 15.21(13.14,17.55) | 416  | 18.17(16.45,20.0 |
|     | 45-54     | 379       | 35.13(32.06,38.33) | 430 | 32.57(29.89,35.36) | 809  | 33.87(31.82,35.9 |
|     | 55-64     | 449       | 46.42(43.00,49.87) | 576 | 50.72(47.54,53.90) | 1025 | 48.59(46.25,50.9 |
|     | 65-74     | 451       | 59.91(55.98,63.71) | 518 | 65.32(61.72,68.76) | 969  | 62.71(60.06,65.2 |
|     | 75+       | 405       | 61.24(57.24,65.10) | 449 | 62.37(58.30,66.28) | 854  | 61.86(59.00,64.6 |
| 494 | CI: confi | idence in | nterval            |     |                    |      |                  |
| 495 |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |
|     |           |           |                    |     |                    |      |                  |

|        |               | Bl            | II            |               |               | Smoking          | Alcohol Drinking |                |              |
|--------|---------------|---------------|---------------|---------------|---------------|------------------|------------------|----------------|--------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0         | Current       | Ever             | Never            | Yes            | No           |
| Male   |               |               |               |               |               |                  |                  |                |              |
| 15-24  | 1.48          | 4.39          | 16.22         | 30.17         | 8.17          | 13.13            | 6.73             | 11.60          | 6.56         |
|        | (0.37,5.76)   | (2.94,6.51)   | (10.62,24.00) | (16.58,48.44) | (3.45,18.15)  | (1.35,62.57)     | (5.10,8.84)      | (5.85,21.69)   | (4.95, 8.66) |
| 25-34  | 1.45          | 5.33          | 9.15          | 30.70         | 11.49         | 6.89             | 6.51             | 10.64          | 7.55         |
|        | (0.20,9.72)   | (3.78,7.46)   | (6.43,12.85)  | (21.42,41.86) | (8.66,15.08)  | (0.88,38.13)     | (4.80,8.78)      | (7.63, 14.64)  | (5.80, 9.77) |
| 35-44  | 5.49          | 14.76         | 25.87         | 45.98         | 23.76         | 36.23            | 18.11            | 28.02          | 16.34        |
|        | (0.97,25.57)  | (11.77,18.34) | (21.16,31.22) | (34.53,57.87) | (19.72,28.33) | (16.51,62.01)    | (14.77,22.00)    | (23.40, 33.16) | (13.35,19.84 |
| 45-54  | 27.39         | 25.02         | 44.90         | 68.73         | 37.10         | 41.53            | 32.74            | 43.01          | 28.76        |
|        | (10.96,53.63) | (21.38,29.05) | (39.57,50.35) | (55.83,79.27) | (32.60,41.83) | (25.83,59.16)    | (28.51,37.27)    | (38.20, 47.96) | (24.95, 32.9 |
| 55-64  | 11.46         | 39.64         | 55.87         | 65.91         | 47.15         | 61.46            | 44.21            | 52.10          | 42.74        |
|        | (2.44,40.14)  | (35.33,44.11) | (50.07,79.30) | (50.62,78.48) | (42.04,52.33) | (46.39,74.61)    | (39.43,49.09)    | (46.61, 57.54) | (38.42, 47.1 |
| 65-74  | 19.58         | 52.27         | 73.86         | 80.86         | 60.60         | 74.69            | 57.84            | 66.86          | 56.58        |
|        | (6.35,46.63)  | (47.16,57.34) | (67.56,15.96) | (61.30,91.85) | (53.60,67.20) | (59.79,85.42)    | (52.78,62.74)    | (60.21, 72.89) | (51.40, 61.0 |
| 75+    | 37.87         | 58.85         | 66.71         | 83.47         | 68.66         | 59.10            | 59.15            | 65.17          | 60.34        |
|        | (21.57,57.45) | (53.77,63.76) | (59.34,73.34) | (57.75,94.91) | (60.13,76.08) | (41.42,74.69)    | (54.42,63.71)    | (55.63, 73.63) | (55.90, 64.6 |
| Female |               |               |               |               |               |                  |                  |                |              |
| 15-24  | 1.50          | 0.91          | 5.62          | 10.02         | 0.00          | 0.00             | 1.88             | 0.00           | 1.89         |
|        | (0.37,5.81)   | (0.42,1.98)   | (2.53,12.01)  | (3.85,23.67)  |               |                  | (1.19,2.97)      |                | (1.19,2.98)  |
| 25-34  | 0.00          | 2.16          | 6.56          | 27.09         | 12.35         | 0.00             | 4.04             | 0.66           | 4.41         |
|        |               | (1.29,3.59)   | (4.03,10.51)  | (16.97,40.31) | (4.36,30.33)  |                  | (2.98,5.44)      | (0.09,4.63)    | (3.29,5.87   |
| 35-44  | 17.78         | 9.70          | 22.05         | 34.59         | 19.76         | 100.00           | 14.75            | 25.47          | 14.74        |
|        | (5.86,42.90)  | (7.67,12.20)  | (17.69,27.14) | (24.35,46.49) | (12.41,29.97) | (100.00, 100.00) | (12.62,17.17)    | (14.99,39.84)  | (12.65,17.1  |

tratified by body 1... d alashalia drinking (0/ 050/CI) Table 4 D f l in d. 

 BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright,אַשָּפּוּקוּשָׁאָשָׁאַפּאַלפּשַלַסְנָפּאַלָּפָאַלָּפָאַלָסָנפּאַלפּאַלָּאָאָשָאַמָלָפָאַ

| 45-54                | 0.00           | 24.68                         | 40.48  | 60.03             | 34.92           | 61.78                                      | 32.13          | 27.45          | 32.73                |         |
|----------------------|----------------|-------------------------------|--|-------------------|-----------------|--|----------------|----------------|----------------------|---------|
|                      | 0.00           | (21.42,28.27)                 | (35.84,45.30)                                  | (49.33,69.86)     | (26.73,44.12)   | (22.45,90.03)                              | (29.31,35.08)  | (15.31,44.19)  | (30.01,35.57)        |         |
| 55-64                | 40.61          | 39.07                         | 61.42  | 70.47             | 51.28           | 62.47                                      | 50.40          | 51.62          | 50.70                |         |
|                      | (23.68,60.12)  | (34.71,43.61)                 |  | (59.27,79.64)     | (43.64,58.86)   | (35.28,83.56)                              | (46.87,53.92)  | (31.60,71.13)  | (47.48,53.91)        |         |
| 65-74                |                | 59.74                         | 74.83  | 72.04             | 65.26           | 57.48                                      | 65.50          | 50.45          | 65.60                |         |
|                      | (24.16,55.33)  | (54.53,64.73)                 | (60 27 70 68)                                  | (57 14 83 28)     | (56 45 73 13)   | (20 24 81 56)                              | (61 / 8 60 31) | (24.78,75.88)  | (61.97,69.05)        |         |
| 75+                  | 45.30          | 60.64                         | 73.24  | 60.53             | 64.01           | 100.00                                     | 61.57          | 51.72          | 62.64                |         |
|                      | (32.73,58.49)  | (55.25,65.79)                 | (65.79,79.57)                                  | (43.53,75.31)     | (52.10,74.41)   | (100.00,100.00)                            | (57.18,65.79)  | (26.49,76.10)  | (58.53,66.58)        |         |
|                      |                |                               |  |                   |                 | (25.24,31.50)<br>100.00<br>(100.00,100.00) |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                | 25                   |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      |                |                               |  |                   |                 |  |                |                |                      |         |
|                      | .ເຂຍເບັດ       | ເດດກວອງ າຣແກຼເອ               | o no ne se | 9 6 uhtip://ebeni | openxanicomi    | iter stand to mideli                       | ມອອີສ່ຊຸ       | μιοιεςιεα βλ   |                      |         |
| l əb əupidqsıgoildi8 |                |                               |  | eur (ABES) .      | nement Superio  | giesn∃                                     |                |                |                      | do avia |
| Biblioaraphiane de l | ennen& ts 2505 | , At anul, no <mark>/n</mark> | noo imd.nanoin                                 | id\\'nttd mort b  | aheolawo(] .8ti | nc doneM 8C no 83                          | c+0C0-710S-n9a | oimd/8811.01 a | e hadzildun tzit :na | NO LMA  |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 3           |        |
|-------------|--------|
| 4           |        |
| 5           |        |
| 0           |        |
| /<br>0      |        |
| 8<br>9<br>1 |        |
| 9           | 0      |
| 1           | 1      |
| 1           | '<br>2 |
| 1           | 3      |
|             | 4      |
| 1           | 5      |
| 1<br>1      | 6      |
| 1           | 7      |
| 1           | 8      |
| 1           | 9      |
| 2<br>2      | 0      |
| 2           | 1      |
| 2           | 2      |
| 2           | 2<br>3 |
| 2           | 4      |
| 2           | 5      |
| - 2         | 6      |
| 2           | 7      |
| 2           | 8      |
| 2           | 9      |
| 3           | 0      |
| 3           |        |
| 3           | 2<br>3 |
| 3           |        |
| 3           | 4<br>5 |
| 3           | 5      |
| 3<br>3      | 6      |
| 3           | 7      |
| 3           | 8      |
| 3           | 9      |
| 4           | 0      |
| 4           | 1      |
| 4           | 2      |
| 4           | 3      |
| 4<br>4      |        |
| 4           |        |
| 4           |        |
| 4           |        |
| 4           |        |
|             | 9<br>0 |
| 5           |        |
| 5           |        |
| 5           |        |
| 5           |        |
|             | +<br>5 |
| 5           |        |
| 5           |        |
| 5           |        |
| 5           |        |
| 6           |        |
|             | -      |

1 2 3

#### Table.5 Risk factors associated with the prevalence of hypertension 497

|                                      | Hypertensic        | on prevalence   |
|--------------------------------------|--------------------|-----------------|
|                                      | Unadjusted         | Adjusted        |
| Age(Ref: 15-24)                      |                    |                 |
| 25-34                                | 1.47(1.09,1.99)    | 1.05(0.71,1.55) |
| 35-44                                | 4.77(3.65,6.24)    | 2.83(1.90,4.22) |
| 45-54                                | 11.01(8.51,14.24)  | 6.93(4.69,10.24 |
| 55-64                                | 20.31(15.69,26.29) | 13.43(9.06,19.9 |
| 65-74                                | 36.14(27.73,47.11) | 26.18(17.56,39. |
| 75+                                  | 34.85(26.65,45.57) | 29.89(19.83,45. |
| Sex(Ref: female)                     | 1.1(1.01,1.2)      | 1.25(1.13,1.39) |
| Region(Ref: Urban)                   | 1.19(1.09,1.3)     | 1.25(1.12,1.39) |
| Race(Ref: Han)                       | 1.15(0.93,1.42)    | 0.93(0.74,1.18) |
| Employment(Ref: be employed)         |                    |                 |
| Retired                              | 2.67(2.22,3.2)     | 0.67(0.53,0.85) |
| Student                              | 0.15(0.11,0.21)    | 1.09(0.71,1.70) |
| Unemployed                           | 1.18(1.07,1.3)     | 0.84(0.74,0.95) |
| Marital(Ref: married)                | 0.72(0.63,0.83)    | 1.29(1.00,1.65) |
| Education level(Ref: college or high | ner)               |                 |
| Illiterate                           | 6.69(5.19,8.63)    | 2.18(1.62,2.93) |
| Primary                              | 3.26(2.7,3.93)     | 1.98(1.60,2.44) |
| Middle                               | 1.55(1.24,1.94)    | 1.24(0.97,1.57) |
| BMI(Ref: Normal)                     |                    |                 |
| Overweight                           | 2.22(2.01,2.46)    | 2.30(2.06,2.57) |
| Obese                                | 3.96(3.31,4.75)    | 5.17(4.20,6.37) |
| AWC(Ref:<90M,<85F)                   |                    |                 |
| ≥90M, ≥85F                           | 1.41(1.23,1.62)    | 1.35(1.16,1.57) |
| ≥95M, ≥90F                           | 1.5(1.32,1.72)     | 1.68(1.43,1.96) |
| Family history of hypertension       | 1.74(1.55,1.96)    | 2.35(2.06,2.67) |
| Family history of stroke             | 1.33(0.85,2.06)    | 1.79(1.09,2.92) |
| Family history of CAD                | 3.18(2.64,3.83)    | 1.65(1.33,2.03) |
| Smoker(Ref: no)                      | 1.37(1.23,1.53)    | 1.23(1.08,1.40) |
| Drinker(Ref: no)                     | 1.56(1.38,1.77)    | 1.47(1.27,1.71) |
| VAI (Ref:<10)                        |                    |                 |
| 10~14                                | 1.6(1.41,1.8)      | 1.40(1.22,1.60) |
| 15~30                                | 2.69(2.29,3.16)    | 2.05(1.69,2.49) |
| BFP(Ref:<10M, <20F)                  |                    | · · · /         |
| 10~19M, 20~29F                       | 1.31(1,1.71)       | 0.95(0.71,1.27) |
| 20~24M, 30~34F                       | 2.72(2.09,3.55)    | 1.24(0.92,1.66) |
| 20 2111, 50 511                      | × / /              | . , ,           |

498 CAD:

499 coronary heart disease; M: male; F: female; VAI: Visceral Fat; BFP: body fat percentage.

500 Adjusted for sex, region, age, education level, employment status, marital status, BMI, and family

501 history of hypertension





Figure 1: Population pyramid by age and sex of participants in Jilin province

83x58mm (300 x 300 DPI)

Page 28 of 32

**BMJ** Open



|            |       |         | Male           |         | Female            |
|------------|-------|---------|----------------|---------|-------------------|
|            | Age   | Mean    | 95%CI          | Mean    | 95%CI             |
| BM         | Total | 1511.50 | (1504.56,      | 1280.52 | (1276.09, 1284.96 |
|            |       |         | 1518.43)       |         |                   |
|            | 15-24 | 1478.92 | (1456.95,      | 1279.31 | (1264.09, 1294.53 |
|            |       |         | 1500.88)       |         |                   |
|            | 25-34 | 1538.93 | (1524.04,      | 1281.66 | (1272.68,1290.64  |
|            |       |         | 1553.81)       |         |                   |
|            | 35-44 | 1534.48 | (1519.02,      | 1293.35 | (1284.03, 1302.67 |
|            |       |         | 1549.95)       |         |                   |
|            | 45-54 | 1528.84 | (1514.65,      | 1293.81 | (1284.74, 1302.87 |
|            |       |         | 1543.02)       |         |                   |
|            | 55-64 | 1499.65 | (1486.40,      | 1274.36 | (1264.67, 1284.06 |
|            |       |         | 1512.90)       |         |                   |
|            | 65-74 | 1460.36 | (1443.82,      | 1241.86 | (1230.00, 1253.73 |
|            |       |         | 1476.89)       |         |                   |
|            | 75+   | 1382.81 | (1367.17,      | 1209.84 | (1195.08, 1224.59 |
|            |       |         | 1398.45)       |         | <b>`</b>          |
| Body Fat   | Total | 23.28   | (23.03, 23.53) | 29.19   | (29.02, 29.35)    |
| percentage |       |         |                |         |                   |
|            | 15-24 | 18.46   | (17.52, 19.40) | 24.78   | (24.38, 25.18)    |
|            | 25-34 | 23.26   | (22.87, 23.65) | 27.20   | (26.88,27.52)     |
|            | 35-44 | 24.02   | (23.64, 24.40) | 29.19   | (28.86, 29.52)    |
|            | 45-54 | 24.09   | (23.76, 24.41) | 30.95   | (30.61, 31.29)    |
|            | 55-64 | 25.34   | (24.58, 26.10) | 32.39   | (31.99, 32.80)    |
|            | 65-74 | 25.74   | (25.30, 26.17) | 32.97   | (32.46, 33.48)    |
|            | 75+   | 28.31   | (27.06, 29.56) | 32.08   | (31.15, 33.00)    |
| VAI        | Total | 9.63    | (9.49, 9.77)   | 7.42    | (7.29, 7.55)      |
|            | 15-24 | 6.81    | (6.54, 7.08)   | 6.48    | (6.05, 6.91)      |
|            | 25-34 | 9.13    | (8.81, 9.46)   | 6.07    | (5.83, 6.30)      |
|            | 35-44 | 10.01   | (9.70, 10.32)  | 7.25    | (6.96, 7.54)      |
|            | 45-54 | 10.71   | (10.39, 11.03) | 7.90    | (7.68, 8.11)      |
|            | 55-64 | 11.06   | (10.74, 11.37) | 8.71    | (8.47, 8.96)      |
|            | 65-74 | 11.11   | (10.72, 11.49) | 9.27    | (8.81, 9.73)      |
|            | 75+   | 10.64   | (10.21, 11.07) | 8.95    | (8.56, 9.35)      |
| BMI        | Total | 24.15   | (24.05,24.25)  | 23.88   | (23.78,23.97)     |
|            | 15-24 | 22.20   | (21.93,22.47)  | 21.86   | (21.63,22.10)     |
|            | 25-34 | 24.41   | (24.18,24.63)  | 23.20   | (22.99,23.42)     |
|            | 35-44 | 24.78   | (24.55,25.01)  | 24.29   | (24.08,24.51)     |
|            | 45-54 | 24.75   | (24.54,25.01)  | 24.82   | (24.63,25.02)     |
|            | 55-64 | 24.54   | (24.33,24.76)  | 24.96   | (24.74,25.18)     |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**Supplementary Table** Descriptions of basal metabolism – BM, body fat percentage – BFP, visceral fat index - VFI by age and sex in Jilin province

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| Page 3 | 30 of 32 |
|--------|----------|
|--------|----------|

| 15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)  | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$  | $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |     |       |        |                 |        |                 |
|--|---|--|---|-----|-------|--------|-----------------|--------|-----------------|
| SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03) <t< td=""><td>SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03)      <t< td=""><td>SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03)      <t< td=""><td>SBP       Total       130.44       (129.99,130.88)       127.36       (126.90,127.81)         15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)</td><td></td><td>65-74</td><td>24.14</td><td>(23.88,24.40)</td><td>24.63</td><td>(24.35,24.92)</td></t<></td></t<></td></t<> | SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03) <t< td=""><td>SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03)      <t< td=""><td>SBP       Total       130.44       (129.99,130.88)       127.36       (126.90,127.81)         15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)</td><td></td><td>65-74</td><td>24.14</td><td>(23.88,24.40)</td><td>24.63</td><td>(24.35,24.92)</td></t<></td></t<> | SBP         Total         130.44         (129.99,130.88)         127.36         (126.90,127.81)           15-24         122.45         (121.67,123.24)         116.81         (116.13,117.50)           25-34         124.43         (123.77,125.08)         117.93         (117.28,118.58)           35-44         128.76         (127.85,129.67)         123.85         (122.95,124.75)           45-54         134.69         (133.51,135.87)         132.39         (131.28,133.49)           55-64         137.56         (136.22,138.91)         139.53         (138.17,140.90)           65-74         143.98         (142.25,145.71)         145.16         (143.55,146.76)           75+         143.69         (141.96,145.42)         143.44         (141.60,145.28)           DBP         Total         78.14         (77.84,78.43)         75.45         (75.19,75.71)           15-24         70.98         (70.43,71.53)         69.35         (68.82,69.88)           25-34         76.13         (75.63,76.63)         72.69         (72.25,73.13)           35-44         79.04         (78.42,79.66)         75.47         (74.91,76.03)           45-54         81.24         (80.51,81.96)         78.41         (77.79,79.03) <t< td=""><td>SBP       Total       130.44       (129.99,130.88)       127.36       (126.90,127.81)         15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)</td><td></td><td>65-74</td><td>24.14</td><td>(23.88,24.40)</td><td>24.63</td><td>(24.35,24.92)</td></t<> | SBP       Total       130.44       (129.99,130.88)       127.36       (126.90,127.81)         15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60) |     | 65-74 | 24.14  | (23.88,24.40)   | 24.63  | (24.35,24.92)   |
| 15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)  | 15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)   | 15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)  | 15-24       122.45       (121.67,123.24)       116.81       (116.13,117.50)         25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.41,80.11)                 |     | 75+   | 23.63  | (23.37,23.89)   | 23.56  | (23.24,23.88)   |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$  | 25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 25-34       124.43       (123.77,125.08)       117.93       (117.28,118.58)         35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 25-34 124.43 (123.77,125.08) 117.93 (117.28,118.58)<br>35-44 128.76 (127.85,129.67) 123.85 (122.95,124.75)<br>45-54 134.69 (133.51,135.87) 132.39 (131.28,133.49)<br>55-64 137.56 (136.22,138.91) 139.53 (138.17,140.90)<br>65-74 143.98 (142.25,145.71) 145.16 (143.55,146.76)<br>75+ 143.69 (141.96,145.42) 143.44 (141.60,145.28)<br>DBP Total 78.14 (77.84,78.43) 75.45 (75.19,75.71)<br>15-24 70.98 (70.43,71.53) 69.35 (68.82,69.88)<br>25-34 76.13 (75.63,76.63) 72.69 (72.25,73.13)<br>35-44 79.04 (78.42,79.66) 75.47 (74.91,76.03)<br>45-54 81.24 (80.51,81.96) 78.41 (77.79,79.03)<br>55-64 82.50 (81.67,83.33) 79.87 (79.15,80.60)<br>65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   | SBP | Total | 130.44 | (129.99,130.88) | 127.36 | (126.90,127.81) |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$   | $\begin{array}{cccccccccccccccccccccccccccccccccccc$  | $\begin{array}{cccccccccccccccccccccccccccccccccccc$   | 35-44       128.76       (127.85,129.67)       123.85       (122.95,124.75)         45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 15-24 | 122.45 | (121.67,123.24) | 116.81 | (116.13,117.50) |
| 45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 45-54       134.69       (133.51,135.87)       132.39       (131.28,133.49)         55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 45-54 134.69 (133.51,135.87) 132.39 (131.28,133.49)<br>55-64 137.56 (136.22,138.91) 139.53 (138.17,140.90)<br>65-74 143.98 (142.25,145.71) 145.16 (143.55,146.76)<br>75+ 143.69 (141.96,145.42) 143.44 (141.60,145.28)<br>DBP Total 78.14 (77.84,78.43) 75.45 (75.19,75.71)<br>15-24 70.98 (70.43,71.53) 69.35 (68.82,69.88)<br>25-34 76.13 (75.63,76.63) 72.69 (72.25,73.13)<br>35-44 79.04 (78.42,79.66) 75.47 (74.91,76.03)<br>45-54 81.24 (80.51,81.96) 78.41 (77.79,79.03)<br>55-64 82,50 (81.67,83.33) 79.87 (79.15,80.60)<br>65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   |     | 25-34 | 124.43 | (123.77,125.08) | 117.93 | (117.28,118.58) |
| 55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 55-64       137.56       (136.22,138.91)       139.53       (138.17,140.90)         65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 35-44 | 128.76 | (127.85,129.67) | 123.85 | (122.95,124.75) |
| 65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 65-74       143.98       (142.25,145.71)       145.16       (143.55,146.76)         75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 65-74 143.98 (142.25,145.71) 145.16 (143.55,146.76)<br>75+ 143.69 (141.96,145.42) 143.44 (141.60,145.28)<br>DBP Total 78.14 (77.84,78.43) 75.45 (75.19,75.71)<br>15-24 70.98 (70.43,71.53) 69.35 (68.82,69.88)<br>25-34 76.13 (75.63,76.63) 72.69 (72.25,73.13)<br>35-44 79.04 (78.42,79.66) 75.47 (74.91,76.03)<br>45-54 81.24 (80.51,81.96) 78.41 (77.79,79.03)<br>55-64 82,50 (81.67,83.33) 79.87 (79.15,80.60)<br>65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   |     | 45-54 | 134.69 | (133.51,135.87) | 132.39 | (131.28,133.49) |
| 75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 75+       143.69       (141.96,145.42)       143.44       (141.60,145.28)         DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 55-64 | 137.56 | (136.22,138.91) | 139.53 | (138.17,140.90) |
| DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | DBP       Total       78.14       (77.84,78.43)       75.45       (75.19,75.71)         15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | DBP Total 78.14 (77.84,78.43) 75.45 (75.19,75.71)<br>15-24 70.98 (70.43,71.53) 69.35 (68.82,69.88)<br>25-34 76.13 (75.63,76.63) 72.69 (72.25,73.13)<br>35-44 79.04 (78.42,79.66) 75.47 (74.91,76.03)<br>45-54 81.24 (80.51,81.96) 78.41 (77.79,79.03)<br>55-64 82.50 (81.67,83.33) 79.87 (79.15,80.60)<br>65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   |     | 65-74 | 143.98 | (142.25,145.71) | 145.16 | (143.55,146.76) |
| 15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 15-24       70.98       (70.43,71.53)       69.35       (68.82,69.88)         25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 75+   | 143.69 | (141.96,145.42) | 143.44 | (141.60,145.28) |
| 25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 25-34       76.13       (75.63,76.63)       72.69       (72.25,73.13)         35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | DBP | Total | 78.14  | (77.84,78.43)   | 75.45  | (75.19,75.71)   |
| 35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 35-44       79.04       (78.42,79.66)       75.47       (74.91,76.03)         45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 15-24 | 70.98  | (70.43,71.53)   | 69.35  | (68.82,69.88)   |
| 45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 45-54       81.24       (80.51,81.96)       78.41       (77.79,79.03)         55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 45-54 81.24 (80.51,81.96) 78.41 (77.79,79.03)<br>55-64 82.50 (81.67,83.33) 79.87 (79.15,80.60)<br>65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   |     | 25-34 | 76.13  | (75.63,76.63)   | 72.69  | (72.25,73.13)   |
| 55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   | 55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)  | 55-64       82.50       (81.67,83.33)       79.87       (79.15,80.60)         65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)   |     | 35-44 | 79.04  | (78.42,79.66)   | 75.47  | (74.91,76.03)   |
| 65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)         CI: confidence interval  | 65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)         CI: confidence interval   | 65-74       81.56       (80.72,82.40)       79.13       (78.35,79.91)         75+       80.38       (79.61,81.15)       79.26       (78.41,80.11)         CI: confidence interval  | 65-74 81.56 (80.72,82.40) 79.13 (78.35,79.91)<br>75+ 80.38 (79.61,81.15) 79.26 (78.41,80.11)<br>CI: confidence interval   |     | 45-54 | 81.24  | (80.51,81.96)   | 78.41  | (77.79,79.03)   |
| 75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td></td><td>55-64</td><td>82.50</td><td>(81.67,83.33)</td><td>79.87</td><td>(79.15,80.60)</td></t<></td></t<></td></t<></td></t<>   | 75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td></td><td>55-64</td><td>82.50</td><td>(81.67,83.33)</td><td>79.87</td><td>(79.15,80.60)</td></t<></td></t<></td></t<>  | 75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval <t< td=""><td>75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval   <t< td=""><td></td><td>55-64</td><td>82.50</td><td>(81.67,83.33)</td><td>79.87</td><td>(79.15,80.60)</td></t<></td></t<>   | 75+         80.38         (79.61,81.15)         79.26         (78.41,80.11)           CI: confidence interval <t< td=""><td></td><td>55-64</td><td>82.50</td><td>(81.67,83.33)</td><td>79.87</td><td>(79.15,80.60)</td></t<>  |     | 55-64 | 82.50  | (81.67,83.33)   | 79.87  | (79.15,80.60)   |
| CI: confidence interval  | CI: confidence interval   | CI: confidence interval  | CI: confidence interval   |     | 65-74 | 81.56  | (80.72,82.40)   | 79.13  | (78.35,79.91)   |
|  |   |  |   |     | 75+   | 80.38  | (79.61,81.15)   | 79.26  | (78.41,80.11)   |
|  |   |  |   |     |       |        |                 |        |                 |
|  |   |  |   |     |       |        |                 |        |                 |
|  |   |  |   |     |       |        |                 |        |                 |
|  |   |  |   |     |       |        |                 |        |                 |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

STROBE Statement—checklist of items that should be included in reports of observational studies

| Background/rationale       2         Objectives       3         Methods       3         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       9         Study size       10         Quantitative variables       11                      | <ul> <li>(a) Indicate the study's design with a commonly used term in the title or the (b) Provide in the abstract an informative and balanced summary of what wa and what was found</li> <li>Explain the scientific background and rationale for the investigation being</li> <li>State specific objectives, including any prespecified hypotheses</li> <li>Present key elements of study design early in the paper</li> <li>Describe the setting, locations, and relevant dates, including periods of recrue exposure, follow-up, and data collection</li> <li>(a) Cohort study—Give the eligibility criteria, and the sources and methods a selection of participants. Describe methods of follow-up</li> <li>Case-control study—Give the eligibility criteria, and the sources and methods are ascertainment and control selection. Give the rationale for the choice of and controls</li> <li>Cross-sectional study—Give the eligibility criteria, and the sources and methods as election of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> <li>Case-control study—For matched studies, give matching criteria and the number of exposed and unexposed</li> </ul> | P1-<br>s done<br>P2<br>reporte<br>P4-5<br>itment,<br>P4-5<br>of<br>ls of<br>cases<br>nods of<br>P4 |
|---|--|--|
| Background/rationale       2         Objectives       3         Methods       4         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       9         Study size       10         Quantitative variables       11                      | and what was found         Explain the scientific background and rationale for the investigation being         State specific objectives, including any prespecified hypotheses         Present key elements of study design early in the paper         Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods of and controls         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | P2<br>reporte<br>P<br>P4-5<br>itment,<br>P4-5<br>of<br>ls of<br>cases<br>nods of<br>P4             |
| Background/rationale       2         Objectives       3         Methods       4         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       8         Bias       9         Study size       10         Quantitative variables       11 | Explain the scientific background and rationale for the investigation being<br>State specific objectives, including any prespecified hypotheses<br>Present key elements of study design early in the paper<br>Describe the setting, locations, and relevant dates, including periods of recru<br>exposure, follow-up, and data collection<br>(a) Cohort study—Give the eligibility criteria, and the sources and methods<br>selection of participants. Describe methods of follow-up<br>Case-control study—Give the eligibility criteria, and the sources and methods<br>case ascertainment and control selection. Give the rationale for the choice of<br>and controls<br>Cross-sectional study—Give the eligibility criteria, and the sources and method<br>selection of participants<br>(b) Cohort study—For matched studies, give matching criteria and number of<br>exposed and unexposed   | reporte<br>P<br>P4-5<br>itment,<br>P4-5<br>of<br>ls of<br>cases<br>nods of<br>P4                   |
| Objectives       3         Methods       4         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       9         Study size       10         Quantitative variables       11   | State specific objectives, including any prespecified hypotheses         Present key elements of study design early in the paper         Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods or case ascertainment and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods         selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | P<br>P4-5<br>itment,<br>P4-5<br>of<br>ls of<br>cases<br>nods of<br>P4                              |
| Objectives       3         Methods       4         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       9         Study size       10         Quantitative variables       11   | State specific objectives, including any prespecified hypotheses         Present key elements of study design early in the paper         Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods or case ascertainment and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and methods         selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | P<br>P4-5<br>itment,<br>P4-5<br>of<br>ls of<br>cases<br>nods of<br>P4                              |
| Methods         Study design       4         Setting       5         Participants       6         Variables       7         Data sources/       8*         measurement       8         Bias       9         Study size       10         Quantitative variables       11   | Present key elements of study design early in the paper         Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and method selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | P4-5<br>itment,<br>P4-5<br>of<br>Is of<br>cases<br>nods of<br>P4                                   |
| MethodsStudy design4Setting5Participants6Variables7Data sources/<br>measurement8*Bias9Study size10Quantitative variables11  | Present key elements of study design early in the paper         Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and method selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | itment,<br>P4-5<br>of<br>Is of<br>cases<br>nods of<br>P4   |
| Study design4Setting5Participants6Variables7Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and method selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  | itment,<br>P4-5<br>of<br>Is of<br>cases<br>nods of<br>P4   |
| Setting5Participants6Variables7Data sources/<br>measurement8*Bias9Study size10Quantitative variables11  | Describe the setting, locations, and relevant dates, including periods of recru         exposure, follow-up, and data collection         (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up         Case-control study—Give the eligibility criteria, and the sources and methods of and control selection. Give the rationale for the choice of and controls         Cross-sectional study—Give the eligibility criteria, and the sources and method selection of participants         (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  | itment,<br>P4-5<br>of<br>Is of<br>cases<br>nods of<br>P4   |
| Participants    6      Variables    7      Data sources/    8*      measurement    8*      Bias    9      Study size    10      Quantitative variables    11  | <ul> <li>exposure, follow-up, and data collection</li> <li>(a) Cohort study—Give the eligibility criteria, and the sources and methods a selection of participants. Describe methods of follow-up</li> <li><i>Case-control study</i>—Give the eligibility criteria, and the sources and methods case ascertainment and control selection. Give the rationale for the choice of and controls</li> <li><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and methods selection of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> </ul>  | P4-5<br>of<br>Is of<br>cases<br>nods of<br>P4  |
| Variables7Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | <ul> <li>(a) Cohort study—Give the eligibility criteria, and the sources and methods a selection of participants. Describe methods of follow-up</li> <li>Case-control study—Give the eligibility criteria, and the sources and methods and control selection. Give the rationale for the choice of and controls</li> <li>Cross-sectional study—Give the eligibility criteria, and the sources and method selection of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> </ul>  | ls of<br>cases<br>nods of<br>P4  |
| Variables7Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | <ul> <li>selection of participants. Describe methods of follow-up</li> <li><i>Case-control study</i>—Give the eligibility criteria, and the sources and method case ascertainment and control selection. Give the rationale for the choice of and controls</li> <li><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and method selection of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> </ul>  | ls of<br>cases<br>nods of<br>P4  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | <ul> <li><i>Case-control study</i>—Give the eligibility criteria, and the sources and method case ascertainment and control selection. Give the rationale for the choice of and controls</li> <li><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and method selection of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> </ul>  | cases<br>nods of<br>P4   |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | <ul> <li>case ascertainment and control selection. Give the rationale for the choice of and controls</li> <li><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and meth selection of participants</li> <li>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed</li> </ul>  | cases<br>nods of<br>P4   |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | Cross-sectional study—Give the eligibility criteria, and the sources and metheselection of participants<br>(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  | P4   |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | selection of participants<br>(b) Cohort study—For matched studies, give matching criteria and number of<br>exposed and unexposed   | P4   |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | selection of participants<br>(b) Cohort study—For matched studies, give matching criteria and number of<br>exposed and unexposed   | P4   |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed   | f  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | exposed and unexposed  |  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   |  |  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,  | nber of  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | controls per case  |  |
| Data sources/<br>measurement8*Bias9Study size10Quantitative variables11   | Clearly define all outcomes, exposures, predictors, potential confounders, an  | d effect   |
| measurementBias9Study size10Quantitative variables11  | modifiers. Give diagnostic criteria, if applicable   | Pe   |
| measurementBias9Study size10Quantitative variables11  | For each variable of interest, give sources of data and details of methods of  |  |
| Bias9Study size10Quantitative variables11   | assessment (measurement). Describe comparability of assessment methods i   | f there i  |
| Study size10Quantitative variables11  | more than one group  | Р  |
| Study size10Quantitative variables11  | Describe any efforts to address potential sources of bias  | Р  |
| Quantitative variables 11   | Explain how the study size was arrived at  | F  |
| -   | Explain how quantitative variables were handled in the analyses. If applicable   |  |
| Statistical methods 12  | describe which groupings were chosen and why   | P5-  |
|   | ( <i>a</i> ) Describe all statistical methods, including those used to control for con   |  |
| -   | (b) Describe any methods used to examine subgroups and interactions  | P  |
| -   | (c) Explain how missing data were addressed  | F  |
| -   | (d) Cohort study—If applicable, explain how loss to follow-up was addresse   |  |
|   | <i>Case-control study</i> —If applicable, explain how not bind was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and control   |  |
|   | addressed  | .15 mus  |
|   |  | ount of  |
|   |  | N/2  |
| -   | <i>Cross-sectional study</i> —If applicable, describe analytical methods taking acc sampling strategy  | 1 1/1  |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 2<br>3   |  |
|----------|--|
| 4        |  |
| 5        |  |
| 6        |  |
| 7<br>8   |  |
| o<br>9   |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13<br>14 |  |
| 14       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19<br>20 |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24<br>25 |  |
| 25<br>26 |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30<br>31 |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35<br>36 |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40<br>41 |  |
| 41       |  |
| 43       |  |
| 44       |  |
| 45<br>46 |  |
| 46<br>47 |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51<br>52 |  |
| 52<br>53 |  |
| 54       |  |
| 55       |  |
| 56<br>57 |  |
| 57<br>58 |  |
| 59       |  |
| 60       |  |
|          |  |

1 2

| Participants   | 13*                                       | (a) Report numbers of individuals at each stage of study-eg numbers potentially elig   | gible,  |
|--|---|--|---|
|  |   | examined for eligibility, confirmed eligible, included in the study, completing follow   | -up, and  |
|  |   | analysed   | P7  |
|  |   | (b) Give reasons for non-participation at each stage   | Р7  |
|  |   | (c) Consider use of a flow diagram   | N/A   |
| Descriptive  | 14*                                       | (a) Give characteristics of study participants (eg demographic, clinical, social) and in   | formation   |
| data   |   | on exposures and potential confounders   | P7  |
|  |   | (b) Indicate number of participants with missing data for each variable of interest  | N/A   |
|  |   | (c) Cohort study—Summarise follow-up time (eg, average and total amount)   | N/A   |
| Outcome data   | 15*                                       | Cohort study-Report numbers of outcome events or summary measures over time  |   |
|  |   | Case-control study-Report numbers in each exposure category, or summary measur   | es of   |
|  |   | exposure   |   |
|  |   | Cross-sectional study—Report numbers of outcome events or summary measures   | Р7  |
| Main results   | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and t  | heir  |
|  |   | precision (eg, 95% confidence interval). Make clear which confounders were adjuste   | d for and   |
|  |   | why they were included   | P8  |
|  |   | (b) Report category boundaries when continuous variables were categorized  | P6  |
|  |   |  | -   |
|  |   | (c) If relevant, consider translating estimates of relative risk into absolute risk for a m  |   |
|  |   | (c) If relevant, consider translating estimates of relative risk into absolute risk for a m<br>time period   |   |
| Other analyses   | 17  |  | eaningful<br>N/A  |
| Other analyses   | 17  | time period  | eaningful<br>N/A  |
|  | 17  | time period<br>Report other analyses done—eg analyses of subgroups and interactions, and sensitivi   | eaningful<br>N/A<br>ty  |
| Discussion   | 17  | time period<br>Report other analyses done—eg analyses of subgroups and interactions, and sensitivi   | eaningful<br>N/A<br>ty  |
| Other analyses Discussion Key results Limitations                              |   | time period<br>Report other analyses done—eg analyses of subgroups and interactions, and sensitivi<br>analyses   | eaningful<br>N/A<br>ty<br>P8-9<br>P10                                   |
| <b>Discussion</b><br>Key results   | 18  | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives  | eaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.                       |
| <b>Discussion</b><br>Key results   | 18  | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives Discuss limitations of the study, taking into account sources of potential bias or impre-  | P10<br>P15<br>P15   |
| Discussion<br>Key results<br>Limitations                                       | 18<br>19                                  | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives Discuss limitations of the study, taking into account sources of potential bias or impr Discuss both direction and magnitude of any potential bias   | P10<br>P15<br>P15   |
| Discussion<br>Key results<br>Limitations<br>Interpretation                     | 18<br>19                                  | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives Discuss limitations of the study, taking into account sources of potential bias or impr Discuss both direction and magnitude of any potential bias Give a cautious overall interpretation of results considering objectives, limitations, m  | eaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15<br>ultiplicity |
| Discussion<br>Key results<br>Limitations<br>Interpretation<br>Generalisability | 18           19           20           21 | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives Discuss limitations of the study, taking into account sources of potential bias or impr Discuss both direction and magnitude of any potential bias Give a cautious overall interpretation of results considering objectives, limitations, m of analyses, results from similar studies, and other relevant evidence | P10<br>P10<br>P10<br>P10<br>P10<br>P10<br>P10<br>P10-14                 |
| Discussion<br>Key results<br>Limitations                                       | 18           19           20           21 | time period Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses Summarise key results with reference to study objectives Discuss limitations of the study, taking into account sources of potential bias or impr Discuss both direction and magnitude of any potential bias Give a cautious overall interpretation of results considering objectives, limitations, m of analyses, results from similar studies, and other relevant evidence | P10<br>P10<br>P10<br>P15<br>Ultiplicity<br>P10-14<br>P15                |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen?bmj.com/site/about/guidelines.xhtml

# **BMJ Open**

## **Prevalence and distribution of hypertension and related risk factors in Jilin Province, China 2015: a cross-sectional study**

| Journal:                             | BMJ Open   |
|--------------------------------------|--|
| Manuscript ID                        | bmjopen-2017-020126.R1   |
| Article Type:                        | Research   |
| Date Submitted by the Author:        | 14-Jan-2018  |
| Complete List of Authors:            | Wu, Junduo; the Second Hospital of Jilin University, cardiology<br>Li, Tianyi; the Second Hospital of Jilin University, cardiology<br>Song, Xianjing; the Second Hospital of Jilin University, cardiology<br>Sun, Wei; the Second Hospital of Jilin University, cardiology<br>Zhang, Yangyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Liu, Yingyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Liu, Yingyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Li, Longbo; the Second Hospital of Jilin University, cardiology<br>Yu, Yunpeng; the Second Hospital of Jilin University, cardiology<br>Liu, Yihang; the Second Hospital of Jilin University, cardiology<br>Qi, Chao; the Second Hospital of Jilin University, cardiology<br>Liu, Bin; The Second Hospital of Jilin University, Department of Cardiology |
| <b>Primary Subject<br/>Heading</b> : | Epidemiology   |
| Secondary Subject Heading:           | Public health  |
| Keywords:                            | prevalence, Hypertension < CARDIOLOGY, EPIDEMIOLOGY, China   |
|                                      |  |

SCHOLARONE<sup>™</sup> Manuscripts



| 1        |    |   |
|----------|----|---|
| 2<br>3   |    |   |
| 4        | 1  | Prevalence and distribution of hypertension and related risk  |
| 5        |    |   |
| 6        | 2  | factors in Jilin Province, China 2015: a cross-sectional study  |
| 7        |    |   |
| 8<br>9   | 3  |   |
| 9<br>10  | 4  | Junduo Wu <sup>1</sup> , Tianyi Li <sup>1</sup> , Xianjing Song <sup>1</sup> , Wei Sun <sup>1</sup> , Yangyu Zhang <sup>2</sup> , Yingyu Liu <sup>2</sup> , |
| 11       |    |   |
| 12       | 5  | Longbo Li <sup>1</sup> , Yunpeng Yu <sup>1</sup> , Yihang Liu <sup>1</sup> , Chao Qi <sup>1</sup> , Bin Liu <sup>1*</sup>                                   |
| 13       | _  |   |
| 14<br>15 | 6  |   |
| 15<br>16 |    |   |
| 17       | 7  |   |
| 18       |    |   |
| 19       | 8  | 1 Department of Cardiology, The Second Hospital of Jilin University, Changchun,   |
| 20       |    |   |
| 21<br>22 | 9  | Jilin, China  |
| 23       |    |   |
| 24       | 10 | 2 Department of Epidemiology and Biostatistics, School of Public Health, Jilin  |
| 25       |    |   |
| 26       | 11 | University, No.1163 Xinmin Street, Changchun, Jilin,130021, China   |
| 27<br>28 |    |   |
| 20       | 12 |   |
| 30       |    |   |
| 31       | 13 |   |
| 32       |    |   |
| 33       | 14 |   |
| 34<br>35 |    |   |
| 36       | 15 |   |
| 37       |    |   |
| 38       | 16 | *Corresponding author   |
| 39       |    | E-mail address: liubin3333@vip.sina.com   |
| 40<br>41 | 17 | E-mail address: liubin3333@vip.sina.com   |
| 41       | -/ |   |
| 43       |    |   |
| 44       |    |   |
| 45       |    |   |
| 46<br>47 |    |   |
| 48       |    |   |
| 49       |    |   |
| 50       |    |   |
| 51       |    |   |
| 52<br>53 |    |   |
| 55<br>54 |    |   |
| 55       |    |   |
| 56       |    |   |
| 57       |    | 1   |
| 58<br>59 |    |   |
|          |    |   |

# Abstract **Objective:** To investigate the prevalence and distribution of hypertension and its associated factors in Jilin province, China. Design: a cross-sectional study in four cities and four rural counties in the province as part of a national Chinese study. Participants and setting: A total of 15206 participants aged 15 years old or older selected using a stratified multistage random sampling method. Main outcome measures: prevalence of hypertension. **Results:** The prevalence of hypertension in Jilin province was found to be 24.7%. Moreover, the prevalence of hypertension increased with age in both sexes, and was higher in males than in females. The modifiable factors found to be associated with hypertension were, body mass index, smoking and alcohol drinking. The risk factors identified are similar to those in southern China, except smoking, which has no association with hypertension prevalence in the South. **Conclusions:** Age, sex, body mass index, smoking, and alcohol drinking are risk factors of hypertension. Control of these related risk factors, especially smoking, may be helpful in the treatment and management of hypertension in Jilin province. Strength and limitations of this study This cross-sectional population-based study evaluated a large representative sample of individuals from four cities and four rural counties in Jilin province. A large sample of participants allowed for the subgroups of related factors for

#### **BMJ** Open

| statistical analysis.   |
|---|
| The causality cannot be assumed between the risk factors and hypertension.              |
| Data relevant to physical activity, salt intake and blood lipids were not collected.    |
|   |
| Key words   |
| Prevalence, hypertension, epidemiology, China   |
|   |
| Introduction  |
| As highlighted in the recent World Health Organization report, cardiovascular           |
| diseases (CVD) are at the top of the list of the four prioritized non-communicable      |
| diseases worldwide that require immediate global action plans for prevention and        |
| control[1]. Hypertension is among the leading cause of cardiovascular diseases and      |
| deaths worldwide [2, 3]. It is estimated that the global economic burden related to     |
| hypertension could be as high as US\$ 370 billion [4].                                  |
| In the People's Republic of China, the prevalence of hypertension has been              |
| increasing dramatically from 5.1% in 1959, to 7.7% in 1979, 13.6% in 1991, and 18.8%    |
| in 2002 [5, 6]. Furthermore, there is a disproportionately higher hypertension rate     |
| reported among people living in the northern region of China[7, 8]. There are about     |
| 109.4 million people in the northeastern China. The province of Jilin is located in the |
| northeast of China, with a population of approximately 27.5 million according to the    |
| National Bureau of Statistics. As for other northern provinces, Jilin has a longer      |
| winter season in comparison with the southern China, and, limited by this               |
| 3   |

environment, the lifestyle of the people is different from the other parts of the country. An in-depth analysis of the survey results from Jilin province related to risk factors for hypertension will provide an opportunity to understand the differential reasons for hypertension in the North, and will assist in the development of effective intervention and control strategies for this preventable disease. The objectives of this study were: to estimate the prevalence of hypertension in Jilin province and to explore potential risk factors associated with hypertension in the province. This will provide information for making recommendations on the prevention and control of hypertension in the northern region of China. 

 72 Methods

#### 73 Study population

This cross-sectional study was conducted between July 2014 and December 2015 as a part of national China study. A 4-stage, stratified sampling method was used to select a study sample of the general population age 15 years and older in Jilin province, China. First, four cities from the urban areas and four counties from rural areas were selected using probability proportional to size (PPS). Then two districts or two townships were selected in each city or county using simple random sampling (SRS). Next, in each district and township, three communities or villages were chosen respectively using SRS. Finally, participants stratified by sex (50% men and 50% women) and age (aged 15-24, 25-34, 35-44, 45-54, 55-64, 65-74,  $\geq$ 75 years) were chosen using SRS according to the national population composition. Participants 

#### **BMJ** Open

were chosen from the list provided by the local government registers of households

[9]. Considering a design effect of 2.5 and assuming a prevalence of hypertension of 17.7% among the population aged 15 years and older, an estimated sample size of 15,200 participants was needed to ensure that the bound on the error of estimation (i.e. width of the 95% confidence interval (CI)) for the prevalence in the entire population and subpopulation defined by age and sex were less than 0.4% and 1.8%, respectively [9]. As a result, a total of 15,206 participants living in Jilin province over 6 months and aged 15 years and older were randomly selected to participate in the survey. Measurement A questionnaire interview and physical examination were conducted in the survey. The standardized questionnaire was developed by the national coordinating center of 

97 the Fuwai Hospital (Beijing, China) and included questions on demographic, health
98 behaviors and physical activities. The questionnaire was completed by the participants
99 in a face-to-face interview with trained staff.

The physical examination included blood pressure (BP), body weight and height. BP was measured on the right arm supported at the heart level after participants rested for five minutes, using the Omron HBP-1300 Professional Portable Blood Pressure Monitor (OMRON, Japan). BP was measured three times, with 30 seconds between each measurement. The average of three readings was used for further analysis [10]. Body weight without heavy clothing, basal metabolism (BM), body fat percentage

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 2        |
|----------|
| 3        |
| •        |
| 4        |
| 5        |
| 6        |
| 0        |
| 7        |
| 8        |
| 9        |
|          |
| 10       |
| 11       |
| 12       |
|          |
| 13       |
| 14       |
| 15       |
|          |
| 16       |
| 17       |
| 18       |
|          |
| 19       |
| 20       |
| 21       |
|          |
| 22       |
| 23       |
| 24       |
|          |
| 25       |
| 26       |
| 27       |
|          |
| 28       |
| 29       |
| 30       |
|          |
| 31       |
| 32       |
| 33       |
|          |
| 34       |
| 35       |
| 36       |
|          |
| 37       |
| 38       |
| 39       |
|          |
| 40       |
| 41       |
| 42       |
|          |
| 43       |
| 44       |
| 45       |
|          |
| 46       |
| 47       |
| 48       |
|          |
| 49       |
| 50       |
| 51       |
|          |
| 52       |
| 53       |
| 54       |
|          |
| 55       |
| 56       |
| 50<br>57 |
|          |
| 58       |
| 59       |
| 60       |
| 00       |

1

106 (BFP) and visceral fat index (VFI) were measured using an OMRON body fat and weight measurement device (Vbody HBF-371, OMRON, Japan). Height was 107 108 measured without shoes using a standard right-angle device and a fixed measurement tape (to the nearest 0.5 cm). 109

110

#### Definitions 111

112 Hypertension was defined as systolic BP (SBP)≥140mmHg or diastolic BP  $(DBP) \ge 90$  mmHg, or self-reported use of antihypertensive medication [11]. Body 113 mass index (BMI) was calculated as weight in kilograms divided by height in meters 114 squared. Overweight was defined as BMI 25-30kg/m<sup>2</sup>, and obesity was defined as 115 BMI>30kg/m<sup>2</sup>. ê.je 116

117

#### 118 **Statistical analysis**

Data was entered and validated using Epidata<sup>®</sup> 3.0 software[12]. All estimates 119 and analyses were weighted to represent the population in Jilin Province aged 15 120 121 years or older. The weights were calculated based on the 2010 Jilin province population census data, and the sampling age, sex and geographic subgroups were 122 123 taken into account. Continuous data were presented as mean  $\pm$  standard deviation (SD) 124 or mean with 95% confidence intervals (CI), and differences between groups were compared using the t-est. Categorical data were presented as frequency, rate and 95% 125 126 CI, and the prevalence between different groups was compared using the corrected Rao-Scott chi-square test. Logistic regression analysis was conducted assessing the 127

relationship of hypertension with age, sex, obesity, smoking, and alcohol drinking for
hypertension adjusted for demographic factors, that have been included in similar
studies, including sex, region, age, education level, employment status, marital status,
BMI, and family history of hypertension. All analyses were conducted using SPSS<sup>®</sup>
18.0 software[13].

- 133
- 134 **Results**
- 135 Distribution of participants

A total of 14,956 participants from 15,206 eligible participants (6,946 males and 8,010 females; aged 15–97 years) completed the survey and were included in the statistical analysis. The percentage of males and females were 50.63% and 49.37%, respectively. The non-responders (1.6%) were mainly young people with nonresponse likely related to their busy work schedule.

- 141
- 142 Characteristics of participants

The average age of the participants was 45.5 years, with the average age for males being 45.6±19.6 years and for females 45.5±18.9 years. There was no statistically significant difference in age between the sexes (p=0.92). The distribution of participants by age and sex are shown in Table 1. The BMI of the participants was 24.01±3.67 kg/m<sup>2</sup>, BM was (1397.47±244.15), BFP was 26.20±8.4 and VFI was 8.54±4.99. The mean SBP of the participants was 128.92±17.97) mmHg, and the mean DBP was 76.81±10.36 mmHg. These physical characteristics by age and sex are

| 150 | shown in Supplementary Table 1. All these characters were statistically significantly    |
|-----|--|
| 151 | different between males and females (p<0.01). In particular, BM and VFI for males        |
| 152 | was higher than for females in all age groups (Figure 1A and 1B), while BFP for          |
| 153 | females was higher than males in all age groups (Figure 1C). BMI reached its highest     |
| 154 | value for males in the 35-44 year age group and for females in the 55-66 year age        |
| 155 | group (Figure 1D). The SBP was similar between males and females in all age groups       |
| 156 | (Figure 1E), yet the DBP of males was higher than for female in all age groups           |
| 157 | (Figure 1F).   |
| 158 | (Figure IF).   |
| 159 | Lifestyle risk factors - obesity, smoking and alcohol drinking                           |
| 160 | The prevalence of overweight and obesity of participants was 29.8% and 6.2%,             |
| 161 | respectively. The prevalence of overweight for the male participants was 30.9%,          |
| 162 | higher than for the female participants at 28.7% (p=0.013). On the other hand, there     |
| 163 | was no statistical difference between the prevalence of obesity of male participants     |
| 164 | (6.3%) and female participants (6.2%) (p=0.78). The percentage of current smoking        |
| 165 | and ever smoking was 22.7% and 1.4%, respectively. When stratified by sex, the           |
| 166 | percentage of current smoking in males (36.9%) was higher than in females (8.2%)         |
| 167 | (p< $0.001$ ). Similarly, the percentage of ever smoking in males (2.3%) was higher than |
| 168 | that in females (0.5%) (p<0.001). The percentage of alcohol drinking was 17.6%. The      |
| 169 | percentage in males (32.0%) was significantly higher than in females (2.9%)              |
| 170 | (p<0.001). The risk factors BMI, smoking and alcohol drinking, summarized by age         |
| 171 | and sex, are shown in Table 2.   |
|     |  |

| 172 |  |
|-----|--|
|     |  |

# Prevalence of hypertension stratified by non-modifiable factors-age and sex Of the 14,956 participants, 4,332 were diagnosed with hypertension, and the prevalence of hypertension was 24.7% (95% CI: 23.9%, 25.5%). The prevalence of hypertension was larger for the older age groups, and was higher in males (25.6%) than in females (23.8%) (p=0.03). For each age group less than 45 years, the prevalence of hypertension in males was higher than in females (p<0.001); while for the 65-74 year age group, the prevalence of hypertension in females was higher than in males (p=0.04); and in the other age groups, the prevalence of hypertension in males and females showed no statistical difference (p>0.05). The prevalence of hypertension stratified by age and sex is shown in Table 3.

# 184 Prevalence of hypertension stratified by modifiable factors-obesity, smoking and

### 185 alcohol drinking

The prevalence of hypertension was statistically different across BMI categories (p<0.001); the highest prevalence being reported was 48.1% in the obese group, followed by the overweight group at 35.7%. When stratified by smoking, the prevalence of hypertension also showed statistical differences between the current smoking, ever smoking, and never smoking groups (p<0.001); with the highest prevalence of 53.1% in the ever smoking group, followed by 32.2% in the current smoking group and 22.0% in the never smoking group. The prevalence of hypertension in the alcohol drinking group was 34.6%, higher than 22.6% in the 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

no-alcohol drinking group (p<0.001). The prevalence of hypertension stratified by</li>BMI, smoking and alcohol drinking are shown in Table 4.

### 197 Factors associated with hypertension

Several factors, including age, sex, obesity, smoking, and alcohol drinking, are associated with the prevalence of hypertension, both in the crude model and adjusted logistic model. In particular, in the absence of adjusting for other factors, the univariate logistic model indicated that the risk of hypertension was greater in males with an OR=1.1 (95% CI: 1.01, 1.2) than in females, overweight partipants with an OR=2.52 (95% CI: 2.3, 2.77) than in normal participants, obese participants with an OR=4.21 (95% CI: 3.56, 4.96) than in normal participants, smokers with OR=1.64 (95% CI: 1.48, 1.81) than in non-smokers, and alcohol drinkers with OR=1.81 (95% CI: 1.62, 2.02) than in non-alcohol drinkers. All the difference were statistically significant (p < 0.05). A multivariable logistic regression model was used to adjust for potential influencing factors. After adjustment for age, sex, region, education level, employment status, BMI, family history of hypertension, and marital status that may affect hypertension, the risk of hypertension was greater in males with an adjusted OR=1.26 (95% CI:1.13, 1.39) than in females, in overweigh participants with an adjusted OR=2.3 (95% CI: 2.06, 2.58) than in normal participants, in obese participants with an adjusted OR=5.11 (95% CI: 4.16, 6.27) than in normal participants, in smokers with an adjusted OR=1.28 (95% CI: 1.13, 1.46) than in non-smokers, and in alcohol drinkers with an adjusted OR=1.49 (95% CI: 1.28, 1.73). 

| 1              |     |   |
|----------------|-----|---|
| 2<br>3<br>4    | 216 | These results are shown in Table 5.   |
| 5<br>6<br>7    | 217 |   |
| 8<br>9         | 218 | Discussion  |
| 10<br>11       | 219 | With the estimated prevalence of hypertension in Jilin province of 24.7%, a               |
| 12<br>13<br>14 | 220 | population of approximately 6.8 million in the province are hypertensive. At the          |
| 15<br>16       | 221 | national level, the prevalence of hypertension in Jilin is comparable to that in          |
| 17<br>18<br>19 | 222 | Zhejiang province [12]; while the prevalence is lower than in other regions in China,     |
| 20<br>21       | 223 | including Jiangxi [13], Inner Mongolia [14], and Macau [15], as well as, lower than       |
| 22<br>23<br>24 | 224 | the overall prevalence in China [16]. Worldwide, this prevalence is lower than that in    |
| 25<br>26       | 225 | the US, the UK, but is higher than that in Canada [4]. However, there are some            |
| 27<br>28<br>29 | 226 | limitations in terms of the direct comparisons among these studies, given the varying     |
| 30<br>31       | 227 | methods and environments and variations of population genetics, and the different         |
| 32<br>33       | 228 | population age structures.  |
| 34<br>35<br>36 | 229 | Although the prevalence of 24.7% is lower than 30.8% that was found in 2012               |
| 37<br>38       | 230 | [17], it is still not acceptable in terms of optimal hypertension health in the province. |
| 39<br>40<br>41 | 231 | Our study found that the prevalence of overweight and obesity was 29.8% and 6.2%,         |
| 42<br>43       | 232 | respectively, which is higher than that reported at the national level of 17.7% and       |
| 44<br>45<br>46 | 233 | 5.6%, respectively[18]. Several studies have shown that obesity is a risk factor for the  |
| 47<br>48       | 234 | development of hypertension[19-21]. Obesity can increase hypertension through             |
| 49<br>50<br>51 | 235 | multiple mechanisms, including insulin resistance, activation of sympathetic nervous      |
| 52<br>53       | 236 | system, sodium retention leading to increase in renal reabsorption, and activation of     |
| 54<br>55       | 237 | the renin-angiotensin system[22]. The growing number of people with obesity and           |
| 56<br>57<br>58 |     | 11  |
| 59             |     | For peer review only - http://bmiopen.hmi.com/site/about/quidelines.xhtml                 |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 238 | being overweight in the province of Jilin presents a strong indicator of the potential        |
|-----|---|
| 239 | risk of future increasing incidence of hypertension. Unfortunately, this modifiable risk      |
| 240 | factor has exhibited no change in between the report in 2012 and now[17], not to              |
| 241 | mention that the population of overweight and obesity may have been underestimated,           |
| 242 | since the standard definition of overweight and obesity used in our research may be           |
| 243 | set too high for asian people[23, 24]. Moreover, some people may be abdominal obese           |
| 244 | with a normal BMI value (18.5-24.9kg/m <sup>2</sup> ). Studies have reported that despite the |
| 245 | normal BMI value, abdominal obesity is also a risk factor for hypertension                    |
| 246 | worldwide[25, 26]. This modifiable risk factor deserves attention and requires an             |
| 247 | effective proactive intervention program to slow and ultimately reduce the number of          |
| 248 | individuals with obesity becoming hypertensive.   |
| 249 | Our study found that the overall prevalence of hypertension increases with age in             |
| 250 | both males and females, especially in the range of 35-74 years of age. This result            |
| 251 | supports the hypothesis that age is one of the risk factors of hypertension [27-30]. An       |
| 252 | increasing lifespan among the population in Jilin requires that a practical and effective     |
|     |   |

both males and females, especially in the range of 35-74 years of age. This result supports the hypothesis that age is one of the risk factors of hypertension [27-30]. An increasing lifespan among the population in Jilin requires that a practical and effective hypertension management strategy of intervention and control targeting the aging population be devloped. The overall prevalence of hypertension is higher in males than in females. However, the prevalence in females increased more rapidly than in males aged 65-74 years. This may be partially explained by hormonal changes in post-menopausal women and the difference in lifespan between males and females [4, 31]. However, the exact mechanisms need to be explored.

Consistent with previous studies [32, 33], our study also showed that smoking,

| 260 | both current and ever smoking, is associated with an increased risk of hypertension.      |
|-----|---|
| 261 | Smoking can increase blood viscosity, stimulate the adrenergic nervous system, and        |
| 262 | contribute to the development of both micro- and macro-vascular diseases[34].             |
| 263 | Although some studies reported weak associations between smoking and hypertension         |
| 264 | [13, 20], smoking is considered a major risk factor worldwide [13, 20, 35-37],            |
| 265 | Additionally, drinking of alcohol is also a factor associated with increasing the risk of |
| 266 | hypertension in our study, which is consistent with previous studies [4, 38-40]. These    |
| 267 | results indicate that changes in living habits, including quitting smoking and alcohol    |
| 268 | drinking, should help to reduce the prevalence of hypertension.                           |
| 269 | National studies reported that the prevalence of hypertension is higher in northern       |
| 270 | China than that in southern China[7, 16]. When comparing the associations between         |
| 271 | risk factors and hypertension with Zhejiang province located in the South[12], we         |
| 272 | found that the risk of hypertension with demographic factors, such as age, sex, and       |
| 273 | region, and clinical factors, such as family history of hypertension and abdominal        |
| 274 | waist circumference, were similar in Jilin province and in southern China. When it        |
| 275 | comes to the lifestyle factors, the risk of hypertension with obesity and alcohol         |
| 276 | drinking were similar, however, there was a marked difference in the modifiable risk      |
| 277 | factor smoking; in particular, in Jilin province there was a strong association with an   |
| 278 | adjusted OR=1.28 (95% CI: 1.13, 1.46), whereas no association between smoking and         |
| 279 | hypertension in southern China was found, with an adjusted OR=1.0 (95% CI: 0.9,           |
| 280 | 1.1). These findings indicate that programs aimed at reducing smoking would be an         |
| 281 | important step to mitigate the prevalence of hypertension in Jilin province. Some         |
|     |   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 282 | social factors including retirement status, marital status, and educationan level were   |
|-----|--|
| 283 | also different between the North and the South. Of interest, there was a difference on   |
| 284 | BFP categories. In particular, for category 10-19 for males and 20-29 for females,       |
| 285 | there was no association between BFP and hypertension in Jilin province with an          |
| 286 | adjusted OR=0.95 (95%CI: 0.71, 1.27), whereas in this category BFP is protective         |
| 287 | againt hypertension in south China with an adjusted OR=0.6 (95% CI: 0.5, 0.8). In the    |
| 288 | range of over 25 for males and over 35 for females, BFP is strongly associated with      |
| 289 | hypertension in Jilin province with an adjusted OR=1.45 (95% CI: 1.07, 1.96),            |
| 290 | whereas no association was found in the South with an adjusted OR=1.3 (95%CI: 1.0,       |
| 291 | 1.5). These results indicate that BFP tends to be more of a risk for hypertension in the |
| 292 | North compared to the South. Studies have reported that high BFP increase blood          |
| 293 | pressure[41, 42]. There are also studies reporting that the relationship between BFP     |
| 294 | and BMI may be different in different ethnic groups[43], and the latter is already       |
| 295 | known to be a risk factor for hypertension. These studies provide inside of the          |
| 296 | different role BFP has on hypertension in the northern and southern China. Further       |
| 297 | studies on the relationship between BFP and hypertension need to be done.                |
| 298 | A survey in 2012 found a prevalence of hypertension of 30.8% [17]. The                   |

prevalence of hypertension in our study was lower. This reduction may be related to the following two factors. First, the government of Jilin province is aware of the damage and burdern of hypertension and is dedicated to increase the funding of medical insurance, especially for rural residents, from RMB ¥3.9 billion in 2012 to RMB ¥6.4 billion, according to the statistical bureau of Jilin province. Second, new

Page 15 of 43

### **BMJ** Open

| 304 | hypertension guidelines on grass-roots management of hypertension[44] and patient        |
|-----|--|
| 305 | education[45] have been published in China since 2012. However, some key                 |
| 306 | modifiable risk factors have exhibited slight negative changes, in particular, the trend |
| 307 | towards obesity, drinking and smoking. This can be due in part to the evolving           |
| 308 | economy of Jilin province with the gross domestic product increasing from RMB            |
| 309 | ¥361.5 billion in 2015, to RMB ¥857.8 billion in 2010, to RMB ¥1.4 trillion in 2015,     |
| 310 | according to the statistical bureau of Jilin province. To reverse these trends will      |
| 311 | require an effective and workable intervention program to control hypertension by        |
| 312 | incorporating best practices identified in theory and practice. For example, rates of    |
| 313 | hypertension awareness have greatly improved from 24.4% to 42.6%, treatment from         |
| 314 | 20.0% to 24.2% based on national surveys[16]. However, the control rate is only 9.3%     |
| 315 | in comparison with 53% in the USA[4]. One of the challenges is to improve                |
| 316 | adherence to anti-hypertension drugs.  |
| 317 | There are some limitations in this study. First, this is a cross-sectional study         |
| 318 | design, thus the causality cannot be assumed between the risk factors and                |
| 319 | hypertension. Second, due to limited financial resource, data relevant to physical       |
| 320 | activity, salt intake and blood lipids were not collected. Third, the decrease of        |
| 321 | prevalence of hypertension in our study compared with that in 2012 may be related        |
| 322 | with sampling factor.  |
|     |  |

In summary, the prevalence of hypertension in Jilin province decreased compared with that in 2012, and is lower than the overall prevalence in China. In addition, the study showed that hypertension is associated with age, sex, obesity, smoking and

alcohol drinking. In particular, smoking seemed to be responsible for the different prevalence of hypertension in northern and southern China. These factors above, especially smoking, might be important points to control and manage hypertension in Jilin province. Reference 1. Organization WH: Global action plan for the prevention and control of noncommunicable diseases 2013-2020, 2013. 2. Cifkova R, Fodor G, Wohlfahrt P: Changes in Hypertension Prevalence, Awareness, Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update. Current hypertension reports 2016, 18(8):62. 3. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U: Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. Journal of human hypertension 2015, 29(4):247-253. 4. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, McAlister FA, Johansen H, Baclic O, Campbell N: Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ open 2013, 3(8):e003423. 5. Wu X, Duan X, Gu D, Hao J, Tao S, Fan D: Prevalence of hypertension and its trends in Chinese populations. International journal of cardiology 1995, 52(1):39-44. 6. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li X, Chalmers J, Gao R et al: Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008, 118(25):2679-2686. 7. Reynolds K, Gu D, Muntner P, Wu X, Chen J, Huang G, Duan X, Whelton PK, He J, Inter ACG: Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J Hypertens 2003, 21(7):1273-1281. 8. Wang X, Bots ML, Yang F, Hoes AW, Vaarties I: Prevalence of hypertension in China: a systematic review and meta-regression analysis of trends and regional differences. J Hypertens 2014, **32**(10):1919-1927; discussion 1927. 9. Wang Z, Zhang L, Chen Z, Wang X, Shao L, Guo M, Zhu M, Gao R, China Hypertension Survey G: Survey on prevalence of hypertension in China: background, aim, method and design. International journal of cardiology 2014, 174(3):721-723. 10. Fodor JG, Leenen FH, Helis E, Turton P: 2006 Ontario Survey on the Prevalence and Control of Hypertension (ON-BP): Rationale and design of a community-based cross-sectional survey. Canadian Journal of Cardiology 2008, 24(6):503-505. 11. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7). Hypertension 2003, 41(6):1178-1179. 

### BMJ Open

| 1        |            |     |  |
|----------|------------|-----|--|
| 2<br>3   | 365        | 12. | Yang L, Yan J, Tang X, Xu X, Yu W, Wu H: Prevalence, Awareness, Treatment, Control and Risk      |
| 4        | 366        | 12. | Factors Associated with Hypertension among Adults in Southern China, 2013. PloS one 2016,        |
| 5        | 367        |     | <b>11</b> (1):e0146181.  |
| 6        |            | 10  |  |
| 7        | 368        | 13. | Hu L, Huang X, You C, Li J, Hong K, Li P, Wu Y, Wu Q, Bao H, Cheng X: <b>Prevalence and Risk</b> |
| 8        | 369        |     | Factors of Prehypertension and Hypertension in Southern China. PloS one 2017,                    |
| 9<br>10  | 370        |     | <b>12</b> (1):e0170238.  |
| 11       | 371        | 14. | Li G, Wang H, Wang K, Wang W, Dong F, Qian Y, Gong H, Xu G, Li Y, Pan L: Prevalence,             |
| 12       | 372        |     | awareness, treatment, control and risk factors related to hypertension among urban adults        |
| 13       | 373        |     | in Inner Mongolia 2014: differences between Mongolian and Han populations. BMC public            |
| 14       | 374        |     | health 2016, <b>16</b> (1):294.  |
| 15<br>16 | 375        | 15. | Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Li Y, Feng X, Van F, Lau W, Brock KE: Prevalence,        |
| 17       | 376        |     | awareness, treatment and control of hypertension in Macau: results from a cross-sectional        |
| 18       | 377        |     | epidemiological study in Macau, China. Am J Hypertens 2015, 28(2):159-165.                       |
| 19       | 378        | 16. | Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease          |
| 20       | 379        |     | Working G: Prevalence, awareness, treatment, and control of hypertension in China: results       |
| 21       | 380        |     | from a national survey. Am J Hypertens 2014, 27(11):1355-1361.                                   |
| 22<br>23 | 381        | 17. | Yang G, Ma Y, Wang S, Su Y, Rao W, Fu Y, Yu Y, Kou C: Prevalence and Correlates of               |
| 24       | 382        |     | Prehypertension and Hypertension among Adults in Northeastern China: A Cross-Sectional           |
| 25       | 383        |     | Study. International journal of environmental research and public health 2015, 13(1):82.         |
| 26       | 384        | 18. | Li L, Rao K, Kong L, Yao C, Xiang H, Zhai F, Ma G, Yang X: A description on the Chinese          |
| 27       | 385        |     | national nutrition and health survey in 2002. Zhonghua liu xing bing xue za zhi= Zhonghua        |
| 28       | 386        |     | liuxingbingxue zazhi 2005, <b>26</b> (7):478-484.  |
| 29<br>30 | 387        | 19. | Crump C, Sundquist J, Winkleby MA, Sundquist K: Interactive Effects of Physical Fitness and      |
| 31       | 388        | -   | Body Mass Index on the Risk of Hypertension. JAMA internal medicine 2016,                        |
| 32       | 389        |     | <b>176</b> (2):210-216.  |
| 33       | 390        | 20. | Papathanasiou G, Zerva E, Zacharis I, Papandreou M, Papageorgiou E, Tzima C,                     |
| 34       | 391        | 20. | Georgakopoulos D, Evangelou A: Association of high blood pressure with body mass index,          |
| 35<br>36 | 392        |     | smoking and physical activity in healthy young adults. The open cardiovascular medicine          |
| 37       | 393        |     | journal 2015, <b>9</b> :5.   |
| 38       | 393<br>394 | 21. | Tyson CC, Appel LJ, Vollmer WM, Jerome GJ, Brantley PJ, Hollis JF, Stevens VJ, Ard JD, Patel UD, |
| 39       |            | 21. |  |
| 40       | 395        |     | Svetkey LP: Impact of 5 - year weight change on blood pressure: results from the Weight          |
| 41       | 396        |     | Loss Maintenance trial. The Journal of Clinical Hypertension 2013, <b>15</b> (7):458-464.        |
| 42<br>43 | 397        | 22. | Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new                 |
| 44       | 398        |     | insights into mechanisms. Hypertension 2005, <b>45</b> (1):9-14.                                 |
| 45       | 399        | 23. | Organization WH: The Asia-Pacific perspective: redefining obesity and its treatment. In.:        |
| 46       | 400        |     | Sydney: Health Communications Australia; 2000.   |
| 47       | 401        | 24. | Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, Shimono K, Yamane Y: The new BMI            |
| 48<br>49 | 402        |     | criteria for asians by the regional office for the western pacific region of WHO are suitable    |
| 49<br>50 | 403        |     | for screening of overweight to prevent metabolic syndrome in elder Japanese workers.             |
| 51       | 404        |     | Journal of occupational health 2003, <b>45</b> (6):335-343.                                      |
| 52       | 405        | 25. | Okosun IS, Prewitt TE, Cooper RS: Abdominal obesity in the United States: prevalence and         |
| 53       | 406        |     | attributable risk of hypertension. Journal of human hypertension 1999, 13(7):425-430.            |
| 54       | 407        | 26. | Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M: Abdominal          |
| 55<br>56 | 408        |     | obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. The           |
| 57       |            |     |  |
| 58       |            |     | 17   |
| 59       |            |     |  |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

| 1        |     |     |   |
|----------|-----|-----|---|
| 2<br>3   | 409 |     | American journal of medicine 2007, <b>120</b> (2):S3-S8.  |
| 4        | 410 | 27. | Yang L, Xu X, Yan J, Yu W, Tang X, Wu H, Parkin CL: Analysis on associated factors of                   |
| 5        | 411 |     | uncontrolled hypertension among elderly hypertensive patients in Southern China: a                      |
| 6        | 412 |     | community-based, cross-sectional survey. BMC public health 2014, <b>14</b> (1):903.                     |
| 7        | 413 | 28. | Yip W, Wong TY, Jonas JB, Zheng Y, Lamoureux EL, Nangia V, Sabanayagam C: <b>Prevalence</b> ,           |
| 8<br>9   |     | 28. |   |
| 9<br>10  | 414 |     | awareness, and control of hypertension among Asian Indians living in urban Singapore and                |
| 11       | 415 |     | rural India. Journal of hypertension 2013, <b>31</b> (8):1539-1546.                                     |
| 12       | 416 | 29. | Doulougou B, Gomez F, Alvarado B, Guerra RO, Ylli A, Guralnik J, Zunzunegui MV: Factors                 |
| 13       | 417 |     | associated with hypertension prevalence, awareness, treatment and control among                         |
| 14       | 418 |     | participants in the International Mobility in Aging Study (IMIAS). Journal of human                     |
| 15       | 419 |     | hypertension 2016, <b>30</b> (2):112-119.   |
| 16<br>17 | 420 | 30. | Cheng S, Xanthakis V, Sullivan LM, Vasan RS: Blood pressure tracking over the adult life                |
| 17<br>18 | 421 |     | course. Hypertension 2012:HYPERTENSIONAHA. 112.201780.  |
| 19       | 422 | 31. | Guo X, Zheng L, Li Y, Yu S, Zhou X, Wang R, Zhang X, Sun Z, Sun Y: Gender-specific prevalence           |
| 20       | 423 |     | and associated risk factors of prehypertension among rural children and adolescents in                  |
| 21       | 424 |     | Northeast China: a cross-sectional study. European journal of pediatrics 2013,                          |
| 22       | 425 |     | <b>172</b> (2):223-230.   |
| 23       | 426 | 32. | Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V: Prevalence of                    |
| 24       |     | 52. |   |
| 25<br>26 | 427 |     | hypertension and associated cardiovascular risk factors in Central India. Journal of family &           |
| 20<br>27 | 428 |     | community medicine 2014, <b>21</b> (1):29.  |
| 28       | 429 | 33. | Malekzadeh MM, Etemadi A, Kamangar F, Khademi H, Golozar A, Islami F, Pourshams A,                      |
| 29       | 430 |     | Poustchi H, Navabakhsh B, Naemi M: Prevalence, awareness and risk factors of hypertension               |
| 30       | 431 |     | in a large cohort of Iranian adult population. <i>Journal of hypertension</i> 2013, <b>31</b> (7):1364. |
| 31       | 432 | 34. | Heitmar R, Summers RJ: Assessing vascular function using dynamic retinal diameter                       |
| 32       | 433 |     | measurements: a new insight on the endothelium. Thromb Haemost 2012,                                    |
| 33<br>34 | 434 |     | <b>107</b> (6):1019-1026.   |
| 34<br>35 | 435 | 35. | Meng XJ, Dong GH, Wang D, Liu MM, Lin Q, Tian S, Xu LX, Hou H, Ren YF, Lee YL: Prevalence,              |
| 36       | 436 |     | awareness, treatment, control, and risk factors associated with hypertension in urban                   |
| 37       | 437 |     | adults from 33 communities of China: the CHPSNE study. J Hypertens 2011,                                |
| 38       | 438 |     | <b>29</b> (7):1303-1310.  |
| 39       | 439 | 36. | Pereira M, Lunet N, Azevedo A, Barros H: Differences in prevalence, awareness, treatment                |
| 40       | 440 | 50. |   |
| 41<br>42 |     |     | and control of hypertension between developing and developed countries. Journal of                      |
| 42<br>43 | 441 |     | hypertension 2009, <b>27</b> (5):963-975.   |
| 44       | 442 | 37. | Bowman TS, Gaziano JM, Buring JE, Sesso HD: A prospective study of cigarette smoking and                |
| 45       | 443 |     | risk of incident hypertension in women. Journal of the American College of Cardiology 2007,             |
| 46       | 444 |     | <b>50</b> (21):2085-2092.   |
| 47       | 445 | 38. | Stranges S, Wu T, Dorn JM, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH,                 |
| 48       | 446 |     | Trevisan M: Relationship of alcohol drinking pattern to risk of hypertension: a                         |
| 49<br>50 | 447 |     | population-based study. Hypertension 2004, 44(6):813-819.   |
| 50<br>51 | 448 | 39. | Grucza RA, Krueger RF, Racette SB, Norberg KE, Hipp PR, Bierut LJ: The emerging link                    |
| 52       | 449 |     | between alcoholism risk and obesity in the United States. Archives of general psychiatry                |
| 53       | 450 |     | 2010, <b>67</b> (12):1301-1308.   |
| 54       | 451 | 40. | Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Feng X, Van F, Leong S, Lau W, Lueng P: Modifiable risk         |
| 55       | 452 |     | factors including sunlight exposure and fish consumption are associated with risk of                    |
| 56       | 472 |     | inclusion including sumfine exposure and rish consumption are associated with risk of                   |
| 57       |     |     | 18  |
| 58<br>59 |     |     |   |
| 59<br>60 |     |     | For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml                               |

| 1        |     |  |
|----------|-----|--|
| 2<br>3   | 453 | hypertension in a large representative population from Macau. The Journal of steroid             |
| 4        | 454 | biochemistry and molecular biology 2014, <b>144</b> :152-155.                                    |
| 5        | 455 | 41. Shea JL, King MTC, Yi Y, Gulliver W, Sun G: Body fat percentage is associated with           |
| 6<br>7   | 456 | cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutrition,                  |
| 8        | 457 | Metabolism and Cardiovascular Diseases 2012, <b>22</b> (9):741-747.                              |
| 9        | 458 | 42. Weinsier RL, Norris DJ, Birch R, Bernstein RS, Wang J, Yang M-U, Pierson RN, Van Itallie TB: |
| 10       | 459 | The relative contribution of body fat and fat pattern to blood pressure level. Hypertension      |
| 11<br>12 | 460 | 1985, <b>7</b> (4):578-585.  |
| 13       | 461 | 43. Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I: Appropriate body-mass index for Asian   |
| 14       | 462 | populations and its implications for policy and intervention strategies. The lancet 2004,        |
| 15       | 463 | <b>363</b> (9403):157.   |
| 16<br>17 | 464 | 44. Wang W: Guidelines for the management of hypertension in China Chinese Journal of            |
| 18       | 465 | Hypertension 2015, <b>23</b> (1):24-43.  |
| 19       | 466 | 45. Wu Z, Yong H, Wang W, Zhao L, Zhu D: Guidelines for Hypertension Education in China.         |
| 20       | 467 | Chinese Journal of Hypertension 2014(3):78-110.  |
| 21<br>22 | 468 |  |
| 23       | 460 |  |
| 24       | 469 | Footnotes<br>Contributors  |
| 25<br>26 | 470 | Footnotes  |
| 20<br>27 | 471 | Contributors   |
| 28       | 471 |  |
| 29       | 472 | BL is involved in the design, JW, XS, LL, YY, YL, and CQ collected the data, YZ                  |
| 30<br>31 | 473 | and YL performed the statistical analysis, TL, WS, and BL wrote the paper. All                   |
| 32<br>33 | 474 | authors reviewed and approved the final version of the paper.                                    |
| 34       | 475 |  |
| 35<br>36 | 476 | Ethics approval  |
| 37       |     |  |
| 38<br>39 | 477 | This study was approved by the Fuwai Hospital Ethics Review Board.                               |
| 40       | 478 |  |
| 41       | 479 | Funding  |
| 42<br>43 | 4/9 |  |
| 44       | 480 | This work was supported by the National Key R&D Program in the Twelfth                           |
| 45       | 481 | Five-year Plan (No. 2011BAI11B01) from the Chinese Ministry of Science and                       |
| 46<br>47 |     |  |
| 48       | 482 | Technology and the National Clinical Key Specialty Project.                                      |
| 49       | 483 |  |
| 50<br>51 | 404 | Composing interests  |
| 51<br>52 | 484 | Competing interests  |
| 53       | 485 | None declared.   |
| 54       | 486 |  |
| 55<br>56 |     |  |
| 50<br>57 | 487 | Data sharing statement   |
| 58       |     | 19   |
| 59<br>60 |     | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                        |
| 60       |     | For peer review only - http://binjopen.binj.com/site/about/guidelines.xhtml                      |

| 1<br>2<br>3<br>4<br>5   | 488 | No additional data are available.   |   |
|---|-----|---|---|
| 5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25 |     |   | Protected by copyright, including for uses related                      |
| 26<br>27<br>28<br>29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41<br>42<br>43<br>44        |     |   | related to text and data mining, Al training, and similar technologies. |
| 45<br>46<br>47<br>48<br>49<br>50<br>51<br>52<br>53<br>54<br>55<br>56<br>57<br>58<br>59<br>60                          |     | 20<br>For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | technologies.   |

Page 21 of 43

# 489 Figure Captions

| 490 | Figure 1: Trends of physical characteristics by age and sex. (A) basal metabolism BM |
|-----|--|
| 491 | (B) body fat percentage - BFP (C) visceral fat index - VFI (D) body mass index - BMI |
| 492 | (E) systolic blood pressure - SBP (F) diastolic blood pressure - DBP                 |

**Table 1:** Distribution of participants by age and sex in Jilin province (N, %)

| Δαρ   | Ma   | ale   | Fen  | nale  | То    | Total |  |
|-------|------|-------|------|-------|-------|-------|--|
| Age   | Ν    | %     | Ν    | %     | Ν     | %     |  |
| 15-24 | 1120 | 9.07  | 1146 | 8.51  | 2266  | 17.59 |  |
| 25-34 | 1316 | 8.91  | 1520 | 8.52  | 2836  | 17.43 |  |
| 35-44 | 1084 | 11.95 | 1359 | 11.40 | 2443  | 23.35 |  |
| 45-54 | 1043 | 10.02 | 1333 | 9.68  | 2376  | 19.70 |  |
| 55-64 | 950  | 6.36  | 1121 | 6.47  | 2071  | 12.83 |  |
| 65-74 | 755  | 3.01  | 823  | 3.23  | 1578  | 6.24  |  |
| 75+   | 678  | 1.31  | 708  | 1.55  | 1386  | 2.86  |  |
| Total | 6946 | 50.63 | 8010 | 49.37 | 14956 | 100.0 |  |
|       |      |       |      |       |       |       |  |
|       |      |       |      |       |       |       |  |

| 1        |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 14<br>15 |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 30<br>31 |  |
| 31<br>32 |  |
|          |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 40       |  |

47

1

|        |               | BN            | /II           |              |               | Alcohol Drinking |               |                |
|--------|---------------|---------------|---------------|--------------|---------------|------------------|---------------|----------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0        | Current       | Ever             | Never         |                |
| Male   |               |               |               |              |               |                  |               |                |
| 15-24  | 13.33         | 67.57         | 14.85         | 4.25         | 6.95          | 0.36             | 92.69         | 5.80           |
|        | (11.11,15.91) | (64.24,70.73) | (12.58,17.46) | (3.03,5.93)  | (5.47,8.80)   | (0.10,1.22)      | (90.79,94.22) | (4.62, 7.26)   |
| 25-34  | 2.80          | 57.76         | 31.36         | 8.08         | 39.19         | 0.64             | 60.17         | 29.70          |
|        | (1.98,3.93)   | (54.70,60.77) | (28.57,34.30) | (6.52,9.96)  | (36.20,42.26) | (0.30,1.37)      | (57.09,63.17) | (26.96, 32.60) |
| 35-44  | 1.89          | 54.86         | 35.26         | 7.99         | 46.92         | 1.32             | 51.76         | 39.90          |
|        | (0.18,3.01)   | (51.49,58.18) | (32.10,38.55) | (6.35,10.02) | (43.57,50.30) | (0.79,2.18)      | (48.39,55.12) | (36.62, 43.26) |
| 45-54  | 1.56          | 55.63         | 36.25         | 6.56         | 48.42         | 3.19             | 48.38         | 44.70          |
|        | (0.93,2.60)   | (52.33,58.88) | (33.14,39.47) | (5.11,8.39)  | (45.13,51.73) | (2.25,4.52)      | (45.10,51.68) | (41.44, 48.00) |
| 55-64  | 0.79          | 59.10         | 35.17         | 4.94         | 44.79         | 5.19             | 50.02         | 39.30          |
|        | (0.39,1.60)   | (55.67,62.44) | (31.96,38.52) | (3.65,6.66)  | (41.38,48.25) | (3.88,6.91)      | (46.57,53.47) | (35.99, 42.71) |
| 65-74  | 2.16          | 60.45         | 33.51         | 3.88         | 32.13         | 6.99             | 60.88         | 34.30          |
|        | (1.26,3.69)   | (56.54,64.22) | (29.91,37.33) | (2.66,5.62)  | (28.57,35.91) | (5.22,9.30)      | (56.97,64.65) | (30.65, 38.14) |
| 75+    | 3.71          | 62.83         | 30.22         | 3.23         | 22.06         | 5.58             | 72.35         | 18.74          |
|        | (2.53,5.42)   | (58.82,66.68) | (26.61,34.10) | (2.01,5.15)  | (18.85,25.64) | (3.96,7.82)      | (68.54,75.87) | (15.72, 22.19) |
| Female |               |               |               |              |               |                  |               |                |
| 15-24  | 13.46         | 70.77         | 12.55         | 3.22         | 0.36          | 0.00             | 99.64         | 0.76           |
|        | (11.24,16.03) | (67.48,73.85) | (10.34,15.16) | (2.34,4.43)  | (0.11,1.16)   |                  | (98.84,99.89) | (0.43,1.35)    |
| 25-34  | 6.46          | 66.10         | 22.33         | 5.11         | 2.90          | 0.06             | 97.04         | 3.50           |
|        | (5.25,7.94)   | (63.37,68.72) | (20.06,24.79) | (3.97,6.55)  | (2.05,4.08)   | (0.01,0.44)      | (95.85,97.89) | (2.65,4.62)    |
| 35-44  | 1.81          | 61.59         | 29.86         | 6.74         | 8.00          | 0.07             | 91.93         | 4.40           |
|        | (1.16,2.81)   | (58.64,64.45) | (27.18,32.67) | (5.38,8.41)  | (6.45,9.88)   | (0.01,0.50)      | (90.05,93.49) | (3.37,5.73)    |

Table 2: Distribution of participants by age and sex stratified by body mass index, smoking and alcoholic drinking in Jilin province (%, 95%CI) 496

22

| ruge 25 of 15 |       |              |               |               | bins op      |               |             |
|---------------|-------|--------------|---------------|---------------|--------------|---------------|-------------|
|               |       |              |               |               |              |               |             |
| 1             |       |              |               |               |              |               |             |
| 2             |       |              |               |               |              |               |             |
| 3             |       |              |               |               |              |               |             |
| 4             |       |              |               |               |              |               |             |
| 5<br>6        |       |              |               |               |              |               |             |
| 7             | 45-54 | 1.99         | 54.20         | 36.38         | 7.44         | 10.36         | 0.52        |
| 8             |       | (1.29,3.04)  | (51.27,57.09) | (33.62,39.24) | (6.05,9.11)  | (8.69,12.31)  | (0.23,1.17) |
| 9             | 55-64 | 2.53         | 48.89         | 40.24         | 8.34         | 16.81         | 1.46        |
| 10            |       | (1.72,3.71)  | (45.72,52.08) | (37.17,43.39) | (6.72,10.30) | (14.58,19.30) | (0.85,2.49) |
| 11            | 65-74 | 4.89         | 50.05         | 38.50         | 6.57         | 17.61         | 1.68        |
| 12<br>13      |       | (3.53,6.72)  | (46.31,53.78) | (34.91,42.22) | (4.94,8.67)  | (14.97,20.60) | (0.93,2.99) |
| 14            | 75+   | 10.17        | 57.46         | 26.17         | 6.20         | 12.82         | 1.27        |
| 15            |       | (7.87,13.04) | (53.37,61.45) | (22.77,29.89) | (4.50,8.50)  | (10.29,15.87) | (0.64,2.50) |
| 16            |       | ()           | ()            | (,)           | (            | (,,           | (,)         |
| 17            |       |              |               |               |              |               |             |
| 18            |       |              |               |               |              |               |             |
| 19<br>20      |       |              |               |               |              |               |             |
| 20            |       |              |               |               |              |               |             |
| 22            |       |              |               |               |              |               |             |
| 23            |       |              |               |               |              |               |             |
| 24            |       |              |               |               |              |               |             |
| 25            |       |              |               |               |              |               |             |
| 26<br>27      |       |              |               |               |              |               |             |
| 28            |       |              |               |               |              |               |             |
| 29            |       |              |               |               |              |               |             |
| 30            |       |              |               |               |              |               |             |
| 31            |       |              |               |               |              |               |             |
| 32            |       |              |               |               |              |               |             |
| 33<br>34      |       |              |               |               |              |               |             |
| 34<br>35      |       |              |               |               |              |               |             |
| 36            |       |              |               |               |              |               |             |
| 37            |       |              |               |               |              |               |             |
|               |       |              |               |               |              |               |             |

Page 23 of 43

38 39 40

45 46 47

**BMJ** Open

89.12

(87.14,90.83)

81.73

(79.16,84.05)

80.71 (77.62,83.47)

85.91

(82.77,88.55)

3.08

(2.23, 4.25)

2.53

(1.68,3.81) 1.81

(1.03, 3.16)

2.48

(1.45, 4.23)

6

8 

|     | Age       |           | Male               |      | Female             |      | Total      |
|-----|-----------|-----------|--------------------|------|--------------------|------|------------|
|     | group     | n         | CR(95%CI)          | n    | CR(95%CI)          | n    | CR(959     |
| -   | 15-24     | 80        | 6.86(5.27,8.87)    | 23   | 1.88(1.19,2.96)    | 103  | 4.45(3.5   |
|     | 25-34     | 106       | 8.47(6.89,10.36)   | 50   | 4.28(3.20,5.69)    | 156  | 6.42(5.4   |
|     | 35-44     | 221       | 21.00(18.36,23.91) | 195  | 15.21(13.14,17.55) | 416  | 18.17(16.4 |
|     | 45-54     | 379       | 35.13(32.06,38.33) | 430  | 32.57(29.89,35.36) | 809  | 33.87(31.8 |
|     | 55-64     | 449       | 46.42(43.00,49.87) | 576  | 50.72(47.54,53.90) | 1025 | 48.59(46.2 |
|     | 65-74     | 451       | 59.91(55.98,63.71) | 518  | 65.32(61.72,68.76) | 969  | 62.71(60.0 |
|     | 75+       | 405       | 61.24(57.24,65.10) | 449  | 62.37(58.30,66.28) | 854  | 61.86(59.0 |
|     | Total     | 2091      | 25.60(24.41,26.79) | 2241 | 23.84(22.80,24.89) | 4332 | 24.73(23.9 |
| 498 | CI: confi | idence in | nterval            |      |                    |      |            |
| 499 |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           | nterval            |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |
|     |           |           |                    |      |                    |      |            |

Page 25 of 43

1

**BMJ** Open

| י<br>ר   |   |
|--|---|
| 2<br>3   |   |
| 4  |   |
| 5  |   |
| 6  |   |
| 7  | 5 |
| 8  |   |
| 9  |   |
| 10   |   |
| 11   |   |
| 12   |   |
| 12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20 |   |
| 14   |   |
| 16   |   |
| 17   |   |
| 18   |   |
| 19   |   |
| 20   |   |
| 21   |   |
| 22   |   |
| 23   |   |
| 24   |   |
| 25<br>26   |   |
| 20<br>27   |   |
| 28   |   |
| 29   |   |
| 30   |   |
| 30<br>31<br>32<br>33<br>34                         |   |
| 32   |   |
| 33   |   |
| 34   |   |
| 35   |   |
| 36   |   |
| 37<br>38   |   |
| 30<br>39   |   |
| 40   |   |
| 41   |   |
| 42   |   |
| 43   |   |
| 44   |   |
| 45   |   |
| 46   | ŧ |
|  |   |

47

|        |               | Bl            | II            |               |               | Smoking         | Alcohol Drinking |                |                |
|--------|---------------|---------------|---------------|---------------|---------------|-----------------|------------------|----------------|----------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0         | Current       | Ever            | Never            | Yes            | No             |
| Male   |               |               |               |               |               |                 |                  |                |                |
| 15-24  | 1.48          | 4.39          | 16.22         | 30.17         | 8.17          | 13.13           | 6.73             | 11.60          | 6.56           |
|        | (0.37,5.76)   | (2.94,6.51)   | (10.62,24.00) | (16.58,48.44) | (3.45,18.15)  | (1.35,62.57)    | (5.10,8.84)      | (5.85,21.69)   | (4.95, 8.66)   |
| 25-34  | 1.45          | 5.33          | 9.15          | 30.70         | 11.49         | 6.89            | 6.51             | 10.64          | 7.55           |
|        | (0.20,9.72)   | (3.78,7.46)   | (6.43,12.85)  | (21.42,41.86) | (8.66,15.08)  | (0.88,38.13)    | (4.80,8.78)      | (7.63, 14.64)  | (5.80, 9.77)   |
| 35-44  | 5.49          | 14.76         | 25.87         | 45.98         | 23.76         | 36.23           | 18.11            | 28.02          | 16.34          |
|        | (0.97,25.57)  | (11.77,18.34) | (21.16,31.22) | (34.53,57.87) | (19.72,28.33) | (16.51,62.01)   | (14.77,22.00)    | (23.40, 33.16) | (13.35,19.84)  |
| 45-54  | 27.39         | 25.02         | 44.90         | 68.73         | 37.10         | 41.53           | 32.74            | 43.01          | 28.76          |
|        | (10.96,53.63) | (21.38,29.05) | (39.57,50.35) | (55.83,79.27) | (32.60,41.83) | (25.83,59.16)   | (28.51,37.27)    | (38.20, 47.96) | (24.95, 32.91) |
| 55-64  | 11.46         | 39.64         | 55.87         | 65.91         | 47.15         | 61.46           | 44.21            | 52.10          | 42.74          |
|        | (2.44,40.14)  | (35.33,44.11) | (50.07,79.30) | (50.62,78.48) | (42.04,52.33) | (46.39,74.61)   | (39.43,49.09)    | (46.61, 57.54) | (38.42, 47.18) |
| 65-74  | 19.58         | 52.27         | 73.86         | 80.86         | 60.60         | 74.69           | 57.84            | 66.86          | 56.58          |
|        | (6.35,46.63)  | (47.16,57.34) | (67.56,15.96) | (61.30,91.85) | (53.60,67.20) | (59.79,85.42)   | (52.78,62.74)    | (60.21, 72.89) | (51.40, 61.04) |
| 75+    | 37.87         | 58.85         | 66.71         | 83.47         | 68.66         | 59.10           | 59.15            | 65.17          | 60.34          |
|        | (21.57,57.45) | (53.77,63.76) | (59.34,73.34) | (57.75,94.91) | (60.13,76.08) | (41.42,74.69)   | (54.42,63.71)    | (55.63, 73.63) | (55.90, 64.62) |
| Female |               |               |               |               |               |                 |                  |                |                |
| 15-24  | 1.50          | 0.91          | 5.62          | 10.02         | 0.00          | 0.00            | 1.88             | 0.00           | 1.89           |
|        | (0.37,5.81)   | (0.42,1.98)   | (2.53,12.01)  | (3.85,23.67)  |               |                 | (1.19,2.97)      |                | (1.19,2.98)    |
| 25-34  | 0.00          | 2.16          | 6.56          | 27.09         | 12.35         | 0.00            | 4.04             | 0.66           | 4.41           |
|        |               | (1.29,3.59)   | (4.03,10.51)  | (16.97,40.31) | (4.36,30.33)  |                 | (2.98,5.44)      | (0.09,4.63)    | (3.29,5.87)    |
| 35-44  | 17.78         | 9.70          | 22.05         | 34.59         | 19.76         | 100.00          | 14.75            | 25.47          | 14.74          |
|        | (5.86,42.90)  | (7.67,12.20)  | (17.69,27.14) | (24.35,46.49) | (12.41,29.97) | (100.00,100.00) | (12.62,17.17)    | (14.99,39.84)  | (12.65,17.11   |

Table 4 Prevalence of hypertension by age and say stratified by body mass index, smoking and alcoholic drinking (%, 95% CD) 500

25

34.92

61.78

32.13

27.45

32.73

 45-54

0.00

24.68

40.48

60.03

|       |               |               |               | 00.00         | 0.1.7         | 01170           | 02.10         | _/e           | 00        |
|-------|---------------|---------------|---------------|---------------|---------------|-----------------|---------------|---------------|-----------|
|       |               |               | (35.84,45.30) | (49.33,69.86) | (26.73,44.12) | (22.45,90.03)   | (29.31,35.08) | (15.31,44.19) | (30.01,35 |
| 55-64 | 40.61         | 39.07         | 61.42         | 70.47         | 51.28         | 62.47           | 50.40         | 51.62         | 50.70     |
|       | (23.68,60.12) | (34.71,43.61) | (56.48,66.14) | (59.27,79.64) | (43.64,58.86) | (35.28,83.56)   | (46.87,53.92) | (31.60,71.13) | (47.48,53 |
| 65-74 | 38.58         | 59.74         | 74.83         | 72.04         | 65.26         | 57.48           | 65.50         | 50.45         | 65.60     |
|       | (24.16,55.33) | (54.53,64.73) | (69.27,79.68) | (57.14,83.28) | (56.45,73.13) | (29.24,81.56)   | (61.48,69.31) | (24.78,75.88) | (61.97,69 |
| 75+   | 45.30         | 60.64         | 73.24         | 60.53         | 64.01         | 100.00          | 61.57         | 51.72         | 62.64     |
|       | (32.73,58.49) | (55.25,65.79) | (65.79,79.57) | (43.53,75.31) | (52.10,74.41) | (100.00,100.00) | (57.18,65.79) | (26.49,76.10) | (58.53,66 |
|       |               |               |               |               |               |                 |               |               |           |


BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright,אַשָּפּוּקוּשָׁאָשָׁאַפּאַלפּשַלַסְנָפּאַלָּפָאַלָּפָאַלָסָנפּאַלפּאַלָּאָאָשָאַמָלָפָאַ

|     |   | Hypertensio                           | n prevalence          |
|-----|---|---------------------------------------|-----------------------|
|     |   | Unadjusted                            | Adjusted              |
|     | Age(Ref: 15-24)                                   |                                       |                       |
|     | 25-34   | 1.47(1.09,1.99)                       | 1.05(0.71,1.55)       |
|     | 35-44   | 4.77(3.65,6.24)                       | 2.83(1.90,4.22)       |
|     | 45-54   | 11.01(8.51,14.24)                     | 6.93(4.69,10.24)      |
|     | 55-64   | 20.31(15.69,26.29)                    | 13.43(9.06,19.90)     |
|     | 65-74   | 36.14(27.73,47.11)                    | 26.18(17.56,39.03)    |
|     | 75+   | 34.85(26.65,45.57)                    | 29.89(19.83,45.03)    |
|     | Sex(Ref: female)                                  | 1.1(1.01,1.2)                         | 1.25(1.13,1.39)       |
|     | Region(Ref: Urban)                                | 1.19(1.09,1.3)                        | 1.25(1.12,1.39)       |
|     | Race(Ref: Han)                                    | 1.15(0.93,1.42)                       | 0.93(0.74,1.18)       |
|     | Employment(Ref: be employed)                      | 1.15(0.95,1.42)                       | 0.99(0.74,1.10)       |
|     | Retired   | 2.67(2.22,3.2)                        | 0.67(0.53,0.85)       |
|     |   |                                       |                       |
|     | Student   | 0.15(0.11,0.21)                       | 1.09(0.71,1.70)       |
|     | Unemployed  | 1.18(1.07,1.3)                        | 0.84(0.74,0.95)       |
|     | Marital(Ref: married)                             | 0.72(0.63,0.83)                       | 1.29(1.00,1.65)       |
|     | Education level(Ref: college or higher)           |                                       |                       |
|     | Illiterate  | 6.69(5.19,8.63)                       | 2.18(1.62,2.93)       |
|     | Primary   | 3.26(2.7,3.93)                        | 1.98(1.60,2.44)       |
|     | Middle  | 1.55(1.24,1.94)                       | 1.24(0.97,1.57)       |
|     | BMI(Ref: Normal)                                  |                                       |                       |
|     | Overweight  | 2.22(2.01,2.46)                       | 2.30(2.06,2.57)       |
|     | Obese   | 3.96(3.31,4.75)                       | 5.17(4.20,6.37)       |
|     | AWC(Ref:<90M,<85F)                                |                                       |                       |
|     | ≥90M, ≥85F  | 1.41(1.23,1.62)                       | 1.35(1.16,1.57)       |
|     | ≥95M, ≥90F  | 1.5(1.32,1.72)                        | 1.68(1.43,1.96)       |
|     | Family history of hypertension                    | 1.74(1.55,1.96)                       | 2.35(2.06,2.67)       |
|     | Family history of stroke                          | 1.33(0.85,2.06)                       | 1.79(1.09,2.92)       |
|     | Family history of CAD                             | 3.18(2.64,3.83)                       | 1.65(1.33,2.03)       |
|     | Smoker(Ref: no)                                   | 1.37(1.23,1.53)                       | 1.23(1.08,1.40)       |
|     | Drinker(Ref: no)                                  | 1.56(1.38,1.77)                       | 1.47(1.27,1.71)       |
|     | VAI (Ref:<10)                                     |                                       |                       |
|     | 10~14   | 1.6(1.41,1.8)                         | 1.40(1.22,1.60)       |
|     | 15~30   | 2.69(2.29,3.16)                       | 2.05(1.69,2.49)       |
|     | BFP(Ref: $<10M$ , $<20F$ )                        | 2.03 (2.23,0.10)                      | 2.00(1.0),2.1))       |
|     | 10~19M, 20~29F                                    | 1.31(1,1.71)                          | 0.95(0.71,1.27)       |
|     | 20~24M, 30~34F                                    | 2.72(2.09,3.55)                       | 1.24(0.92,1.66)       |
|     | $\geq 25M$ , $\geq 35F$                           | 3.48(2.67,4.54)                       | 1.45(1.07,1.96)       |
| 502 |   | · · · · · · · · · · · · · · · · · · · |                       |
| 502 | CI: confidence interval; BMI: body mass inde      |                                       |                       |
| 503 | coronary heart disease; M: male; F: female; VAI   |                                       |                       |
| 504 | Adjusted for sex, region, age, education level, e | mpioyment status, ma                  | irnai status, BMI, an |

Page 28 of 43

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open



|            |  |                | y age and sex in Jili<br>Male | 1              | Female              |
|------------|--|----------------|-------------------------------|----------------|---------------------|
|            | Age  | Maan           | 95%CI                         | Mean           |                     |
| D) (       | - The second sec | Mean           |                               |                | 95%CI               |
| BM         | Total  | 1511.50        | (1504.56,                     | 1280.52        | (1276.09, 1284.9    |
|            | 15.04  | 1 450 00       | 1518.43)                      | 1070.01        | (12 ( 1 00 1 20 1 5 |
|            | 15-24  | 1478.92        | (1456.95,                     | 1279.31        | (1264.09, 1294.5)   |
|            |  | 1 500 00       | 1500.88)                      | 1001 44        |                     |
|            | 25-34  | 1538.93        | (1524.04,                     | 1281.66        | (1272.68,1290.64    |
|            |  |                | 1553.81)                      |                |                     |
|            | 35-44  | 1534.48        | (1519.02,                     | 1293.35        | (1284.03, 1302.6    |
|            |  |                | 1549.95)                      |                |                     |
|            | 45-54  | 1528.84        | (1514.65,                     | 1293.81        | (1284.74, 1302.8    |
|            |  |                | 1543.02)                      |                |                     |
|            | 55-64  | 1499.65        | (1486.40,                     | 1274.36        | (1264.67, 1284.0    |
|            |  |                | 1512.90)                      |                |                     |
|            | 65-74  | 1460.36        | (1443.82,                     | 1241.86        | (1230.00, 1253.7)   |
|            |  |                | 1476.89)                      |                |                     |
|            | 75+  | 1382.81        | (1367.17,                     | 1209.84        | (1195.08, 1224.5    |
|            |  |                | 1398.45)                      |                |                     |
| Body Fat   | Total  | 23.28          | (23.03, 23.53)                | 29.19          | (29.02, 29.35)      |
| percentage |  |                |                               |                |                     |
|            | 15-24  | 18.46          | (17.52, 19.40)                | 24.78          | (24.38, 25.18)      |
|            | 25-34  | 23.26          | (22.87, 23.65)                | 27.20          | (26.88,27.52)       |
|            | 35-44  | 24.02          | (23.64, 24.40)                | 29.19          | (28.86, 29.52)      |
|            | 45-54  | 24.09          | (23.76, 24.41)                | 30.95          | (30.61, 31.29)      |
|            | 55-64  | 25.34          | (24.58, 26.10)                | 32.39          | (31.99, 32.80)      |
|            | 65-74  | 25.74          | (25.30, 26.17)                | 32.97          | (32.46, 33.48)      |
|            | 75+  | 28.31          | (27.06, 29.56)                | 32.08          | (31.15, 33.00)      |
| VAI        | Total  | 9.63           | (9.49, 9.77)                  | 7.42           | (7.29, 7.55)        |
|            | 15-24  | 6.81           | (6.54, 7.08)                  | 6.48           | (6.05, 6.91)        |
|            | 25-34  | 9.13           | (8.81, 9.46)                  | 6.07           | (5.83, 6.30)        |
|            | 35-44  | 10.01          | (9.70, 10.32)                 | 7.25           | (6.96, 7.54)        |
|            | 45-54  | 10.71          | (10.39, 11.03)                | 7.90           | (7.68, 8.11)        |
|            | 55-64  | 11.06          | (10.74, 11.37)                | 8.71           | (8.47, 8.96)        |
|            | 65-74  | 11.11          | (10.72, 11.49)                | 9.27           | (8.81, 9.73)        |
|            | 75+  | 10.64          | (10.21, 11.07)                | 8.95           | (8.56, 9.35)        |
| BMI        | Total  | 24.15          | (24.05,24.25)                 | 23.88          | (23.78,23.97)       |
|            | 15-24  | 22.20          | (21.93,22.47)                 | 21.86          | (21.63,22.10)       |
|            | 25-34  | 24.41          | (24.18,24.63)                 | 23.20          | (22.99,23.42)       |
|            | 35-44  | 24.78          | (24.55,25.01)                 | 23.20          | (24.08,24.51)       |
|            | 45-54  | 24.78<br>24.75 | (24.53,25.01)                 | 24.29<br>24.82 | (24.63,25.02)       |
|            | 43-34<br>55-64   | 24.73<br>24.54 | (24.33,24.76)                 | 24.82<br>24.96 | (24.74,25.18)       |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.


| Page | 30 | of | 43 |
|------|----|----|----|
|------|----|----|----|


|     | 65-74 | 24.14  | (23.88,24.40)   | 24.63  | (24.35,24.92)   |
|-----|-------|--------|-----------------|--------|-----------------|
|     | 75+   | 23.63  | (23.37,23.89)   | 23.56  | (23.24,23.88)   |
| SBP | Total | 130.44 | (129.99,130.88) | 127.36 | (126.90,127.81) |
|     | 15-24 | 122.45 | (121.67,123.24) | 116.81 | (116.13,117.50) |
|     | 25-34 | 124.43 | (123.77,125.08) | 117.93 | (117.28,118.58) |
|     | 35-44 | 128.76 | (127.85,129.67) | 123.85 | (122.95,124.75) |
|     | 45-54 | 134.69 | (133.51,135.87) | 132.39 | (131.28,133.49) |
|     | 55-64 | 137.56 | (136.22,138.91) | 139.53 | (138.17,140.90) |
|     | 65-74 | 143.98 | (142.25,145.71) | 145.16 | (143.55,146.76) |
|     | 75+   | 143.69 | (141.96,145.42) | 143.44 | (141.60,145.28) |
| DBP | Total | 78.14  | (77.84,78.43)   | 75.45  | (75.19,75.71)   |
|     | 15-24 | 70.98  | (70.43,71.53)   | 69.35  | (68.82,69.88)   |
|     | 25-34 | 76.13  | (75.63,76.63)   | 72.69  | (72.25,73.13)   |
|     | 35-44 | 79.04  | (78.42,79.66)   | 75.47  | (74.91,76.03)   |
|     | 45-54 | 81.24  | (80.51,81.96)   | 78.41  | (77.79,79.03)   |
|     | 55-64 | 82.50  | (81.67,83.33)   | 79.87  | (79.15,80.60)   |
|     | 65-74 | 81.56  | (80.72,82.40)   | 79.13  | (78.35,79.91)   |
|     | 75+   | 80.38  | (79.61,81.15)   | 79.26  | (78.41,80.11)   |

CI: confidence interval

80.38 (79.61,81.15) 79.26 (78.41,80.11)


|  | ì市  | 区/县   | 居/村委会   | ID 号:  |   |
|--|---|---|---|--|---|
| A2 姓名: _   |   |   |   | A3 性别: 1=  | 男 2=女 🗌   |
| A4 出生日   | 期:  |   |   | ——————————————————————————————————————   | □月□□日   |
| A5 身份证   | 号:  |   |   |  |   |
| A6 工作单   | 位(或村)及  | 部门:   |   |  |   |
| A7 家庭详   | 细住址:  |   |   |  |   |
| A8 电话:   |   | (家)   | ( <i>ī</i>  | 办公室)   | (手机)  |
| A9 联系人   | 姓名:   |   | A10   | ) 与本人关系:   |   |
| A11 联系人  | 工作单位:_  | _   |   |  |   |
| A12 联系人  | 、住址:  | -   |   |  |   |
| A13 联系人  | 、电话:  | 10  | _(家)  | (办公室)  | (手机)  |
| A14 民族:  |   |   |   |  |   |
| 1 汉族   | 2蒙古族  | 3回族 4 新   | <b>蔵族 5</b> 维吾尔族  | <b>6</b> 苗族 7 彝族   | 8 壮族  |
|  | 医 10 西磁波  |   |   |  |   |
| 9 布依於  | 大 10 朝軒族  | 11 满族 12  | 2 侗族 13 瑶族  | 14 白族 15 土家游   | 矢 16 哈尼族  |
|  |   |   |   | 14 白族     15 土家彦       〔注明〕  | 5 16 哈尼族  |
| 17 哈萨  | 克族 18 傣   | 族 19黎族  | 20 其它民族(  |  |   |
| 17 哈萨<br>A15 文化程   | 克族 18 傣<br>程度: 1=未上   | 族 19 黎族<br>二学 2=小学 3  | 20 其它民族(  | (注明)<br>专 5=大学 6=研究生   | 失 16 哈尼族  |
| 17 哈萨<br>A15 文化程<br>A16 婚姻状  | 克族 18 傣<br>星度: 1=未上<br>代况: 0=未タ   | 族 19 黎族<br>:学 2=小学 3<br>婚 1=已婚/再9   | 20 其它民族 (<br>=初中 4=高中/中<br>碈/同居 2=分居 3  | (注明)<br>专 5=大学 6=研究生   | 失 16 哈尼族  |
| 17 哈萨<br>A15 文化程<br>A16 婚姻为<br>A17 所享受   | 克族 18 傣<br>星度: 1=未上<br>代况: 0=未タ   | 族 19 黎族<br>:学 2=小学 3<br>婚 1=已婚/再<br>川度:(多选,   | 20 其它民族 (<br>=初中 4=高中/中<br>婚/同居 2=分居 3<br>有在方框中填 1,   | 〔注明)<br>专 5=大学 6=研究生<br>=离异 4=丧偶   | 失 16 哈尼族  |
| 17 哈萨<br>A15 文化種<br>A16 婚姻状<br>A17 所享受<br>1=城镇I  | 克族 18 傣<br>呈度: 1=未上<br>代况: 0=未<br>的医疗保障制  | 族 19 黎族<br>:学 2=小学 3<br>婚 1=已婚/再续<br>川度:(多选,  | 20 其它民族 (<br>=初中 4=高中/中<br>碈/同居 2=分居 3<br>有在方框中填 1,<br>合 🔲 3=城镇   | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>④</li> </ul>   | 失 16 哈尼族  |
| 17 哈萨<br>A15 文化種<br>A16 婚姻却<br>A17 所享受<br>1=城镇I<br>4=商业[   | 克族 18 傣<br>建度: 1=未上<br>代况: 0=未<br>的医疗保障制<br>职工医疗保险<br>医疗保险  | 族 19 黎族<br>:学 2=小学 3<br>婚 1=己婚/再<br>□ (多选,<br>□ 2=新农<br>□ 5=公费  | 20 其它民族 (<br>=初中 4=高中/中<br>碈/同居 2=分居 3<br>有在方框中填 1,<br>合 🔲 3=城镇   | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>眞居民医疗保险□</li> <li>Ц□</li> </ul>  | 失 16 哈尼族  |
| 17 哈萨<br>A15 文化種<br>A16 婚姻却<br>A17 所享受<br>1=城镇I<br>4=商业[<br>A18 就业状  | 克族 18 傣<br>程度: 1=未上<br>代况: 0=未<br>的医疗保障制<br>职工医疗保险<br>医疗保险<br>无疗保险  | 族 19 黎族<br>:学 2=小学 3<br>婚 1=己婚/再<br>□ (多选,<br>□ 2=新农<br>□ 5=公费  | 20 其它民族 (<br>=初中 4=高中/中<br>碈/同居 2=分居 3<br>有在方框中填 1,<br>合 3=城辑<br>医疗 6=其他<br>3=在校学生 4=   | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>眞居民医疗保险□</li> <li>Ц□</li> </ul>  | <ul> <li>失 16 哈尼族</li> <li>□</li> <li>□</li></ul> |
| 17 哈萨<br>A15 文化種<br>A16 婚姻状<br>A17 所享受<br>1=城镇I<br>4=商业[<br>A18 就业状<br>A19 职业(                                       | 克族 18 傣<br>建度: 1=未上<br>式况: 0=未対<br>的医疗保障制<br>职工医疗保险<br>医疗保险<br>流: 1=在业<br>当前,包括返                                | <ul> <li>族 19 黎族</li> <li>:学 2=小学 3</li> <li>婚 1=已婚/再好</li> <li>问度: (多选,</li> <li>□ 2=新农</li> <li>□ 5=公费</li> <li>2=离退休 3</li> <li>聘者当前职业</li> </ul>                              | 20 其它民族 (<br>=初中 4=高中/中<br>碈/同居 2=分居 3<br>有在方框中填 1,<br>合 3=城辑<br>医疗 6=其他<br>3=在校学生 4=   | <ul> <li>注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>每居民医疗保险□</li> <li>4</li> <li>□</li> <li>无业或失业</li> </ul>  |   |
| 17 哈萨<br>A15 文化種<br>A16 婚姻为<br>A17 所享受<br>1=城镇I<br>4=商业I<br>A18 就业状<br>A19 职业(<br>1=机关、                              | 克族 18 傣<br>建度: 1=未上<br>式况: 0=未対<br>的医疗保障制<br>职工医疗保险<br>医疗保险<br>流: 1=在业<br>当前,包括返                                | <ul> <li>族 19 黎族</li> <li>:学 2=小学 3</li> <li>婚 1=已婚/再经</li> <li>问度:(多选,</li> <li>□ 2=新农:</li> <li>□ 5=公费</li> <li>2=离退休 3</li> <li>聘者当前职业</li> <li>单位管理者</li> </ul>               | 20 其它民族 (<br>=初中 4=高中/中<br>婚/同居 2=分居 3<br>有在方框中填 1,<br>合 [] 3=城镇<br>医疗[] 6=其他<br>3=在校学生 4=  | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>④</li> <li>⑤</li> <li>④</li> <li>五业或失业</li> <li>▲</li> <li>3=一般办事人员</li> </ul>                             | □<br>□<br>和有关人员   |
| 17 哈萨<br>A15 文化種<br>A16 婚姻却<br>A17 所享受<br>1=城镇I<br>4=商业I<br>A18 就业状<br>A19 职业(<br>1=机关、<br>4=商业、                     | 克族 18 傣<br>建度: 1=未上<br>代况: 0=未禁<br>的医疗保障制<br>职工医疗保险<br>医疗保险<br>完況: 1=在业<br>当前,包括返<br>、企业、事业                     | <ul> <li>族 19 黎族</li> <li>:学 2=小学 3</li> <li>语 1=已婚/再約</li> <li>问度: (多选,)</li> <li>□ 2=新农:</li> <li>□ 5=公费</li> <li>2=离退休 3</li> <li>聘者当前职业</li> <li>单位管理者</li> </ul>             | 20 其它民族 (<br>=初中 4=高中/中<br>婚/同居 2=分居 3<br>有在方框中填 1,<br>合 3=城键<br>医疗 6=其他<br>3=在校学生 4=<br>2=专业技术人员<br>5=个体工商户                            | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>④</li> <li>④</li> <li>①</li> <li>无业或失业</li> <li>③</li> <li>3=一般办事人员</li> </ul>                             | □<br>□<br>和有关人员   |
| 17 哈萨<br>A15 文化種<br>A16 婚姻切<br>A17 所享受<br>1=城镇I<br>4=商业[<br>A18 就业状<br>A19 职业(<br>1=机关、<br>4=商业、<br>7=从事             | 克族 18 傣<br>建度: 1=未上<br>代况: 0=未刻<br>的医疗保障制<br>取工医疗保险<br>医疗保险<br>二次: 1=在业<br>当前,包括返<br>、企业、事业<br>、服务业人员<br>非农业劳动的 | <ul> <li>族 19 黎族</li> <li>注学 2=小学 3</li> <li>语 1=已婚/再刻</li> <li>问度: (多选,)</li> <li>□ 2=新农:</li> <li>□ 5=公费</li> <li>2=离退休 3</li> <li>聘者当前职业</li> <li>单位管理者</li> <li>农民</li> </ul> | 20 其它民族 (<br>=初中 4=高中/中<br>婚/同居 2=分居 3<br>有在方框中填 1,<br>合 3=城镇<br>医疗 6=其他<br>3=在校学生 4=<br>2)<br>2=专业技术人员<br>5=个体工商户<br>8=农业劳动者           | <ul> <li>注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>每居民医疗保险□</li> <li>4</li> <li>□</li> <li>无业或失业</li> <li>3=一般办事人员:</li> <li>6=非农户产业人</li> </ul>               | □<br>□<br>和有关人员<br>员<br>9=其他  |
| 17 哈萨<br>A15 文化種<br>A16 婚姻切<br>A17 所享受<br>1=城镇耳<br>4=商业[<br>A18 就业状<br>A19 职业(<br>1=机关、<br>4=商业、<br>7=从事<br>A19.1 如已 | 克族 18 傣<br>星度: 1=未上<br>代况: 0=未结<br>的医疗保障障<br>职工医疗保险<br>医疗保险<br>法的 1=在业<br>当前,包括返<br>、服务业人员<br>非农业劳动的<br>离退休,离退  | <ul> <li>族 19 黎族</li> <li>注学 2=小学 3</li> <li>语 1=已婚/再刻</li> <li>问度: (多选,)</li> <li>□ 2=新农:</li> <li>□ 5=公费</li> <li>2=离退休 3</li> <li>聘者当前职业</li> <li>单位管理者</li> <li>农民</li> </ul> | 20 其它民族 (<br>=初中 4=高中/中<br>婚/同居 2=分居 3<br>有在方框中填 1,<br>合 □ 3=城镇<br>医疗□ 6=其他<br>3=在校学生 4=<br>2=专业技术人员<br>5=个体工商户<br>8=农业劳动者 (<br>关同上,未退休 | <ul> <li>(注明)</li> <li>专 5=大学 6=研究生</li> <li>=离异 4=丧偶</li> <li>无在方框中填 0)</li> <li>④</li> <li>④</li> <li>①</li> <li>无业或失业</li> <li>3=一般办事人员:</li> <li>6=非农户产业人</li> <li>(从事农林牧渔工作)</li> </ul> | □<br>□<br>和有关人员<br>员<br>9=其他  |





国家心血管病中心 中国医学科学院阜外心血管病医院 version 201200628 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open



B2.7 您饮酒的种类和饮酒量(当前饮酒者填当前情况,当前不饮酒者填既往情况):

|                   | 饮用频度*   | 次数**   | 平均每次饮用量       | 月数/年  | 酒精度 |
|-------------------|---------|--------|---------------|-------|-----|
| B2.7.1 啤酒         |         |        | , □, □, ſ, ſ, |       |     |
| B2.7.2 白酒         |         |        | 两             |       |     |
| B2.7.3 葡萄酒        |         |        | 两             |       |     |
| B2.7.4 黄酒         |         |        | 两             |       |     |
| B2.7.5 米酒         |         |        | 两             |       |     |
| B2.7.6 其它酒<br>注明: |         |        | 两             |       |     |
|                   | 下饮,1=天, | 2=周,3= | =月,4=年 ** 与   | 频度对应的 | 的次数 |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

国家科技支撑计划项目《中国重要心血管病患病率调查及关键技术研究》

# Ⅲ. 饮食(了解您过去一年食用下列食物的频率和食用量)

| B3.1 食物                        | 食用频度(选择其中的一种)        | 食用量   |
|--------------------------------|----------------------|-------|
| B3.1.1 大米、面粉、杂粮(小米、高粱、<br>玉米等) | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.2 薯类(红薯、山药、芋头、土豆等)        | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.3 新鲜蔬菜(不包括干菜和咸菜)          | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.4 畜肉(猪、牛、羊等)              | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.5 禽肉(鸡、鸭、鹅等)              | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.6 鱼类                      | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.7 虾、蟹、贝等其它水产品             | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.8 蛋类(鸡蛋、鸭蛋等)              | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.9 奶类(折合成鲜奶)               | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.10 豆制品(以豆腐计)              | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.11 新鲜水果                   | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.12 干果(花生、瓜子、核桃)           | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |
| B3.1.13 咸菜/泡菜/腌菜               | 0=不吃 1=天 2=周 3=月 4=年 | □□斤□两 |

# B32 请请写你最近一个日在下述地占的就努次数

| B3.2 谊垺 | 具与您最近 <b>一个月</b> 在下 | ·还地点的就餐伏数 |         |         |
|---------|---------------------|-----------|---------|---------|
|         | 餐次                  | 家         | 单位食堂    | 餐馆或街头   |
| B3.2.1  | 早餐                  | 早餐 🗌 🗌    |         |         |
| B3.2.2  | 午餐                  |           |         |         |
| B3.2.3  | 晚餐                  | 晚餐 🔲 🔲    |         |         |
| B3.3 您家 | <b>采通常有多少人在一起</b>   |           |         |         |
| B3.4 其中 | 96岁及以下的人数?          |           |         |         |
| B3.5 您家 | 《通常每个月吃多少斤          |           | 斤/月     |         |
| B3.6 您家 | 《通常每个月吃多少斤          |           | 斤/月 🔲 🗌 |         |
| B3.7 您家 | <b>买通常每个月吃多少</b> 斤  | 盐?        |         | 斤/月 🔲 🛄 |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## 国家心血管病中心 中国医学科学院阜外心血管病医院 version 201200628 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Ⅳ.体力活动

|        |                                      | 宫友 六语相关故真体活击          |
|--------|--------------------------------------|-----------------------|
|        | 过是通常一周您进行各类身体活动(包括干农活、工作、            | ,豕务、父迪相大的身体活动、        |
|        | 》炼或运动等)的情况。                          |                       |
| В4.1 ⊥ | 工作、农业及家务性身体活动                        |                       |
|        | 在您的工作、农活及家务活动中,有没有 <u>高强度</u>        |                       |
|        | <u>活动</u> ,并且活动时间持续 <u>10分钟以上</u> ?  |                       |
| B4.1.1 | (高强度活动是指如搬运重物、挖掘等需要付出                | 1=有 2=没有(转 B4.1.4)    |
|        | 较大体力,或引起呼吸、心跳显著增加的活动)                |                       |
|        | 调查员注意:可出示身体活动分类表                     |                       |
| B4.1.2 | 在您的工作、农活及家务活动中,通常一周内有                | □天                    |
| D7.1.2 | 多少天会进行上述高强度活动?                       |                       |
|        | 在您的工作、农活及家务活动中,通常一天内累                |                       |
| B4.1.3 | <u>计</u> 有多长时间进行上述高强度活动?             | 小时一分钟                 |
|        | (每次活动时间若少于 10 分钟,则不计算在内)             |                       |
|        | 在您的工作、农活及家务活动中,有没有中等强                |                       |
|        | <u>度活动</u> ,并且活动时间持续 <u>10分钟以上</u> ? |                       |
| D414   | (中等强度活动是指如锯木头、洗衣服、打扫卫                | 1 左 2 汎左 (枯 10 4 2) 🗖 |
| B4.1.4 | 生等需要付出中等体力,或引起呼吸、心跳轻度                | 1=有 2=没有(转 B4.2)      |
|        | 增加的活动)                               |                       |
|        | 调查员注意:可出示身体活动分类表                     |                       |
| D415   | 在您的工作、农活及家务活动中,通常一周内有                | □天                    |
| B4.1.5 | 多少天会进行上述中等强度活动?                      |                       |
|        | 在您的工作、农活及家务活动中,通常一天内累                | 5                     |
| B4.1.6 | <u>计</u> 有多长时间进行上述中等强度活动?            | □□小时□□分钟              |
|        | (每次活动时间若少于 10 分钟,则不计算在内)             |                       |
| B4.2 交 | <b>通相关的身体活动</b> (以下问题不包括上述已提及的2      | <b>牧业性身体活动和工作及家务</b>  |
| 性身体活   | 5动)                                  |                       |
| B4.2.1 | 您在外出时,有没有步行或骑自行车 <u>持续至少10</u>       | 1=有 2=没有(转 B4.3)      |
| D7.2.1 | <u>分钟</u> 的情况?                       |                       |
| B4.2.2 | 通常一周内,您有多少天外出时步行或骑自行车                | □天                    |
| D7.2.2 | 持续至少10分钟?                            |                       |
| B4.2.3 | 通常一天内,您步行或骑自行车多长时间?                  | 小时一分钟                 |
| B4.3 休 | 闲相关的身体活动(以下问题不包括上述已提及的               | 农业性、工作、家务和交通相         |
|        |                                      |                       |

## Page 36 of 43

## BMJ Open

| 国空到开于探开到理由 | 《中国重要心血管病患病率调查及关键技术研究》 |
|------------|------------------------|
| 国家科拉又崔订划坝日 | 《中国里安小川官协思协举调官及大键拉木册五》 |
|            |                        |

| 关的身体;   |                                       |                           |
|---------|---------------------------------------|---------------------------|
|         |                                       |                           |
|         | 您是否进行 <u>持续至少 10 分钟,引起呼吸、心跳显</u>      |                           |
| B4.3.1  | <u>著增加</u> 的高强度活动吗?( <b>如长跑、踢足球等)</b> | 1=有 2=没有(转 B4.3.4)        |
|         | 调查员注意:可出示身体活动分类表                      |                           |
| B4.3.2  | 通常一周内,您有多少天进行上述高强度的运动                 | □天                        |
|         | 或休闲活动?                                |                           |
| B4.3.3  | <u>通常一天内</u> ,您累计有多长时间进行上述高强度         |                           |
|         | 的运动或休闲活动?                             |                           |
|         | 您是否进行持续至少10分钟,引起呼吸、心跳轻                |                           |
| B4.3.4  | <u>度增加</u> 的中等强度运动和休闲活动吗? (如快步        |                           |
|         | 走、游泳、打排球等)                            | 1-17 2-仅有(将 <b>D4.4</b> ) |
|         | 调查员注意:可出示身体活动分类表                      |                           |
|         | 通常一周内,您有多少天进行上述中等强度的运                 |                           |
| B4.3.5  | 动或休闲活动?                               | □ □ 天                     |
|         | 通常一天内,您累计有多长时间进行上述中等强                 |                           |
| B4.3.6  | 度的运动或休闲活动? (调查员注意:每次活动                | □□小时□□分钟                  |
|         | 时间若少于10分钟,则不计算在内)                     |                           |
| B4.4 静态 | 5行为                                   |                           |
| -       | 通常工作日一天内,您累计有多少时间坐着、靠                 |                           |
| B4.4.1  | 着或躺着? (包括坐着工作、学习、阅读、看电                | □□小时□□分钟                  |
|         | 视、用电脑、休息等所有静态行为的时间,但不                 |                           |
|         | 包括睡觉时间)                               |                           |
|         | 通常非工作日一天内,您累计有多少时间坐着、                 | 3                         |
| B4.4.2  | 靠着或躺着? (包括坐着学习、阅读、看电视、                | □□小时□□分钟                  |
|         | 用电脑、休息等所有静态行为的时间,但 <u>不包括</u>         |                           |
|         | 工作和睡觉时间)                              |                           |
| B4.5 睡眼 | 民行为                                   | L                         |
| B4.5.1  | 通常工作日一天内,您睡觉累计有多少时间?                  | 小时一分钟                     |
| B4.5.2  | 通常非工作日一天内,您睡觉累计有多少时间?                 | 小时一分钟                     |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 第二部分:个人疾病9                     | 1                |           |          |                   |           |    |
|--------------------------------|------------------|-----------|----------|-------------------|-----------|----|
| C1 您上次测量血压到现在                  | 有多长时间了           | ? 0=从き    | 未 99=    | 不知道               | 年         | Ē  |
| C1.1 您是否被诊断为高                  |                  |           |          |                   |           |    |
| 0=无 (转问 C2) 1                  | =有 ───_          |           |          |                   |           |    |
| C1.1.1 您患高血压                   | 有多少年了?           |           |          |                   | 白         | Ξ[ |
| C1.1.2 最高诊断单                   | 立级别 1=区          | /县级以下     | 2=区/县    | 县级 3=区/-          | 县级以上      |    |
| C1.1.3 您近一年服                   | <b> 哥降压药的情</b> ( | 兄? 0=才    | 「服       | 1=偶服              | 2=经常服     |    |
| C1.1.4 您两周内服                   |                  |           |          |                   |           | [  |
| C1.1.5 您目前服用                   |                  |           |          |                   |           |    |
| C1.1.6 是否接受高」<br>C2 您是否被诊断为患过心 |                  | 0=省       | · _      | 三是                | 9=个许      | L  |
| 0=无(转问 C3)                     |                  | SV-6)     |          | 9=不详              | (转间C3     | )  |
|                                | Ľ.               | ~~~~)     | ↓        |                   |           |    |
| C2.1 首次发病日期                    |                  |           |          |                   |           | 年  |
| C2.2 最高诊断单位                    | 级别 1=区/县         | 县级以下 2    | 是一区/县约   | 及 3=区/县约          | 级以上       |    |
| C3 您是否接受过冠脉血管                  | <b></b>          | 直入?       |          |                   |           |    |
| 0=无(转问 C4)                     | 1=有(填写表          | SV-7) —   | <b>_</b> | 9=不详              | (转问 C4    | )  |
| C3.1 首次治疗日期                    |                  | ~         |          |                   |           | 年  |
| C3.2 最高诊治单位                    | 级别 1=区/县         | 县级以下 2    | 2=区/县约   | 及 3=区/县约          | 级以上       | Γ  |
| C4 您是否接受过冠状动脉                  | <b>亲路</b> 塔桥手术?  | ,         |          |                   |           |    |
| 0=无(转问 C5)                     |                  |           |          | 9=不详              | (转问 C5 )  | L  |
|                                | <b>`</b>         | . 5 (-8)  | <b>↓</b> | у т. <del>и</del> | (14) (15) |    |
| C4.1 首次治疗日期                    |                  |           |          |                   |           | 年  |
| C4.2 最高诊治单位                    | 级别 1=区/县         | 县级以下 2    | 2=区/县约   | 及 3=区/县约          | 级以上       |    |
| C5 您是否被诊断为患有脑                  | 中风 (脑卒中)         | ?         |          |                   |           | Γ  |
| 0=无(转问 D1)                     | 1=有(填写表          | : SV-9) — |          | 9=不详              | (转问 D1    | )  |
|                                |                  |           | +        |                   |           |    |
| C5.1 首次发病日期                    |                  |           |          |                   |           | 年  |
| C5.2 最高诊断单位                    | 级别 1=区/县         | 县级以下 2    | =区/县约    | 及 3=区/县约          | 级以上       |    |
| C5.3 是否能够独立                    | 完成下列事情           | (不需要他     | 2人帮助     | ) 0=              | 不能 1=     | 能  |
|                                | 中风前              | 目前        |          |                   | 中风前       | 目前 |
| C5.3.1 吃饭、饮水                   |                  |           | C5.3.5   | 上厕所               |           |    |
| C5.3.2 洗漱梳头                    |                  |           | C5.3.6   | 洗澡                |           |    |
| C5.3.3 穿脱衣服                    |                  |           | C5.3.7   | 室内活动              |           |    |
| C5.3.4 上下床                     |                  |           |          |                   |           |    |
|                                |                  |           |          |                   |           |    |

国家科技支撑计划项目《中国重要心血管病患病率调查及关键技术研究》

# 第三部分:家族史

D1 您是否有如下疾病家族史?

0=无 1=有 9=不详(兄弟姐妹不包括本人)

| \$ 78 - 11 > |   |    |      |    |
|--------------|---|----|------|----|
|              | 父 | 母: | 兄弟姐妹 | 子女 |
| D1.1 高血压     |   |    |      |    |
| D1.2 高血脂     |   |    |      |    |
| D1.3 糖尿病     |   |    |      |    |
| D1.4 脑卒中     |   |    |      |    |
| D1.5 冠心病     |   |    |      |    |

#### D2 您是否有早发心血管病家族史(发病年龄:男性<55 岁,女性<65 岁)? 0=无 1=有 9=不详(兄弟姐妹不包括本人)

| · / · · · · · · · |   |    |      |    |
|-------------------|---|----|------|----|
|                   | 父 | 母: | 兄弟姐妹 | 子女 |
| D2.1 高血压          |   |    |      |    |
| D2.2 高血脂          |   |    |      |    |
| D2.3 糖尿病          |   |    |      |    |
| D2.4 脑卒中          |   |    |      |    |
| D2.5 冠心病          |   |    |      |    |

### D3 您目前仍在世的家庭成员中是否有以下年龄组者?请标明,0=否,1=是。

| D3 芯口的 M 正臣  |    |    |     |     |   |   |    |    |
|--------------|----|----|-----|-----|---|---|----|----|
|              | 祖父 | 祖母 | 外祖父 | 外祖母 | 父 | 母 | 兄弟 | 姐妹 |
|              |    |    |     |     |   |   |    |    |
| D3.1 80~85 岁 |    |    |     |     |   |   |    |    |
| D3.2 85~90 岁 |    |    |     |     |   |   |    |    |
| D3.3 ≥90 岁   |    |    |     |     |   |   |    |    |

| 2        |   |
|----------|---|
| 3        | 第四部分:月经史及生育史(只问女性)  |
| 4        | 第四部 <b>分:</b> 月经文及生肖文(六问文性)   |
| 5        |   |
| 6<br>7   | E1 您月经来潮年龄  |
| 8<br>9   | E2 您是否已绝经?  |
| 10<br>11 | 0=否 1=是 ───   |
| 12<br>13 | E2.1 您多大岁数绝经的?  |
| 14       | E2.2 您是否使用雌激素替代?  |
| 15<br>16 | 0=否 1=现在服 2=过去服,现在不服  |
| 17<br>18 | E3 您服用过避孕药吗? 0=否 1=是  |
| 19<br>20 | E3.1 您服用避孕药累计有多长时间?   |
| 21<br>22 |   |
| 23       | E4 您怀孕过吗(包括当前怀孕者)? 0=否 1=是       □         E4.1 您怀孕过多少次?       99=不详       次□ |
| 24<br>25 |   |
| 26<br>27 | E4.2 您活产婴儿数量?       个         E4.3 您现在是否怀孕?       0=否 1=是                     |
| 28       | E4.3 您现在是否怀孕?       0=否       1=是          E4.4 您有过哺乳经历吗?       0=否       1=是 |
| 29<br>30 | E4.4 您有过哺乳经历吗: 0-否 1-是  |
| 31<br>32 | E4.3 忽现住定省正任哺乳: 0-百 1-定   |
| 33       |   |
| 34<br>35 |   |
| 36<br>37 |   |
| 38       |   |
| 39<br>40 | 询问者编码:  |
| 41<br>42 | 填表日期: 年月月日日   |
| 43       |   |
| 44<br>45 |   |
| 46<br>47 |   |
| 48       |   |
| 49<br>50 |   |
| 51<br>52 |   |
| 53       |   |
| 54<br>55 |   |
| 56<br>57 |   |
| 58       |   |
| 59<br>60 |   |

| 国家科技支撑计划项目 | 《中国重要心 | 血管病患病率调 | 查及关键技术研究》 |
|------------|--------|---------|-----------|

| 国家科技支撑计划项目《中国重                        | 這要心血管病患病率调查及关键技    | 乏术研究》              |
|---------------------------------------|--------------------|--------------------|
| 存                                     | 本格检查               |                    |
| 室内温度: □□.□℃                           |                    |                    |
| 王···································· | H2 体重              | 公斤                 |
| H3 腰围 []]. 厘米                         |                    |                    |
| H4 体脂测定                               |                    |                    |
| H4.1 基础代谢                             | H4.2 身体脂肪率         |                    |
| H4.3 内脏脂肪指数                           |                    |                    |
|                                       |                    | 测量者编码:             |
| 0                                     |                    |                    |
| H5 静息 60 秒脉搏 次/60 秒                   |                    |                    |
| H6外周血压(mmHg)(每50人需同时用                 |                    |                    |
| 电子血压计: 收缩压 舒张压                        | <b>汞柱血压计</b> : 收缩压 | 舒张压                |
|                                       | 第一次                |                    |
|                                       | 第二次 1              |                    |
| 第三次 []]                               | 第三次                | 」/□□□□<br>测具夹炉刀 □□ |
|                                       | 4.                 | 测量者编码:             |
|                                       | 填表日期:              | 年月                 |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |
|                                       |                    |                    |

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

| 1<br>2<br>3<br>4   |        | 检查项目完 | Z成情况记录单 |  |
|--|--------|-------|---------|--|
| 5<br>6<br>7  | 一、调查表  | 0=未完成 | 1=已完成   |  |
| 8<br>9   | 二、血压   | 0=未完成 | 1=已完成   |  |
| 10<br>11<br>12<br>13   | 三、体格测量 | 0=未完成 | 1=已完成   |  |
| 14 $15$ $16$ $17$ $18$ $19$ $20$ $21$ $22$ $23$ $24$ $25$ $26$ $27$ $28$ $29$ $30$ $31$ $32$ $33$ $34$ $35$ $36$ $37$ $38$ $39$ $40$ $41$ $42$ $43$ $44$ $45$ $46$ $47$ $48$ $49$ $50$ $51$ $52$ $53$ $54$ $55$ $56$ $57$ $58$ $59$ $60$ |        |       |         |  |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## STROBE Statement-checklist of items that should be included in reports of observational studies

|  | Item<br>No          | Recommendation   |   |
|--|---------------------|--|---|
| Title and abstract   | 1                   | ( <i>a</i> ) Indicate the study's design with a commonly used term in the title or   | the abstra<br>P1·   |
|  |                     | (b) Provide in the abstract an informative and balanced summary of what  | was done  |
|  |                     | and what was found   | P2  |
| Introduction   |                     |  |   |
| Background/rationale   | 2                   | Explain the scientific background and rationale for the investigation bei  | ng reporte<br>I   |
| Objectives   | 3                   | State specific objectives, including any prespecified hypotheses   | P   |
| Methods  |                     |  |   |
| Study design   | 4                   | Present key elements of study design early in the paper  | P4-5  |
| Setting  | 5                   | Describe the setting, locations, and relevant dates, including periods of rec  |   |
| Seving   |                     | exposure, follow-up, and data collection   | P4-:  |
| Participants   | 6                   | (a) Cohort study—Give the eligibility criteria, and the sources and method   |   |
| I I I I I  |                     | selection of participants. Describe methods of follow-up   |   |
|  |                     | <i>Case-control study</i> —Give the eligibility criteria, and the sources and meth   | nods of   |
|  |                     | case ascertainment and control selection. Give the rationale for the choice  |   |
|  |                     | and controls   |   |
|  |                     | Cross-sectional study—Give the eligibility criteria, and the sources and m   | ethods of   |
|  |                     | selection of participants  | P4  |
|  |                     | (b) Cohort study—For matched studies, give matching criteria and number  |   |
|  |                     | exposed and unexposed  |   |
|  |                     |  |   |
|  |                     |  | number of   |
|  |                     | Case-control study—For matched studies, give matching criteria and the m   | number of   |
| Variables  | 7                   | <i>Case-control study</i> —For matched studies, give matching criteria and the n controls per case   |   |
| Variables  | 7                   | Case-control study—For matched studies, give matching criteria and the m<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,  | and effec   |
|  |                     | Case-control study—For matched studies, give matching criteria and the n<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,<br>modifiers. Give diagnostic criteria, if applicable  | and effec<br>P  |
| Data sources/  | 7 8*                | Case-control study—For matched studies, give matching criteria and the m<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,<br>modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods of   | and effec   |
|  |                     | Case-control study—For matched studies, give matching criteria and the n<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,<br>modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods of<br>assessment (measurement). Describe comparability of assessment methods   | and effec<br>P<br>of<br>s if there  |
| Data sources/  |                     | Case-control study—For matched studies, give matching criteria and the m<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,<br>modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods of<br>assessment (measurement). Describe comparability of assessment methods<br>more than one group  | and effec<br>Pe<br>of<br>s if there   |
| Data sources/<br>measurement   | 8*                  | Case-control study—For matched studies, give matching criteria and the n<br>controls per case<br>Clearly define all outcomes, exposures, predictors, potential confounders,<br>modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods of<br>assessment (measurement). Describe comparability of assessment methods   | and effec<br>P<br>of<br>s if there<br>1   |
| Data sources/<br>measurement<br>Bias   | 8*                  | Case-control study—For matched studies, give matching criteria and the n         controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at  | and effec<br>P<br>of<br>s if there<br>I<br>I  |
| Data sources/<br>measurement<br>Bias<br>Study size                           | 8*<br>9<br>10       | Case-control study—For matched studies, give matching criteria and the montrols per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If application  | and effec<br>P<br>of<br>s if there<br>1<br>1<br>2<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3<br>3  |
| Data sources/<br>measurement<br>Bias<br>Study size                           | 8*<br>9<br>10       | Case-control study—For matched studies, give matching criteria and the n         controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at  | and effec<br>P<br>of<br>s if there<br>l<br>l<br>able,<br>P5-<br>onfoundi  |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the montrols per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If application describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for c   | and effec<br>P<br>of<br>s if there<br>I<br>able,<br>P5-<br>onfoundi   |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe any methods used to examine subgroups and interactions  | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundi  |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicated describe which groupings were chosen and why         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed  | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundir<br>I<br>I<br>I<br>I   |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the montrols per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicated describe which groupings were chosen and why         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address  | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundii<br>I<br>I<br>ssed   |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicated describe which groupings were chosen and why         (a) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address Case-control study—If applicable, explain how matching of cases and complexity.  | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundii<br>I<br>I<br>ssed   |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicate describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for c         (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address Case-control study—If applicable, explain how matching of cases and con addressed           | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundi<br>I<br>sed<br>trols was   |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n         controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicad describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for c         (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how matching of cases and con addressed         Case-control study—If applicable, describe analytical methods taking a | and effec<br>Prof<br>s if there<br>I<br>able,<br>P5-<br>onfoundii<br>I<br>ssed<br>trols was<br>ccount of  |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | Case-control study—For matched studies, give matching criteria and the n controls per case         Clearly define all outcomes, exposures, predictors, potential confounders, modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicate describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for c         (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address Case-control study—If applicable, explain how matching of cases and con addressed           | and effec<br>Provide the provided and the |

For peer review only - http://bmjopen!bmj.com/site/about/guidelines.xhtml

| Results          |     |   |             |
|------------------|-----|---|-------------|
| Participants     | 13* | (a) Report numbers of individuals at each stage of study-eg numbers potentially elig        | gible,      |
|                  |     | examined for eligibility, confirmed eligible, included in the study, completing follow      | -up, and    |
|                  |     | analysed  | P7          |
|                  |     | (b) Give reasons for non-participation at each stage  | P7          |
|                  |     | (c) Consider use of a flow diagram  | N/A         |
| Descriptive      | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and in    | formation   |
| data             |     | on exposures and potential confounders  | P7          |
|                  |     | (b) Indicate number of participants with missing data for each variable of interest         | N/A         |
|                  |     | (c) Cohort study—Summarise follow-up time (eg, average and total amount)                    | N/A         |
| Outcome data     | 15* | Cohort study-Report numbers of outcome events or summary measures over time                 |             |
|                  |     | Case-control study-Report numbers in each exposure category, or summary measur              | es of       |
|                  |     | exposure  |             |
|                  |     | Cross-sectional study—Report numbers of outcome events or summary measures                  | P7          |
| Main results     | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and t       | heir        |
|                  |     | precision (eg, 95% confidence interval). Make clear which confounders were adjuste          | d for and   |
|                  |     | why they were included  | P8          |
|                  |     | (b) Report category boundaries when continuous variables were categorized                   | P6          |
|                  |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a n | eaningful   |
|                  |     | time period   | N/A         |
| Other analyses   | 17  | Report other analyses done-eg analyses of subgroups and interactions, and sensitivi         | ty          |
|                  |     | analyses  | P8-9        |
| Discussion       |     |   |             |
| Key results      | 18  | Summarise key results with reference to study objectives                                    | P10         |
| Limitations      | 19  | Discuss limitations of the study, taking into account sources of potential bias or impr     | ecision.    |
|                  |     | Discuss both direction and magnitude of any potential bias                                  | P15         |
| Interpretation   | 20  | Give a cautious overall interpretation of results considering objectives, limitations, m    | ultiplicity |
|                  |     | of analyses, results from similar studies, and other relevant evidence                      | P10-14      |
| Generalisability | 21  | Discuss the generalisability (external validity) of the study results                       | P15         |
| Other informati  | on  |   |             |
| Funding          | 22  | Give the source of funding and the role of the funders for the present study and, if ap     | plicable,   |
| -                |     | for the original study on which the present article is based                                | P19         |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen?bmj.com/site/about/guidelines.xhtml

# **BMJ Open**

# **Prevalence and distribution of hypertension and related risk factors in Jilin Province, China 2015: a cross-sectional study**

| Journal:                             | BMJ Open   |
|--------------------------------------|--|
| Manuscript ID                        | bmjopen-2017-020126.R2   |
| Article Type:                        | Research   |
| Date Submitted by the Author:        | 15-Feb-2018  |
| Complete List of Authors:            | Wu, Junduo; the Second Hospital of Jilin University, cardiology<br>Li, Tianyi; the Second Hospital of Jilin University, cardiology<br>Song, Xianjing; the Second Hospital of Jilin University, cardiology<br>Sun, Wei; the Second Hospital of Jilin University, cardiology<br>Zhang, Yangyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Liu, Yingyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Liu, Yingyu; School of Public Health, Jilin University, Department of<br>Epidemiology and Biostatistics<br>Li, Longbo; the Second Hospital of Jilin University, cardiology<br>Yu, Yunpeng; the Second Hospital of Jilin University, cardiology<br>Liu, Yihang; the Second Hospital of Jilin University, cardiology<br>Qi, Chao; the Second Hospital of Jilin University, cardiology<br>Liu, Bin; The Second Hospital of Jilin University, Department of Cardiology |
| <b>Primary Subject<br/>Heading</b> : | Epidemiology   |
| Secondary Subject Heading:           | Public health  |
| Keywords:                            | prevalence, Hypertension < CARDIOLOGY, EPIDEMIOLOGY, China   |
|                                      |  |

SCHOLARONE<sup>™</sup> Manuscripts



| 1              |    |   |
|----------------|----|---|
| 2<br>3         |    |   |
| 4              | 1  | Prevalence and distribution of hypertension and related risk  |
| 5<br>6<br>7    | 2  | factors in Jilin Province, China 2015: a cross-sectional study  |
| 8              | 3  |   |
| 9<br>10        | 4  | Junduo Wu <sup>1</sup> , Tianyi Li <sup>1</sup> , Xianjing Song <sup>1</sup> , Wei Sun <sup>1</sup> , Yangyu Zhang <sup>2</sup> , Yingyu Liu <sup>2</sup> , |
| 11<br>12       | 5  | Longbo Li <sup>1</sup> , Yunpeng Yu <sup>1</sup> , Yihang Liu <sup>1</sup> , Chao Qi <sup>1</sup> , Bin Liu <sup>1*</sup>                                   |
| 13<br>14<br>15 | 6  |   |
| 16<br>17       | 7  |   |
| 18<br>19<br>20 | 8  | 1 Department of Cardiology, The Second Hospital of Jilin University, Changchun,   |
| 21<br>22       | 9  | Jilin, China  |
| 23<br>24<br>25 | 10 | 2 Department of Epidemiology and Biostatistics, School of Public Health, Jilin  |
| 26<br>27       | 11 | University, No.1163 Xinmin Street, Changchun, Jilin,130021, China   |
| 28<br>29<br>30 | 12 |   |
| 31<br>32       | 13 |   |
| 33<br>34<br>35 | 14 |   |
| 36<br>37       | 15 |   |
| 38<br>39<br>40 | 16 | *Corresponding author   |
| 41<br>42       | 17 | *Corresponding author<br>E-mail address: liubin3333@vip.sina.com  |
| 43<br>44       |    |   |
| 45             |    |   |
| 46<br>47       |    |   |
| 48             |    |   |
| 49             |    |   |
| 50<br>51       |    |   |
| 52             |    |   |
| 53             |    |   |
| 54<br>55       |    |   |
| 56             |    |   |
| 57             |    | 1   |
|                |    | -   |
| 58<br>59       |    | 1   |

| 18 | Abstract  |
|----|---|
| 19 | Objective: This study aimed to investigate the prevalence and distribution of               |
| 20 | hypertension and its related factors in Jilin province, China.                              |
| 21 | Design: A cross-sectional study in four cities and four rural counties in Jilin as part of  |
| 22 | a national Chinese study.   |
| 23 | <b>Participants and setting:</b> A total of 15206 participants who were $\geq$ 15 years old |
| 24 | and were selected using a stratified multistage random sampling method.                     |
| 25 | Main outcome measures: The prevalence of hypertension.                                      |
| 26 | Results: The prevalence of hypertension in Jilin province was 24.7%. Moreover, the          |
| 27 | prevalence of hypertension increased with age in both sexes, and was higher in males        |
| 28 | than in females. The modifiable factors that were associated with hypertension were         |
| 29 | body mass index, smoking, and alcohol drinking. The risk factors identified are             |
| 30 | similar to those in southern China, except smoking, which has no association with           |
| 31 | hypertension prevalence in the South.   |
| 32 | Conclusions: Age, sex, body mass index, smoking, and alcohol drinking were risk             |
| 33 | factors of hypertension. Control of these related risk factors, especially smoking, may     |
| 34 | be helpful in the treatment and management of hypertension in Jilin province.               |
| 35 |   |
| 36 | Strength and limitations of this study  |
| 37 | This cross-sectional population-based study evaluated a large representative                |
| 38 | sample of individuals from four cities and four rural counties in Jilin province.           |
| 39 | A large sample of participants allowed for subgroups analysis of related factors.           |
|    | 2   |

#### **BMJ** Open

|   | вмЈ Ор   |
|---|--|
| ypertension and the related factors     | en: first pu   |
| ectivity, salt intake, and blood lipid  | BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from htt<br>Enseignement Superieur (ABES<br>Protected by copyright, including for uses related to text and data mini |
|   | 10.1136/b<br>Protected   |
|   | 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://<br>Enseignement Superieur (ABES) .<br>Protected by copyright, including for uses related to text and data mining,                    |
|   | 917-020126<br>ght, incluc  |
|   | on 28 Ma<br>E<br>ding for us   |
| ndicated that cardiovascular diseases   | irch 2011<br>Inseigne<br>ses relat   |
| oritized non-communicable diseases      | 8. Dowr<br>ement S<br>ed to te   |
| bal action plans for prevention and     | hloaded<br>Superieu<br>ext and   |
| cardiovascular diseases and related     | l from h<br>ur (ABE<br>data m  |
| global economic burden related to       | ES) .<br>≣S) .<br>ining, /   |
| [4].                                    |  |
| evalence of hypertension has been       | ing, an  |
| 7% in 1979, 13.6% in 1991, and 18.8%    | mjopen.bmj.com/ on June 14, 2025 a<br>Al training, and similar technologies.   |
| ortionately higher hypertension rate    | June 1<br>ar tech  |
| 7, 8]. There are about 109.4 million    | 4, 2025<br>nologie   |
| of Jilin is located in the northeast of | 5 at Age<br>,s.  |
| 5 million according to the National     | ence Bi  |
| provinces, Jilin has a longer winter    | njopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de<br>I training, and similar technologies.   |
| 3                                       | nphique  |
| om/site/about/guidelines.xhtml          | del  |

The causality of the relationships between h cannot be confirmed. Data were not collected regarding physical a levels. Key words Prevalence, hypertension, epidemiology, China 

Introduction 

A recent World Health Organization report in (CVD) are at the top of the list of the four price worldwide, and that they require immediate glo control [1]. Hypertension is a leading cause of deaths worldwide [2, 3]. It is estimated that the hypertension could be as high as US\$ 370 billion 

In the People's Republic of China, the pr increasing dramatically from 5.1% in 1959, to 7.7 in 2002 [5, 6]. Furthermore, there is a disproper reported among people living in northern China people in the northeastern China. The province of China, with a population of approximately 27.5 Bureau of Statistics. Similar to other northern 

| 62 | season than the southern China, and, limited by this environment, the lifestyle of the    |
|----|---|
| 63 | people is different from the other parts of the country.                                  |
| 64 | An in-depth analysis of data from Jilin province regarding hypertension and its           |
| 65 | risk factors would improve our understanding of the differential reasons for              |
| 66 | hypertension in the North. Moreover, the analysis would assist in the development of      |
| 67 | locally effective intervention and control strategies for this preventable disease. Thus, |
| 68 | the objectives of this study were: to estimate the prevalence of hypertension in Jilin    |
| 69 | province and to explore potential risk factors that are associated with hypertension in   |
| 70 | the province. This will provide information for making recommendations on the             |
| 71 | prevention and control of hypertension in the northern region of China.                   |
| 72 |   |
| 73 | Methods   |
| 74 | Study population  |
| 75 | This cross-sectional study was conducted between July 2014 and December 2015              |
| 76 | as a part of national China study. A 4-stage, stratified sampling method was used to      |
| 77 | select participants who were aged 15 years and older from the general population of       |
| 78 | Jilin province, China. First, four cities from the urban areas and four counties from     |
| 79 | rural areas were selected using a probability proportional to size. Then two districts or |
| 80 | two townships were selected in each city or county using simple random sampling           |
| 81 | (SRS). Next, in each district and township, three communities or villages were chosen     |
| 82 | manualization of SDS Finally marticipants startified has see (500/ manual 500/            |
|    | respectively using SRS. Finally, participants stratified by sex (50% men and 50%          |
| 83 | women) and age (aged 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, , 65-74, $\geq$ 75 years)  |

were chosen using SRS according to the national population composition. Participants were chosen from the list provided by the local government registers of households [9]. Based on a design effect of 2.5 and assuming a prevalence of hypertension of 17.7% among the population aged 15 years and older, an estimated sample size of 15,200 participants was needed to ensure that the bound on the error of estimation (i.e. width of the 95% confidence interval (CI)) for the prevalence in the entire population and subpopulation defined by age and sex were less than 0.4% and 1.8%, respectively [9]. As a result, a total of 15,206 participants living in Jilin province over 6 months and aged 15 years and older were randomly selected to participate in the survey. Measurement The survey involved a questionnaire interview and physical examination. The standardized questionnaire was developed by the national coordinating center of Fuwai Hospital (Beijing, China) and included questions on demographic characters, 

99 health behaviors and physical activities. The questionnaire was completed by the100 participants in a face-to-face interview with trained staff.

101 The physical examination evaluated blood pressure (BP), body weight and height. 102 BP was measured at the right arm supported at the heart level after participants resting 103 for five minutes, using the Omron HBP-1300 Professional Portable Blood Pressure 104 Monitor (OMRON, Japan). BP was measured three times, with 30 seconds between 105 each measurement. The average of three readings was used for further analysis [10].

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Body weight, basal metabolism (BM), body fat percentage (BFP) and visceral fat index (VFI) were measured without heavy clothing using an OMRON body fat and weight measurement device (Vbody HBF-371, OMRON, Japan). Height was measured without shoes using a standard right-angle device and a fixed measurement tape (to the nearest 0.5 cm). 

- Definitions

Hypertension was defined as systolic BP (SBP)≥140mmHg or diastolic BP (DBP)≥90mmHg, or self-reported use of antihypertensive medication [11]. Body mass index (BMI) was calculated as kg/m<sup>2</sup>. Overweight was defined as BMI 25-30kg/m<sup>2</sup>, and obesity was defined as BMI>30kg/m<sup>2</sup>. 

#### **Statistical analysis**

Data was entered and validated using Epidata<sup>®</sup> 3.0 software[12]. All estimates and analyses were weighted to represent the population in Jilin Province aged 15 years or older. The weights were calculated based on the 2010 Jilin province population census data, as well as the sampling age, sex and geographic subgroups. Continuous data were presented as mean  $\pm$  standard deviation (SD) or mean with 95% confidence intervals (CI), and differences between groups were compared using the t-est. Categorical data were presented as frequency, rate and 95% CI, and the prevalence between different groups was compared using the corrected Rao-Scott chi-square test. Logistic regression analysis was conducted assessing the relationship 

#### BMJ Open

| Enseignement Superieur (ABES) .<br>Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. | 3MJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de |
|---|--|
|---|--|

| 128 | of hypertension with age, sex, obesity, smoking, and alcohol drinking adjusted for                           |
|-----|--|
| 129 | demographic factors, that have been included in similar studies, including sex, region,                      |
| 130 | age, education level, employment status, marital status, BMI, and family history of                          |
| 131 | hypertension. All analyses were conducted using SPSS® 18.0 software[13].                                     |
| 132 |  |
| 133 | Results  |
| 134 | Distribution of participants   |
| 135 | A total of 14,956 participants from 15,206 eligible participants (6,946 males and                            |
| 136 | 8,010 females; aged 15-97 years) completed the survey and were included in the                               |
| 137 | statistical analysis. The percentages of male and female respondents were 50.63% and                         |
| 138 | 49.37%, respectively. The non-responders (1.6%) were mainly young people, and                                |
| 139 | their non-response was likely attributable to their busy work schedule.                                      |
| 140 |  |
| 141 | Characteristics of participants  |
| 142 | The average age of the participants was 45.5 years, with the average age for                                 |
| 143 | males being $45.6 \pm 19.6$ years and for females $45.5 \pm 18.9$ years. There was no                        |
| 144 | statistically significant difference in age between the sexes (p=0.92). The distribution                     |
| 145 | of participants by age and sex are shown in Table 1. The participants had average                            |
| 146 | values of 24.01 $\pm$ 3.67 kg/m <sup>2</sup> for BMI, 1,397.47 $\pm$ 244.15 for BM, 26.20 $\pm$ 8.4 for BFP, |
| 147 | and 8.54 $\pm$ 4.99 for VFI. The mean SBP was 128.92 $\pm$ 17.97 mmHg, and the mean                          |
| 148 | DBP was $76.81 \pm 10.36$ mmHg. These physical characteristics by age and sex are                            |
| 149 | shown in Supplementary Table 1. All these characters were statistically significantly                        |
|     |  |

different between males and females (p<0.01). In particular, male participants had</li>
higher BM and VFI values than female participants in all age groups (Figure 1A, 1B),
while female participants had higher BFP values in all age groups (Figure 1C). BMI
reached its highest value for males in the 35-44 year age group and for females in the
55-64 year age group (Figure 1D). The SBP was similar between males and females
in all age groups (Figure 1E), although male participants had higher DBP values in all

The overall prevalence of overweight and obesity of participants was 29.8% and 6.2%, respectively. Male participants had a higher prevalence of overweight than female participants (30.9% vs. 28.7%, p = 0.013). No statistical difference was observed in the prevalence of obesity among male and female participants (6.3% vs.)6.2%, p = 0.78). The overall percentages of current smoking and ever smoking were 22.7% and 1.4%, respectively. When stratified by sex, the percentage of current smoking in males (36.9%) was significantly higher than that in females (8.2%)(p<0.001). Similarly, the percentage of ever smoking in males (2.3%) was significantly higher than that in females (0.5%) (p<0.001). The overall percentage of alcohol drinking was 17.6%. The percentage in males (32.0%) was significantly higher than in females (2.9%) (p<0.001). The risk factors BMI, smoking and alcohol drinking, summarized by age and sex, are shown in Table 2.

#### 170 Prevalence of hypertension stratified by non-modifiable factors-age and sex

Of the 14,956 participants, 4,332 were diagnosed with hypertension, and the

prevalence of hypertension was 24.7% (95% CI: 23.9%, 25.5%). The prevalence of hypertension increased as older ages, and was higher in males (25.6%) than in females (23.8%) (p=0.03), among the age groups under 45 years old, the prevalence of hypertension in males was significantly higher than in females (p<0.001); while for the 65-74 year age group, the prevalence of hypertension in females was higher than in males (p=0.04); and in the other age groups, the prevalence of hypertension in males and females showed no statistical difference (p>0.05). The prevalences of hypertension stratified by age and sex are shown in Table 3. Prevalence of hypertension stratified by modifiable factors-obesity, smoking and alcohol drinking The prevalences of hypertension varifed statisticallybetween the BMI categories (p < 0.001); the highest prevalence being reported was 48.1% in the obese group, followed by the overweight group at 35.7%. The prevalence of hypertension also verified significantly when stratified by smoking (p < 0.001); with the highest 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 193 Factors associated with hypertension

prevalence of 53.1% in the ever smoking group, followed by 32.2% in the current

smoking group and 22.0% in the never smoking group. The prevalence of

hypertension was significantly higher in the alcohol drinking group than in the

no-alcohol drinking group (34.6% vs. 22.6%, p < 0.001). The prevalence of

hypertension stratified by BMI, smoking and alcohol drinking are shown in Table 4.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 194 | Several factors, including age, sex, obesity, smoking, and alcohol drinking, are         |
|-----|--|
| 195 | associated with the prevalence of hypertension, in both the crude model and the          |
| 196 | adjusted logistic model. In particular, the univariate logistic model indicated that the |
| 197 | risk of hypertension was greater in males with an OR=1.1 (95% CI: 1.01, 1.2) than in     |
| 198 | females, overweight partipants with an OR=2.52 (95% CI: 2.3, 2.77) than in normal        |
| 199 | participants, obese participants with an OR=4.21 (95% CI: 3.56, 4.96) than in normal     |
| 200 | participants, smokers with OR=1.64 (95% CI: 1.48, 1.81) than in non-smokers, and         |
| 201 | alcohol drinkers with OR=1.81 (95% CI: 1.62, 2.02) than in non-alcohol drinkers. All     |
| 202 | the difference were statistically significant (p<0.05). After adjustment for age, sex,   |
| 203 | region, education level, employment status, BMI, family history of hypertension, and     |
| 204 | marital status that may affect hypertension, the risk of hypertension was greater in     |
| 205 | males with an adjusted OR=1.26 (95% CI:1.13, 1.39) than in females, in overweigh         |
| 206 | participants with an adjusted OR=2.3 (95% CI: 2.06, 2.58) than in normal participants,   |
| 207 | in obese participants with an adjusted OR=5.11 (95% CI: 4.16, 6.27) than in normal       |
| 208 | participants, in smokers with an adjusted OR=1.28 (95% CI: 1.13, 1.46) than in           |
| 209 | non-smokers, and in alcohol drinkers with an adjusted OR=1.49 (95% CI: 1.28, 1.73).      |
| 210 | These results are shown in Table 5.  |
|     |  |

211

212 Discussion

Based on an estimated prevalence of 24.7% for hypertension in Jilin province, approximately 6.8 million residents would be considered hypertensive. At the national level, the prevalence of hypertension in Jilin is comparable to that in Zhejiang

| 216 | province [12]; while the prevalence is lower than in other regions in China, including      |
|-----|---|
| 217 | Jiangxi [13], Inner Mongolia [14], and Macau [15], as well as, lower than the overall       |
| 218 | prevalence in China [16]. At the global level, the prevalence in Jilin is lower than that   |
| 219 | in the US and the UK, but is higher than that in Canada [4]. However, there are some        |
| 220 | limitations in terms of the direct comparisons among these studies, given the varying       |
| 221 | methods, environments, population genetics, and population age structures.                  |
| 222 | Although the prevalence from the present study is lower than the prevalence form            |
| 223 | 2012 (24.7% vs. 30.8%) [17], it remains unacceptably high in terms of optimal               |
| 224 | hypertension health in the province. Our study found that the prevalence of                 |
| 225 | overweight and obesity was 29.8% and 6.2%, respectively, which is higher than that          |
| 226 | reported at the national level of 17.7% and 5.6%, respectively[18]. Several studies         |
| 227 | have shown that obesity is a risk factor for the development of hypertension[19-21].        |
| 228 | Obesity can increase hypertension through multiple mechanisms, including insulin            |
| 229 | resistance, activation of sympathetic nervous system, sodium retention leading to           |
| 230 | increased renal reabsorption, and activation of the renin-angiotensin system[22]. Thus,     |
| 231 | the increasing populations of overweight and ovese Jilin residents suggest thepotential     |
| 232 | risk of future increasing incidence of hypertension. Unfortunately, this modifiable risk    |
| 233 | factor has exhibited no change in between the report in 2012 and now[17], and the           |
| 234 | population of overweight and obesity may even beunderestimated, because the                 |
| 235 | standard definitions for overweight and obesity used in our research may be too high        |
| 236 | for Asian population [23, 24]. Moreover, abdominal obesity can be present in                |
| 237 | individuals with normal BMI values ( $18.5-24.9$ kg/m <sup>2</sup> ), and some studies have |
|     |   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

indicated that this condition could be a risk factor for hypertension [25, 26]. Thus, as
overweight and ovesity are modifiable risk factors, effective proactive intervention
program could help slow and ultimately reduce the number of individuals with obesity
becoming hypertensive.

Our study found that the overall prevalence of hypertension increased with age in both males and females, especially at ages of 35-74 years. This result supports the hypothesis that age is a risk factor for hypertension [27-30]. An increasing lifespan among the population in Jilin requires a practical and effective hypertension management strategy that targets its aging population. The overall prevalence of hypertension was higher in males than in females. However, the prevalence in females increased more rapidly than in males aged 65-74 years. This may be partially explained by hormonal changes in post-menopausal women and the difference in lifespan between males and females [4, 31]. However, the exact mechanisms need to be explored.

Consistent with previous studies [32, 33], our study also showed that smoking, both current and ever smoking, was associated with an increased risk of hypertension. Smoking can increase blood viscosity, stimulate the adrenergic nervous system, and contribute to the development of both micro-vascular and macro-vascular diseases[34]. Although some studies reported weak associations between smoking and hypertension [13, 20], smoking is still considered a major risk factor worldwide [13, 20, 35-37], Additionally, drinking of alcohol is also a risk factor for hypertension in our study, which is consistent with previous studies [4, 38-40]. These results indicate 

Page 13 of 31

#### **BMJ** Open

that some lifestyle changes, such as quitting smoking and reducing or stopping alcohol consumption, should help to reduce the prevalence of hypertension. National studies reported that the prevalence of hypertension is higher in northern China than that in southern China [7, 16]. When comparing the associations between risk factors and hypertension with Zhejiang province located in the South[12], we found that the risk of hypertension with demographic factors, such as age, sex, and region, and clinical factors, such as family history of hypertension and abdominal waist circumference, were similar in Jilin province and in southern China. When it comes to the lifestyle factors, the risk of hypertension with obesity and alcohol drinking were similar, however, there was a marked difference in the modifiable risk factor smoking; in particular, in Jilin province there was a strong association with an adjusted OR=1.28 (95% CI: 1.13, 1.46), whereas no association between smoking and hypertension in southern China was found, with an adjusted OR=1.0 (95% CI: 0.9, 1.1). These findings indicate that smoking cessation programs could help mitigate the prevalence of hypertension in Jilin province. Some social factors including retirement status, marital status, and education level were also different between the North and the South. Of interest, there was a difference on BFP categories. In particular, for category 10-19 for males and 20-29 for females, there was no association between BFP and hypertension in Jilin province with an adjusted OR=0.95 (95%CI: 0.71, 1.27), whereas in this category BFP is protective againt hypertension in south China with an adjusted OR=0.6 (95% CI: 0.5, 0.8). In the range of over 25 for males and over 35 for females, BFP is strongly associated with hypertension in Jilin province 

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

| 3        |
|----------|
| 4        |
| 5        |
| 6        |
| 7        |
| 8        |
| 9        |
|          |
|          |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
| 16       |
| 17       |
| 18       |
| 19       |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
|          |
| 31<br>32 |
|          |
| 33       |
| 34       |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46       |
| 47       |
| 48       |
| 49       |
| 50       |
| 51       |
| 52       |
| 52<br>53 |
| 53<br>54 |
| 54<br>55 |
|          |
| 56       |
| 57       |
| 58       |
| 59       |
| 60       |
|          |

1 2

| 282 | with an adjusted OR=1.45 (95% CI: 1.07, 1.96), whereas no association was found in   |
|-----|--|
| 283 | the South with an adjusted OR=1.3 (95%CI: 1.0, 1.5). These results indicate that BFP |
| 284 | tends to be more of a risk for hypertension in the North compared to the South. High |
| 285 | BFP values are associated with increased blood pressure[41, 42], and there may be    |
| 286 | ethnicity-based differences in the relationship between BFP and BMI [43]. Those      |
| 287 | results may help explain the region-specific relationships between BFP and           |
| 288 | hypertension in northern and southern China, although further studies are needed to  |
| 289 | better understand these relationships.   |

A survey from 2012 found a prevalence of hypertension of 30.8% [17]. The 290 prevalence of hypertension in our study was lower. This reduction may be related to 291 the following two factors. First, the Jilin government is aware of the damage and 292 293 burdern of hypertension and has increased medical insurance funding (especially for 294 rural residents), from RMB ¥3.9 billion in 2012 to RMB ¥6.4 billion in 2015, according to the statistical bureau of Jilin province. Second, new hypertension 295 guidelines for China were published since 2012, and these guidelines addressed the 296 297 grass-roots management of hypertension [44] and patient education [45]. However, some key modifiable risk factors have exhibited slight negative changes, in particular, 298 299 the trend towards obesity, drinking and smoking. This can be due in part to the Jilin's 300 growing economy, which has increased from a gross domestic product of RMB ¥361.5 billion in 1995, to RMB ¥857.8 billion in 2010, to RMB ¥1.4 trillion in 2015, 301 302 according to the statistical bureau of Jilin province. To reverse these trends will require an effective and workable intervention program to control hypertension by 303

| 304 | incorporating best practices identified in theory and practice. For example, rates of  |
|-----|--|
| 305 | hypertension awareness have greatly improved from 24.4% to 42.6%, and the              |
| 306 | treatment rates have improved from 20.0% to 24.2% based on national surveys [16].      |
| 307 | However, the control rate is only 9.3% in comparison with 53% in the USA[4]. One       |
| 308 | of the challenges is to improve adherence to anti-hypertension drugs.                  |
| 309 | This study was a cross-sectional study and contained a large representative            |
| 310 | sample. These factors will allow for the generalisation of our findings to residents   |
| 311 | aged 15 years and over in northern China. However, there are some limitations in this  |
| 312 | study. First, this is a cross-sectional study design, thus the causality cannot be     |
| 313 | assumed between the risk factors and hypertension. Second, financial limitations       |
| 314 | precluded collection of data regarding physical activity, salt intake and blood lipid  |
| 315 | levels. Third, the decrease of prevalence of hypertension in our study compared with   |
| 316 | that in 2012 may be related with sampling factor.                                      |
| 317 | In summary, the prevalence of hypertension in Jilin province decreased compared        |
| 318 | with that in 2012, and is lower than the overall prevalence in China. In addition, the |
| 319 | study showed that hypertension was associated with age, sex, obesity, smoking and      |
| 320 | alcohol drinking. In particular, smoking may be responsible for the different          |
| 321 | prevalences of hypertension in northern and southern China. These factors above,       |
| 322 | especially smoking, will be important points to control and manage hypertension in     |
| 323 | Jilin province.  |
| 324 |  |
| 325 |  |
| 326 | Reference  |
|     | 15   |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Page 16 of 31

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

| 2  |  |
|--|--|
| 2  |  |
| 2  |  |
| 4  |  |
| 5  |  |
| 6  |  |
| 7  |  |
| 8  |  |
| õ  |  |
| 9  |  |
| 10   |  |
| 11   |  |
| 12   |  |
| 13   |  |
| 14   |  |
| 15   |  |
| 16   |  |
| 10   |  |
| 17   |  |
| 18   |  |
| 19   |  |
| 20   |  |
| 21   |  |
| 22   |  |
| 25<br>25   |  |
| ∠⊃<br>>4   |  |
| 24   |  |
| 25   |  |
| 26   |  |
| 27   |  |
| 3         4         5         6         7         8         9         10         11         12         13         14         15         16         17         18         20         21         22         23         24         25         26         27         28         29         30         32         33         34         35         36         37         38         36         37         38         36         37         36         37         36         37         36         37         36         37         38         36         37          38          37          38          37 |  |
| 29   |  |
| 20   |  |
| 30   |  |
| 31   |  |
| 32   |  |
| 33   |  |
| 34   |  |
| 35   |  |
| 20   |  |
| 30   |  |
| 37   |  |
| 38   |  |
| 39   |  |
| 40   |  |
| 41   |  |
|  |  |
| 42   |  |
| 43   |  |
| 44   |  |
| 45   |  |
| 46   |  |
| 47   |  |
| 48   |  |
|  |  |
| 49   |  |
| 50   |  |
| 51   |  |
| 52   |  |
| 53   |  |
| 53<br>54   |  |
|  |  |
| 55   |  |
| 56   |  |
| 57   |  |
| 58   |  |
| 59   |  |
|  |  |

60

1

327 1. Organization WH: Global action plan for the prevention and control of noncommunicable 328 diseases 2013-2020. 2013. 329 2. Cifkova R, Fodor G, Wohlfahrt P: Changes in Hypertension Prevalence, Awareness, 330 Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update. Current 331 hypertension reports 2016, 18(8):62. 332 3. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U: Hypertension prevalence, 333 awareness, treatment and control in Germany 1998 and 2008-11. Journal of human 334 hypertension 2015, 29(4):247-253. 335 4. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, McAlister FA, Johansen 336 H, Baclic O, Campbell N: Hypertension prevalence, awareness, treatment and control in 337 national surveys from England, the USA and Canada, and correlation with stroke and 338 ischaemic heart disease mortality: a cross-sectional study. BMJ open 2013, 3(8):e003423. 339 Wu X, Duan X, Gu D, Hao J, Tao S, Fan D: Prevalence of hypertension and its trends in 5. 340 Chinese populations. International journal of cardiology 1995, 52(1):39-44. 341 6. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li X, Chalmers J, Gao R et al: 342 Prevalence, awareness, treatment, and control of hypertension in China: data from the 343 China National Nutrition and Health Survey 2002. Circulation 2008, 118(25):2679-2686. 344 7. Reynolds K, Gu D, Muntner P, Wu X, Chen J, Huang G, Duan X, Whelton PK, He J, Inter ACG: 345 Geographic variations in the prevalence, awareness, treatment and control of hypertension 346 in China. J Hypertens 2003, 21(7):1273-1281. 347 8. Wang X, Bots ML, Yang F, Hoes AW, Vaartjes I: Prevalence of hypertension in China: a 348 systematic review and meta-regression analysis of trends and regional differences. J 349 Hypertens 2014, 32(10):1919-1927; discussion 1927. 350 9. Wang Z, Zhang L, Chen Z, Wang X, Shao L, Guo M, Zhu M, Gao R, China Hypertension Survey 351 G: Survey on prevalence of hypertension in China: background, aim, method and design. 352 International journal of cardiology 2014, **174**(3):721-723. 353 10. Fodor JG, Leenen FH, Helis E, Turton P: 2006 Ontario Survey on the Prevalence and Control 354 of Hypertension (ON-BP): Rationale and design of a community-based cross-sectional 355 survey. Canadian Journal of Cardiology 2008, 24(6):503-505. 356 11. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the joint national 357 committee on the prevention, detection, evaluation, and treatment of high blood pressure 358 (JNC 7). Hypertension 2003, 41(6):1178-1179. 359 12. Yang L, Yan J, Tang X, Xu X, Yu W, Wu H: Prevalence, Awareness, Treatment, Control and Risk 360 Factors Associated with Hypertension among Adults in Southern China, 2013. PloS one 2016, 361 **11**(1):e0146181. 362 13. Hu L, Huang X, You C, Li J, Hong K, Li P, Wu Y, Wu Q, Bao H, Cheng X: Prevalence and Risk 363 Factors of Prehypertension and Hypertension in Southern China. PloS one 2017, 364 12(1):e0170238. 365 14. Li G, Wang H, Wang K, Wang W, Dong F, Qian Y, Gong H, Xu G, Li Y, Pan L: Prevalence, 366 awareness, treatment, control and risk factors related to hypertension among urban adults 367 in Inner Mongolia 2014: differences between Mongolian and Han populations. BMC public 368 health 2016, 16(1):294. 369 15. Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Li Y, Feng X, Van F, Lau W, Brock KE: Prevalence, 370 awareness, treatment and control of hypertension in Macau: results from a cross-sectional

#### BMJ Open

| 1        |     |     |  |
|----------|-----|-----|--|
| 2        | 274 |     |  |
| 3        | 371 |     | epidemiological study in Macau, China. Am J Hypertens 2015, 28(2):159-165.                               |
| 4<br>5   | 372 | 16. | Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease                  |
| 6        | 373 |     | Working G: Prevalence, awareness, treatment, and control of hypertension in China: results               |
| 7        | 374 |     | from a national survey. Am J Hypertens 2014, 27(11):1355-1361.   |
| 8        | 375 | 17. | Yang G, Ma Y, Wang S, Su Y, Rao W, Fu Y, Yu Y, Kou C: Prevalence and Correlates of                       |
| 9        | 376 |     | Prehypertension and Hypertension among Adults in Northeastern China: A Cross-Sectional                   |
| 10       | 377 |     | <b>Study</b> . International journal of environmental research and public health 2015, <b>13</b> (1):82. |
| 11       | 378 | 18. | Li L, Rao K, Kong L, Yao C, Xiang H, Zhai F, Ma G, Yang X: A description on the Chinese                  |
| 12<br>13 | 379 |     | national nutrition and health survey in 2002. Zhonghua liu xing bing xue za zhi= Zhonghua                |
| 13<br>14 | 380 |     | liuxingbingxue zazhi 2005, <b>26</b> (7):478-484.  |
| 15       | 381 | 19. | Crump C, Sundquist J, Winkleby MA, Sundquist K: Interactive Effects of Physical Fitness and              |
| 16       | 382 | 15. |  |
| 17       |     |     | Body Mass Index on the Risk of Hypertension. JAMA internal medicine 2016,                                |
| 18       | 383 |     | <b>176</b> (2):210-216.  |
| 19       | 384 | 20. | Papathanasiou G, Zerva E, Zacharis I, Papandreou M, Papageorgiou E, Tzima C,                             |
| 20       | 385 |     | Georgakopoulos D, Evangelou A: Association of high blood pressure with body mass index,                  |
| 21       | 386 |     | smoking and physical activity in healthy young adults. The open cardiovascular medicine                  |
| 22<br>23 | 387 |     | journal 2015, <b>9</b> :5.   |
| 23       | 388 | 21. | Tyson CC, Appel LJ, Vollmer WM, Jerome GJ, Brantley PJ, Hollis JF, Stevens VJ, Ard JD, Patel UD,         |
| 25       | 389 |     | Svetkey LP: Impact of 5 - year weight change on blood pressure: results from the Weight                  |
| 26       | 390 |     | Loss Maintenance trial. The Journal of Clinical Hypertension 2013, <b>15</b> (7):458-464.                |
| 27       | 391 | 22. | Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new                         |
| 28       | 392 |     | insights into mechanisms. Hypertension 2005, <b>45</b> (1):9-14.   |
| 29       |     | 22  |  |
| 30       | 393 | 23. | Organization WH: The Asia-Pacific perspective: redefining obesity and its treatment. In.:                |
| 31<br>32 | 394 |     | Sydney: Health Communications Australia; 2000.   |
| 33       | 395 | 24. | Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, Shimono K, Yamane Y: The new BMI                    |
| 34       | 396 |     | criteria for asians by the regional office for the western pacific region of WHO are suitable            |
| 35       | 397 |     | for screening of overweight to prevent metabolic syndrome in elder Japanese workers.                     |
| 36       | 398 |     | Journal of occupational health 2003, <b>45</b> (6):335-343.  |
| 37       | 399 | 25. | Okosun IS, Prewitt TE, Cooper RS: Abdominal obesity in the United States: prevalence and                 |
| 38       | 400 |     | attributable risk of hypertension. Journal of human hypertension 1999, 13(7):425-430.                    |
| 39<br>40 | 401 | 26. | Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M: Abdominal                  |
| 40<br>41 | 402 |     | obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. The                   |
| 42       | 403 |     | American journal of medicine 2007, <b>120</b> (2):S3-S8.   |
| 43       | 404 | 27. | Yang L, Xu X, Yan J, Yu W, Tang X, Wu H, Parkin CL: Analysis on associated factors of                    |
| 44       | 404 | 27. | uncontrolled hypertension among elderly hypertensive patients in Southern China: a                       |
| 45       |     |     |  |
| 46       | 406 |     | community-based, cross-sectional survey. BMC public health 2014, <b>14</b> (1):903.                      |
| 47       | 407 | 28. | Yip W, Wong TY, Jonas JB, Zheng Y, Lamoureux EL, Nangia V, Sabanayagam C: Prevalence,                    |
| 48<br>49 | 408 |     | awareness, and control of hypertension among Asian Indians living in urban Singapore and                 |
| 49<br>50 | 409 |     | rural India. Journal of hypertension 2013, <b>31</b> (8):1539-1546.                                      |
| 51       | 410 | 29. | Doulougou B, Gomez F, Alvarado B, Guerra RO, Ylli A, Guralnik J, Zunzunegui MV: Factors                  |
| 52       | 411 |     | associated with hypertension prevalence, awareness, treatment and control among                          |
| 53       | 412 |     | participants in the International Mobility in Aging Study (IMIAS). Journal of human                      |
| 54       | 413 |     | hypertension 2016, <b>30</b> (2):112-119.  |
| 55       | 414 | 30. | Cheng S, Xanthakis V, Sullivan LM, Vasan RS: Blood pressure tracking over the adult life                 |
| 56       |     | - • |  |
| 57<br>58 |     |     | 17   |
| 59       |     |     |  |

Page 18 of 31

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

1

| 1        |     |     |   |
|----------|-----|-----|---|
| 2<br>3   | 415 |     | course. Hypertension 2012:HYPERTENSIONAHA. 112.201780.  |
| 4        | 416 | 31. | Guo X, Zheng L, Li Y, Yu S, Zhou X, Wang R, Zhang X, Sun Z, Sun Y: Gender-specific prevalence           |
| 5        | 417 |     | and associated risk factors of prehypertension among rural children and adolescents in                  |
| 6        | 418 |     | Northeast China: a cross-sectional study. European journal of pediatrics 2013,                          |
| 7        | 419 |     | <b>172</b> (2):223-230.   |
| 8<br>9   | 419 | 22  |   |
| 10       |     | 32. | Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V: <b>Prevalence of</b>             |
| 11       | 421 |     | hypertension and associated cardiovascular risk factors in Central India. Journal of family &           |
| 12       | 422 |     | community medicine 2014, <b>21</b> (1):29.  |
| 13       | 423 | 33. | Malekzadeh MM, Etemadi A, Kamangar F, Khademi H, Golozar A, Islami F, Pourshams A,                      |
| 14       | 424 |     | Poustchi H, Navabakhsh B, Naemi M: Prevalence, awareness and risk factors of hypertension               |
| 15<br>16 | 425 |     | in a large cohort of Iranian adult population. <i>Journal of hypertension</i> 2013, <b>31</b> (7):1364. |
| 16<br>17 | 426 | 34. | Heitmar R, Summers RJ: Assessing vascular function using dynamic retinal diameter                       |
| 18       | 427 |     | measurements: a new insight on the endothelium. Thromb Haemost 2012,                                    |
| 19       | 428 |     | <b>107</b> (6):1019-1026.   |
| 20       | 429 | 35. | Meng XJ, Dong GH, Wang D, Liu MM, Lin Q, Tian S, Xu LX, Hou H, Ren YF, Lee YL: Prevalence,              |
| 21       | 430 |     | awareness, treatment, control, and risk factors associated with hypertension in urban                   |
| 22       | 431 |     | adults from 33 communities of China: the CHPSNE study. J Hypertens 2011,                                |
| 23<br>24 | 432 |     | <b>29</b> (7):1303-1310.  |
| 25       | 433 | 36. | Pereira M, Lunet N, Azevedo A, Barros H: Differences in prevalence, awareness, treatment                |
| 26       | 434 |     | and control of hypertension between developing and developed countries. Journal of                      |
| 27       | 435 |     | hypertension 2009, <b>27</b> (5):963-975.   |
| 28       | 436 | 37. | Bowman TS, Gaziano JM, Buring JE, Sesso HD: A prospective study of cigarette smoking and                |
| 29       | 437 | 57. |   |
| 30<br>31 |     |     | risk of incident hypertension in women. Journal of the American College of Cardiology 2007,             |
| 32       | 438 |     | <b>50</b> (21):2085-2092.   |
| 33       | 439 | 38. | Stranges S, Wu T, Dorn JM, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH,                 |
| 34       | 440 |     | Trevisan M: Relationship of alcohol drinking pattern to risk of hypertension: a                         |
| 35       | 441 |     | population-based study. Hypertension 2004, 44(6):813-819.   |
| 36       | 442 | 39. | Grucza RA, Krueger RF, Racette SB, Norberg KE, Hipp PR, Bierut LJ: The emerging link                    |
| 37       | 443 |     | between alcoholism risk and obesity in the United States. Archives of general psychiatry                |
| 38<br>39 | 444 |     | 2010, <b>67</b> (12):1301-1308.   |
| 40       | 445 | 40. | Ke L, Ho J, Feng J, Mpofu E, Dibley MJ, Feng X, Van F, Leong S, Lau W, Lueng P: Modifiable risk         |
| 41       | 446 |     | factors including sunlight exposure and fish consumption are associated with risk of                    |
| 42       | 447 |     | hypertension in a large representative population from Macau. The Journal of steroid                    |
| 43       | 448 |     | biochemistry and molecular biology 2014, <b>144</b> :152-155.   |
| 44       | 449 | 41. | Shea JL, King MTC, Yi Y, Gulliver W, Sun G: Body fat percentage is associated with                      |
| 45<br>46 | 450 |     | cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutrition,                         |
| 40       | 451 |     | Metabolism and Cardiovascular Diseases 2012, <b>22</b> (9):741-747.                                     |
| 48       | 452 | 42. | Weinsier RL, Norris DJ, Birch R, Bernstein RS, Wang J, Yang M-U, Pierson RN, Van Itallie TB:            |
| 49       | 453 |     | The relative contribution of body fat and fat pattern to blood pressure level. Hypertension             |
| 50       | 454 |     | 1985, <b>7</b> (4):578-585.   |
| 51       | 455 | 43. |   |
| 52<br>52 |     | 45. | Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I: Appropriate body-mass index for Asian              |
| 53<br>54 | 456 |     | populations and its implications for policy and intervention strategies. The lancet 2004,               |
| 55       | 457 |     | <b>363</b> (9403):157.  |
| 56       | 458 | 44. | Wang W: Guidelines for the management of hypertension in China Chinese Journal of                       |
| 57       |     |     | 18  |
| 58       |     |     |   |
| 59<br>60 |     |     | For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml                               |

60

#### **BMJ** Open

| 1        |     |  |
|----------|-----|--|
| 2<br>3   | 459 | Hypertension 2015, <b>23</b> (1):24-43.  |
| 4        | 460 | 45. Wu Z, Yong H, Wang W, Zhao L, Zhu D: Guidelines for Hypertension Education in China. |
| 5        | 461 | <i>Chinese Journal of Hypertension</i> 2014(3):78-110.                                   |
| 6        |     | Chillese Journal of Hypertension 2014(5).76-110.   |
| 7        | 462 |  |
| 8        | 463 |  |
| 9<br>10  | 405 |  |
| 11       | 464 | Footnotes  |
| 12       | 465 | Contributors   |
| 13       | 405 |  |
| 14       | 466 | BL was involved in the study's design, JW, XS, LL, YY, YL, and CQ collected              |
| 15<br>16 | 467 | the data, YZ and YL performed the statistical analysis, TL, WS, and BL wrote the         |
| 17       | 407 | the data, 12 and 12 performed the statistical analysis, 12, w.S, and DL wrote the        |
| 18       | 468 | paper. All authors reviewed and approved the final version of the paper.                 |
| 19       | 460 |  |
| 20       | 469 |  |
| 21<br>22 | 470 | Ethics approval  |
| 23       |     |  |
| 24       | 471 | This study was approved by the Fuwai Hospital Ethics Review Board.                       |
| 25       | 472 |  |
| 26       |     |  |
| 27<br>28 | 473 | Funding  |
| 29       | 474 | This work was supported by the National Key R&D Program in the Twelfth                   |
| 30       |     |  |
| 31       | 475 | Five-year Plan (No. 2011BAI11B01) from the Chinese Ministry of Science and               |
| 32       | 476 | Technology and the National Clinical Key Specialty Project.                              |
| 33<br>34 |     |  |
| 35       | 477 |  |
| 36       | 478 | Competing interests  |
| 37       |     |  |
| 38<br>39 | 479 | None declared.   |
| 40       | 480 |  |
| 41       |     | Data sharing statement   |
| 42       | 481 | Data sharing statement   |
| 43       | 482 | No additional data are available.  |
| 44<br>45 |     |  |
| 46       |     |  |
| 47       |     |  |
| 48       |     |  |
| 49       |     |  |
| 50<br>51 |     |  |
| 52       |     |  |
| 53       |     |  |
| 54       |     |  |
| 55       |     |  |
| 56<br>57 |     |  |
| 57       |     | 19   |

#### 483 Figure Captions

Figure 1: Trends of physical characteristics by age and sex. (A) basal metabolism BM
(B) body fat percentage - BFP (C) visceral fat index - VFI (D) body mass index - BMI
(E) systolic blood pressure - SBP (F) diastolic blood pressure - DBP

**Table 1:** Distribution of participants by age and sex in Jilin province (N, %)

| ٨٩٩   | М    | ale   | Fer  | nale  | Тс    | tal   |
|-------|------|-------|------|-------|-------|-------|
| Age   | Ν    | %     | Ν    | %     | Ν     | %     |
| 15-24 | 1120 | 9.07  | 1146 | 8.51  | 2266  | 17.59 |
| 25-34 | 1316 | 8.91  | 1520 | 8.52  | 2836  | 17.43 |
| 35-44 | 1084 | 11.95 | 1359 | 11.40 | 2443  | 23.35 |
| 45-54 | 1043 | 10.02 | 1333 | 9.68  | 2376  | 19.70 |
| 55-64 | 950  | 6.36  | 1121 | 6.47  | 2071  | 12.83 |
| 65-74 | 755  | 3.01  | 823  | 3.23  | 1578  | 6.24  |
| 75+   | 678  | 1.31  | 708  | 1.55  | 1386  | 2.86  |
| Total | 6946 | 50.63 | 8010 | 49.37 | 14956 | 100.0 |
|       |      |       |      |       |       |       |
|       |      |       |      |       |       |       |

Page 21 of 31

1

BMJ Open

| י<br>ר                           |   |
|----------------------------------|---|
| 2                                |   |
| 3                                |   |
| 4                                |   |
| 5                                |   |
| 6                                |   |
| 7                                |   |
| 8                                |   |
| 9                                |   |
| 10                               |   |
| 11                               |   |
| 12                               |   |
| 13                               |   |
| 14                               |   |
| 15                               |   |
| 11<br>12<br>13<br>14<br>15<br>16 |   |
| 17                               |   |
| 18                               |   |
| 19                               |   |
| 20                               |   |
| 21                               |   |
| 22                               |   |
| 23                               |   |
| 24<br>25<br>26                   |   |
| 25                               |   |
| 26                               |   |
| 27                               |   |
| 28                               |   |
| 29                               |   |
| 30                               |   |
| 31                               |   |
| 32                               |   |
| 33                               |   |
| 34                               |   |
| 35<br>36                         |   |
| 36                               |   |
| 37                               |   |
| 38                               |   |
| 39                               |   |
| 40                               |   |
| 41                               |   |
| 42                               |   |
| 43                               |   |
| 44                               |   |
| 45                               |   |
| 46                               | Т |

47

|        |               |               |               | Smoking      |               |             |               |                 |
|--------|---------------|---------------|---------------|--------------|---------------|-------------|---------------|-----------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0        | Current       | Ever        | Never         | Alcohol Drinkin |
| Male   |               |               |               |              |               |             |               |                 |
| 15-24  | 13.33         | 67.57         | 14.85         | 4.25         | 6.95          | 0.36        | 92.69         | 5.80            |
|        | (11.11,15.91) | (64.24,70.73) | (12.58,17.46) | (3.03,5.93)  | (5.47,8.80)   | (0.10,1.22) | (90.79,94.22) | (4.62, 7.26)    |
| 25-34  | 2.80          | 57.76         | 31.36         | 8.08         | 39.19         | 0.64        | 60.17         | 29.70           |
|        | (1.98,3.93)   | (54.70,60.77) | (28.57,34.30) | (6.52,9.96)  | (36.20,42.26) | (0.30,1.37) | (57.09,63.17) | (26.96, 32.60)  |
| 35-44  | 1.89          | 54.86         | 35.26         | 7.99         | 46.92         | 1.32        | 51.76         | 39.90           |
|        | (0.18,3.01)   | (51.49,58.18) | (32.10,38.55) | (6.35,10.02) | (43.57,50.30) | (0.79,2.18) | (48.39,55.12) | (36.62, 43.26)  |
| 45-54  | 1.56          | 55.63         | 36.25         | 6.56         | 48.42         | 3.19        | 48.38         | 44.70           |
|        | (0.93,2.60)   | (52.33,58.88) | (33.14,39.47) | (5.11,8.39)  | (45.13,51.73) | (2.25,4.52) | (45.10,51.68) | (41.44, 48.00)  |
| 55-64  | 0.79          | 59.10         | 35.17         | 4.94         | 44.79         | 5.19        | 50.02         | 39.30           |
|        | (0.39,1.60)   | (55.67,62.44) | (31.96,38.52) | (3.65,6.66)  | (41.38,48.25) | (3.88,6.91) | (46.57,53.47) | (35.99, 42.71)  |
| 65-74  | 2.16          | 60.45         | 33.51         | 3.88         | 32.13         | 6.99        | 60.88         | 34.30           |
|        | (1.26,3.69)   | (56.54,64.22) | (29.91,37.33) | (2.66,5.62)  | (28.57,35.91) | (5.22,9.30) | (56.97,64.65) | (30.65, 38.14)  |
| 75+    | 3.71          | 62.83         | 30.22         | 3.23         | 22.06         | 5.58        | 72.35         | 18.74           |
|        | (2.53,5.42)   | (58.82,66.68) | (26.61,34.10) | (2.01,5.15)  | (18.85,25.64) | (3.96,7.82) | (68.54,75.87) | (15.72, 22.19)  |
| Female |               |               |               |              |               |             |               |                 |
| 15-24  | 13.46         | 70.77         | 12.55         | 3.22         | 0.36          | 0.00        | 99.64         | 0.76            |
|        | (11.24,16.03) | (67.48,73.85) | (10.34,15.16) | (2.34,4.43)  | (0.11,1.16)   |             | (98.84,99.89) | (0.43,1.35)     |
| 25-34  | 6.46          | 66.10         | 22.33         | 5.11         | 2.90          | 0.06        | 97.04         | 3.50            |
|        | (5.25,7.94)   | (63.37,68.72) | (20.06,24.79) | (3.97,6.55)  | (2.05,4.08)   | (0.01,0.44) | (95.85,97.89) | (2.65,4.62)     |
| 35-44  | 1.81          | 61.59         | 29.86         | 6.74         | 8.00          | 0.07        | 91.93         | 4.40            |
|        | (1.16,2.81)   | (58.64,64.45) | (27.18,32.67) | (5.38,8.41)  | (6.45,9.88)   | (0.01,0.50) | (90.05,93.49) | (3.37,5.73)     |

ce (%, 95%CI) Table 2: Distributio f porticipanta h stratified by body in de d alaahalia drinking in Jilin 1 1... .... 490

21

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) Protected by copyright,אַשָּפּוּקוּשָׁאָשָּלָפָאַלָּאָלָשָּלָפָאַלָּאָלָשָרָפָאָלַפָּאַלָאָיָשָרָפּאַלַפָּלַפָּאַלָאָיָשָרָפּאַלַפָּאַלָאַיָאַטָרָשַרָאַ אַ אַשָּאָנאַקָאָשָרישוואר זירי

| 45-54 | 1.99         | 54.20         | 36.38         | 7.44         | 10.36         | 0.52        | 89.12         | 3.08        |
|-------|--------------|---------------|---------------|--------------|---------------|-------------|---------------|-------------|
|       | (1.29,3.04)  | (51.27,57.09) | (33.62,39.24) | (6.05,9.11)  | (8.69,12.31)  | (0.23,1.17) | (87.14,90.83) | (2.23,4.25) |
| 55-64 | 2.53         | 48.89         | 40.24         | 8.34         | 16.81         | 1.46        | 81.73         | 2.53        |
|       | (1.72,3.71)  | (45.72,52.08) | (37.17,43.39) | (6.72,10.30) | (14.58,19.30) | (0.85,2.49) | (79.16,84.05) | (1.68,3.81) |
| 65-74 | 4.89         | 50.05         | 38.50         | 6.57         | 17.61         | 1.68        | 80.71         | 1.81        |
|       | (3.53,6.72)  | (46.31,53.78) | (34.91,42.22) | (4.94,8.67)  | (14.97,20.60) | (0.93,2.99) | (77.62,83.47) | (1.03,3.16) |
| 75+   | 10.17        | 57.46         | 26.17         | 6.20         | 12.82         | 1.27        | 85.91         | 2.48        |
| _     | (7.87,13.04) | (53.37,61.45) | (22.77,29.89) | (4.50,8.50)  | (10.29,15.87) | (0.64,2.50) | (82.77,88.55) | (1.45,4.23) |
|       |              |               |               |              |               |             |               |             |

Protected by copyright, insuling tornast selected to text and take any mitring, the maining to the protected by copyright of the protected by copyright of the protected by the

BMJ Open: first published as 10.1136/mjopen-20126 on 28 March 2018. Downloaded from http://pmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (SBBA)

| 2        |     |          |           |                               |          |                        |           |                    |
|----------|-----|----------|-----------|-------------------------------|----------|------------------------|-----------|--------------------|
| 3<br>4   | 491 | Table 3  | Preva     | alence of hypertension        | on by ag | ge and sex in Jilin pr | ovince    |                    |
| 5        |     | Age      |           | Male                          |          | Female                 |           | Total              |
| 6        | -   | group    | n         | CR(95%CI)                     | n        | CR(95%CI)              | n         | CR(95%CI)          |
| 7<br>8   |     | 15-24    | 80        | 6.86(5.27,8.87)               | 23       | 1.88(1.19,2.96)        | 103       | 4.45(3.53,5.59)    |
| 9        |     | 25-34    | 106       | 8.47(6.89,10.36)              | 50       | 4.28(3.20,5.69)        | 156       | 6.42(5.43,7.58)    |
| 10       |     | 35-44    | 221       | 21.00(18.36,23.91)            | 195      | 15.21(13.14,17.55)     | 416       | 18.17(16.45,20.03) |
| 11       |     | 45-54    | 379       | 35.13(32.06,38.33)            | 430      | 32.57(29.89,35.36)     | 809       | 33.87(31.82,35.99) |
| 12<br>13 |     | 55-64    | 449       | 46.42(43.00,49.87)            | 576      | 50.72(47.54,53.90)     | 1025      | 48.59(46.25,50.94) |
| 14       |     | 65-74    | 451       | 59.91(55.98,63.71)            | 518      | 65.32(61.72,68.76)     | 969       | 62.71(60.06,65.29) |
| 15       |     | 75+      | 405       | 61.24(57.24,65.10)            | 449      | 62.37(58.30,66.28)     | 854       | 61.86(59.00,64.63) |
| 16       | _   | Total    | 2091      | 25.60(24.41,26.79)            | 2241     | 23.84(22.80,24.89)     | 4332      | 24.73(23.94,25.53) |
| 17       | 492 | CI: conf | idence in | 25.60(24.41,26.79)<br>nterval |          |                        |           |                    |
| 18<br>19 | 493 |          |           |                               |          |                        |           |                    |
| 20       |     |          |           |                               |          |                        |           |                    |
| 21       |     |          |           |                               |          |                        |           |                    |
| 22       |     |          |           |                               |          |                        |           |                    |
| 23<br>24 |     |          |           |                               |          |                        |           |                    |
| 25       |     |          |           |                               |          |                        |           |                    |
| 26       |     |          |           |                               |          |                        |           |                    |
| 27       |     |          |           |                               |          |                        |           |                    |
| 28<br>29 |     |          |           |                               |          |                        |           |                    |
| 30       |     |          |           |                               |          |                        |           |                    |
| 31       |     |          |           |                               |          |                        |           |                    |
| 32       |     |          |           |                               |          |                        |           |                    |
| 33<br>34 |     |          |           |                               |          |                        |           |                    |
| 35       |     |          |           |                               |          |                        |           |                    |
| 36       |     |          |           |                               |          |                        |           |                    |
| 37       |     |          |           |                               |          |                        |           |                    |
| 38<br>39 |     |          |           |                               |          |                        |           |                    |
| 40       |     |          |           |                               |          |                        |           |                    |
| 41       |     |          |           |                               |          |                        |           |                    |
| 42       |     |          |           |                               |          |                        |           |                    |
| 43<br>44 |     |          |           |                               |          |                        |           |                    |
| 44<br>45 |     |          |           |                               |          |                        |           |                    |
| 46       |     |          |           |                               |          |                        |           |                    |
| 47       |     |          |           |                               |          |                        |           |                    |
| 48       |     |          |           |                               |          |                        |           |                    |
| 49<br>50 |     |          |           |                               |          |                        |           |                    |
| 51       |     |          |           |                               |          |                        |           |                    |
| 52       |     |          |           |                               |          |                        |           |                    |
| 53       |     |          |           |                               |          |                        |           |                    |
| 54       |     |          |           |                               |          |                        |           |                    |
| 55<br>56 |     |          |           |                               |          |                        |           |                    |
| 57       |     |          |           |                               |          |                        |           |                    |
| 58       |     |          |           |                               |          |                        |           | 23                 |
| 59       |     |          | For po    | er review only - http://      | 'hmione  | n hmi com/sita/about   | ·/auidal  | ines vhtml         |
| 60       |     |          | i oi pe   | er review only - http://      | onjope   | n.omj.com/site/about   | ./ yuluel |                    |
|          |     |          |           |                               |          |                        |           |                    |

| י<br>ר   |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 14<br>15 |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 10       |  |
| 19<br>20 |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 40<br>41 |  |
| 41<br>42 |  |
| 42<br>43 |  |
|          |  |
| 44       |  |
| 45       |  |
| 46       |  |

1

494

|        |               | B             | MI            |               |               | Smoking         |               | Alcohol        | Drinking      |
|--------|---------------|---------------|---------------|---------------|---------------|-----------------|---------------|----------------|---------------|
|        | <18.5         | 18.5-25.0     | 25.0-30.0     | >30.0         | Current       | Ever            | Never         | Yes            | No            |
| Male   |               |               |               |               |               |                 |               |                |               |
| 15-24  | 1.48          | 4.39          | 16.22         | 30.17         | 8.17          | 13.13           | 6.73          | 11.60          | 6.56          |
|        | (0.37,5.76)   | (2.94,6.51)   | (10.62,24.00) | (16.58,48.44) | (3.45,18.15)  | (1.35,62.57)    | (5.10,8.84)   | (5.85,21.69)   | (4.95, 8.66)  |
| 25-34  | 1.45          | 5.33          | 9.15          | 30.70         | 11.49         | 6.89            | 6.51          | 10.64          | 7.55          |
|        | (0.20,9.72)   | (3.78,7.46)   | (6.43,12.85)  | (21.42,41.86) | (8.66,15.08)  | (0.88,38.13)    | (4.80,8.78)   | (7.63, 14.64)  | (5.80, 9.77)  |
| 35-44  | 5.49          | 14.76         | 25.87         | 45.98         | 23.76         | 36.23           | 18.11         | 28.02          | 16.34         |
|        | (0.97,25.57)  | (11.77,18.34) | (21.16,31.22) | (34.53,57.87) | (19.72,28.33) | (16.51,62.01)   | (14.77,22.00) | (23.40, 33.16) | (13.35,19.84  |
| 45-54  | 27.39         | 25.02         | 44.90         | 68.73         | 37.10         | 41.53           | 32.74         | 43.01          | 28.76         |
|        | (10.96,53.63) | (21.38,29.05) | (39.57,50.35) | (55.83,79.27) | (32.60,41.83) | (25.83,59.16)   | (28.51,37.27) | (38.20, 47.96) | (24.95, 32.9) |
| 55-64  | 11.46         | 39.64         | 55.87         | 65.91         | 47.15         | 61.46           | 44.21         | 52.10          | 42.74         |
|        | (2.44,40.14)  | (35.33,44.11) | (50.07,79.30) | (50.62,78.48) | (42.04,52.33) | (46.39,74.61)   | (39.43,49.09) | (46.61, 57.54) | (38.42, 47.18 |
| 65-74  | 19.58         | 52.27         | 73.86         | 80.86         | 60.60         | 74.69           | 57.84         | 66.86          | 56.58         |
|        | (6.35,46.63)  | (47.16,57.34) | (67.56,15.96) | (61.30,91.85) | (53.60,67.20) | (59.79,85.42)   | (52.78,62.74) | (60.21, 72.89) | (51.40, 61.04 |
| 75+    | 37.87         | 58.85         | 66.71         | 83.47         | 68.66         | 59.10           | 59.15         | 65.17          | 60.34         |
|        | (21.57,57.45) | (53.77,63.76) | (59.34,73.34) | (57.75,94.91) | (60.13,76.08) | (41.42,74.69)   | (54.42,63.71) | (55.63, 73.63) | (55.90, 64.62 |
| Female |               |               |               |               |               |                 |               |                |               |
| 15-24  | 1.50          | 0.91          | 5.62          | 10.02         | 0.00          | 0.00            | 1.88          | 0.00           | 1.89          |
|        | (0.37,5.81)   | (0.42,1.98)   | (2.53,12.01)  | (3.85,23.67)  |               |                 | (1.19,2.97)   |                | (1.19,2.98)   |
| 25-34  | 0.00          | 2.16          | 6.56          | 27.09         | 12.35         | 0.00            | 4.04          | 0.66           | 4.41          |
|        |               | (1.29,3.59)   | (4.03,10.51)  | (16.97,40.31) | (4.36,30.33)  |                 | (2.98,5.44)   | (0.09,4.63)    | (3.29,5.87)   |
| 35-44  | 17.78         | 9.70          | 22.05         | 34.59         | 19.76         | 100.00          | 14.75         | 25.47          | 14.74         |
|        | (5.86,42.90)  | (7.67,12.20)  | (17.69,27.14) | (24.35,46.49) | (12.41,29.97) | (100.00,100.00) | (12.62,17.17) | (14.99,39.84)  | (12.65,17.11  |

1 ° C (0/050/01) $\mathbf{T}$ 

24

| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$  | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$  |            |               | • • • • •     | 40.40         | <pre></pre>   |               | <b>64 -</b> 0   |               |               |          |
|--|--|------------|---------------|---------------|---------------|---------------|---------------|-----------------|---------------|---------------|----------|
| 55-64         40.61         39.07         61.42         70.47         51.28         62.47         50.40         51.62         50.7           (23.68,60.12)         (34.71,43.61)         (56.48,66.14)         (59.27,79.64)         (43.64,58.86)         (35.28,83.56)         (46.87,53.92)         (31.60,71.13)         (47.48,56,65.74)           65-74         38.58         59.74         74.83         72.04         65.26         57.48         65.50         50.45         65.66           (24.16,55.33)         (54.53,64.73)         (69.27,79.68)         (57.14,83.28)         (56.45,73.13)         (29.24,81.56)         (61.48,69.31)         (24.78,75.88)         (61.97,66)   | 55-64         40.61         39.07         61.42         70.47         51.28         62.47         50.40         51.62         50.7           (23.68,60.12)         (34.71,43.61)         (56.48,66.14)         (59.27,79.64)         (43.64,58.86)         (35.28,83.56)         (46.87,53.92)         (31.60,71.13)         (47.48,56,65.74)           65-74         38.58         59.74         74.83         72.04         65.26         57.48         65.50         50.45         65.66           (24.16,55.33)         (54.53,64.73)         (69.27,79.68)         (57.14,83.28)         (56.45,73.13)         (29.24,81.56)         (61.48,69.31)         (24.78,75.88)         (61.97,66)   | 45-54      | 0.00          | 24.68         | 40.48         | 60.03         | 34.92         | 61.78           | 32.13         | 27.45         | 32.7     |
| (23.68,60.12)       (34.71,43.61)       (56.48,66.14)       (59.27,79.64)       (43.64,58.86)       (35.28,83.56)       (46.87,53.92)       (31.60,71.13)       (47.48,328)         65-74       38.58       59.74       74.83       72.04       65.26       57.48       65.50       50.45       65.06         (24.16,55.33)       (54.53,64.73)       (69.27,79.68)       (57.14,83.28)       (56.45,73.13)       (29.24,81.56)       (61.48,69.31)       (24.78,75.88)       (61.97,61.13)  | (23.68,60.12)       (34.71,43.61)       (56.48,66.14)       (59.27,79.64)       (43.64,58.86)       (35.28,83.56)       (46.87,53.92)       (31.60,71.13)       (47.48,328)         65-74       38.58       59.74       74.83       72.04       65.26       57.48       65.50       50.45       65.06         (24.16,55.33)       (54.53,64.73)       (69.27,79.68)       (57.14,83.28)       (56.45,73.13)       (29.24,81.56)       (61.48,69.31)       (24.78,75.88)       (61.97,61.13)  |            |               |               |               |               |               |                 |               |               |          |
| 65-74         38.58         59.74         74.83         72.04         65.26         57.48         65.50         50.45         65.45           (24.16,55.33)         (54.53,64.73)         (69.27,79.68)         (57.14,83.28)         (56.45,73.13)         (29.24,81.56)         (61.48,69.31)         (24.78,75.88)         (61.97,6 | 65-74         38.58         59.74         74.83         72.04         65.26         57.48         65.50         50.45         65.45           (24.16,55.33)         (54.53,64.73)         (69.27,79.68)         (57.14,83.28)         (56.45,73.13)         (29.24,81.56)         (61.48,69.31)         (24.78,75.88)         (61.97,6 | 55-64      |               |               |               |               |               |                 |               |               |          |
| (24.16,55.33) (54.53,64.73) (69.27,79.68) (57.14,83.28) (56.45,73.13) (29.24,81.56) (61.48,69.31) (24.78,75.88) (61.97,6   | (24.16,55.33) (54.53,64.73) (69.27,79.68) (57.14,83.28) (56.45,73.13) (29.24,81.56) (61.48,69.31) (24.78,75.88) (61.97,6   | < <b>-</b> |               |               |               |               |               |                 |               |               |          |
|  |  | 65-74      |               |               |               |               |               |                 |               |               |          |
| 75+ 45.30 60.64 73.24 60.53 64.01 100.00 61.57 51.72 62.6<br>(32.73,58.49) (55.25,65.79) (65.79,79.57) (43.53,75.31) (52.10,74.41) (100.00,100.00) (57.18,65.79) (26.49,76.10) (58.53,6  | /5+ 45.30 60.64 /3.24 60.53 64.01 100.00 61.57 51.72 62.0<br>(32.73,58.49) (55.25,65.79) (65.79,79.57) (43.53,75.31) (52.10,74.41) (100.00,100.00) (57.18,65.79) (26.49,76.10) (58.53,   |            | ,             |               |               |               |               |                 |               |               |          |
|  |  | /5+        |               |               | 73.24         | 60.53         | 64.01         | 100.00          | 61.57         | 51.72         |          |
|  |  |            | (32.73,58.49) | (55.25,65.79) | (65.79,79.57) | (43.53,75.31) | (52.10,74.41) | (100.00,100.00) | (57.18,65.79) | (26.49,76.10) | (58.53,6 |
|  |  |            |               |               |               |               |               |                 |               |               |          |
|  |  |            |               |               |               |               |               |                 |               |               |          |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyrighty/instlughpation for the selected for the second similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25<br>26<br>7<br>28<br>9<br>30<br>31<br>23<br>34<br>35<br>36<br>37<br>38<br>9<br>00 |  |
|---|--|
| 6<br>7  |  |
| 8<br>9  |  |
| 10  |  |
| 12  |  |
| 13<br>14  |  |
| 15<br>16  |  |
| 17  |  |
| 19  |  |
| 20<br>21  |  |
| 22<br>23  |  |
| 24<br>25  |  |
| 26  |  |
| 27  |  |
| 29<br>30  |  |
| 31<br>32  |  |
| 33<br>34  |  |
| 35  |  |
| 30<br>37  |  |
| 38<br>39<br>40  |  |
| 40<br>41  |  |
| 42<br>43  |  |
| 44  |  |
| 45<br>46  |  |
| 47<br>48  |  |
| 49<br>50  |  |
| 51<br>52  |  |
| 53<br>54  |  |
| 55  |  |
| 56<br>57  |  |
| 58<br>59  |  |
| 60  |  |

1 2 3


# 495 **Table.5** Risk factors associated with the prevalence of hypertension

|   | Hypertensio        | n prevalence     |
|---|--------------------|------------------|
|   | Unadjusted         | Adjusted         |
| Age(Ref: 15-24)                         |                    |                  |
| 25-34                                   | 1.47(1.09,1.99)    | 1.05(0.71,1.55)  |
| 35-44                                   | 4.77(3.65,6.24)    | 2.83(1.90,4.22)  |
| 45-54                                   | 11.01(8.51,14.24)  | 6.93(4.69,10.24) |
| 55-64                                   | 20.31(15.69,26.29) | 13.43(9.06,19.90 |
| 65-74                                   | 36.14(27.73,47.11) | 26.18(17.56,39.0 |
| 75+                                     | 34.85(26.65,45.57) | 29.89(19.83,45.0 |
| Sex(Ref: female)                        | 1.1(1.01,1.2)      | 1.25(1.13,1.39)  |
| Region(Ref: Urban)                      | 1.19(1.09,1.3)     | 1.25(1.12,1.39)  |
| Race(Ref: Han)                          | 1.15(0.93,1.42)    | 0.93(0.74,1.18)  |
| Employment(Ref: be employed)            |                    |                  |
| Retired                                 | 2.67(2.22,3.2)     | 0.67(0.53,0.85)  |
| Student                                 | 0.15(0.11,0.21)    | 1.09(0.71,1.70)  |
| Unemployed                              | 1.18(1.07,1.3)     | 0.84(0.74,0.95)  |
| Marital(Ref: married)                   | 0.72(0.63,0.83)    | 1.29(1.00,1.65)  |
| Education level(Ref: college or higher) |                    |                  |
| Illiterate                              | 6.69(5.19,8.63)    | 2.18(1.62,2.93)  |
| Primary                                 | 3.26(2.7,3.93)     | 1.98(1.60,2.44)  |
| Middle                                  | 1.55(1.24,1.94)    | 1.24(0.97,1.57)  |
| BMI(Ref: Normal)                        |                    |                  |
| Overweight                              | 2.22(2.01,2.46)    | 2.30(2.06,2.57)  |
| Obese                                   | 3.96(3.31,4.75)    | 5.17(4.20,6.37)  |
| AWC(Ref:<90M,<85F)                      |                    |                  |
| ≥90M, ≥85F                              | 1.41(1.23,1.62)    | 1.35(1.16,1.57)  |
| ≥95M, ≥90F                              | 1.5(1.32,1.72)     | 1.68(1.43,1.96)  |
| Family history of hypertension          | 1.74(1.55,1.96)    | 2.35(2.06,2.67)  |
| Family history of stroke                | 1.33(0.85,2.06)    | 1.79(1.09,2.92)  |
| Family history of CAD                   | 3.18(2.64,3.83)    | 1.65(1.33,2.03)  |
| Smoker(Ref: no)                         | 1.37(1.23,1.53)    | 1.23(1.08,1.40)  |
| Drinker(Ref: no)                        | 1.56(1.38,1.77)    | 1.47(1.27,1.71)  |
| VAI (Ref:<10)                           | · · · ·            |                  |
| 10~14                                   | 1.6(1.41,1.8)      | 1.40(1.22,1.60)  |
| 15~30                                   | 2.69(2.29,3.16)    | 2.05(1.69,2.49)  |
| BFP(Ref:<10M, <20F)                     |                    |                  |
| 10~19M, 20~29F                          | 1.31(1,1.71)       | 0.95(0.71,1.27)  |
| 20~24M, 30~34F                          | 2.72(2.09,3.55)    | 1.24(0.92,1.66)  |
|   | 3.48(2.67,4.54)    | 1.45(1.07,1.96)  |

498 Adjusted for sex, region, age, education level, employment status, marital status, BMI, and family

499 history of hypertension

CAD:



Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

| 1  |  |
|--|--|
| 2  |  |
| 3  |  |
| 1  |  |
| 2<br>3<br>4<br>5<br>6<br>7<br>8  |  |
| ر<br>د   |  |
| 0  |  |
| /  |  |
| 8  |  |
| 9<br>10  |  |
| 10   |  |
| 11   |  |
| 12   |  |
| 13   |  |
| 13<br>14<br>15<br>16<br>17   |  |
| 15   |  |
| 16   |  |
| 17   |  |
| 10   |  |
| 18   |  |
| 19   |  |
| 20   |  |
| 21   |  |
| 22   |  |
| 23   |  |
| 20<br>21<br>22<br>23<br>24<br>25<br>26<br>27<br>28<br>29<br>30<br>31<br>32 |  |
| 25   |  |
| 26   |  |
| 27   |  |
| 28   |  |
| 29   |  |
| 30   |  |
| 31   |  |
| 37   |  |
| 22   |  |
| 33<br>34   |  |
| 54<br>25   |  |
| 35<br>36   |  |
| 36   |  |
| 37   |  |
| 38   |  |
| 39   |  |
| 40   |  |
| 41   |  |
| 42   |  |
| 43   |  |
| 44   |  |
| 45   |  |
| 46   |  |
| 47   |  |
| 48   |  |
| 49   |  |
| 49<br>50   |  |
|  |  |
| 51   |  |
| 52   |  |
| 53   |  |
| 54   |  |
| 55   |  |
| 56   |  |
| 57   |  |
| 58   |  |
| 59   |  |
| 60   |  |

60

**Supplementary Table** Descriptions of basal metabolism – BM, body fat percentage – BFP, visceral fat index - VFI by age and sex in Jilin province

|            | Age   |         | Male           |         | Female            |
|------------|-------|---------|----------------|---------|-------------------|
|            | Age   | Mean    | 95%CI          | Mean    | 95%CI             |
| BM         | Total | 1511.50 | (1504.56,      | 1280.52 | (1276.09, 1284.9  |
|            |       |         | 1518.43)       |         |                   |
|            | 15-24 | 1478.92 | (1456.95,      | 1279.31 | (1264.09, 1294.5  |
|            |       |         | 1500.88)       |         |                   |
|            | 25-34 | 1538.93 | (1524.04,      | 1281.66 | (1272.68,1290.64  |
|            |       |         | 1553.81)       |         |                   |
|            | 35-44 | 1534.48 | (1519.02,      | 1293.35 | (1284.03, 1302.67 |
|            |       |         | 1549.95)       |         |                   |
|            | 45-54 | 1528.84 | (1514.65,      | 1293.81 | (1284.74, 1302.87 |
|            |       |         | 1543.02)       |         |                   |
|            | 55-64 | 1499.65 | (1486.40,      | 1274.36 | (1264.67, 1284.00 |
|            |       |         | 1512.90)       |         |                   |
|            | 65-74 | 1460.36 | (1443.82,      | 1241.86 | (1230.00, 1253.73 |
|            |       |         | 1476.89)       |         |                   |
|            | 75+   | 1382.81 | (1367.17,      | 1209.84 | (1195.08, 1224.59 |
|            |       |         | 1398.45)       |         |                   |
| Body Fat   | Total | 23.28   | (23.03, 23.53) | 29.19   | (29.02, 29.35)    |
| percentage |       |         |                |         |                   |
|            | 15-24 | 18.46   | (17.52, 19.40) | 24.78   | (24.38, 25.18)    |
|            | 25-34 | 23.26   | (22.87, 23.65) | 27.20   | (26.88,27.52)     |
|            | 35-44 | 24.02   | (23.64, 24.40) | 29.19   | (28.86, 29.52)    |
|            | 45-54 | 24.09   | (23.76, 24.41) | 30.95   | (30.61, 31.29)    |
|            | 55-64 | 25.34   | (24.58, 26.10) | 32.39   | (31.99, 32.80)    |
|            | 65-74 | 25.74   | (25.30, 26.17) | 32.97   | (32.46, 33.48)    |
|            | 75+   | 28.31   | (27.06, 29.56) | 32.08   | (31.15, 33.00)    |
| VAI        | Total | 9.63    | (9.49, 9.77)   | 7.42    | (7.29, 7.55)      |
|            | 15-24 | 6.81    | (6.54, 7.08)   | 6.48    | (6.05, 6.91)      |
|            | 25-34 | 9.13    | (8.81, 9.46)   | 6.07    | (5.83, 6.30)      |
|            | 35-44 | 10.01   | (9.70, 10.32)  | 7.25    | (6.96, 7.54)      |
|            | 45-54 | 10.71   | (10.39, 11.03) | 7.90    | (7.68, 8.11)      |
|            | 55-64 | 11.06   | (10.74, 11.37) | 8.71    | (8.47, 8.96)      |
|            | 65-74 | 11.11   | (10.72, 11.49) | 9.27    | (8.81, 9.73)      |
|            | 75+   | 10.64   | (10.21, 11.07) | 8.95    | (8.56, 9.35)      |
| BMI        | Total | 24.15   | (24.05,24.25)  | 23.88   | (23.78,23.97)     |
|            | 15-24 | 22.20   | (21.93,22.47)  | 21.86   | (21.63,22.10)     |
|            | 25-34 | 24.41   | (24.18,24.63)  | 23.20   | (22.99,23.42)     |
|            | 35-44 | 24.78   | (24.55,25.01)  | 24.29   | (24.08,24.51)     |
|            | 45-54 | 24.75   | (24.54,25.01)  | 24.82   | (24.63,25.02)     |
|            | 55-64 | 24.54   | (24.33,24.76)  | 24.96   | (24.74,25.18)     |

|     | 65-74 | 24.14  | (23.88,24.40)   | 24.63  | (24.35,24.92)   |
|-----|-------|--------|-----------------|--------|-----------------|
|     | 75+   | 23.63  | (23.37,23.89)   | 23.56  | (23.24,23.88)   |
| SBP | Total | 130.44 | (129.99,130.88) | 127.36 | (126.90,127.81) |
|     | 15-24 | 122.45 | (121.67,123.24) | 116.81 | (116.13,117.50) |
|     | 25-34 | 124.43 | (123.77,125.08) | 117.93 | (117.28,118.58) |
|     | 35-44 | 128.76 | (127.85,129.67) | 123.85 | (122.95,124.75) |
|     | 45-54 | 134.69 | (133.51,135.87) | 132.39 | (131.28,133.49) |
|     | 55-64 | 137.56 | (136.22,138.91) | 139.53 | (138.17,140.90) |
|     | 65-74 | 143.98 | (142.25,145.71) | 145.16 | (143.55,146.76) |
|     | 75+   | 143.69 | (141.96,145.42) | 143.44 | (141.60,145.28) |
| DBP | Total | 78.14  | (77.84,78.43)   | 75.45  | (75.19,75.71)   |
|     | 15-24 | 70.98  | (70.43,71.53)   | 69.35  | (68.82,69.88)   |
|     | 25-34 | 76.13  | (75.63,76.63)   | 72.69  | (72.25,73.13)   |
|     | 35-44 | 79.04  | (78.42,79.66)   | 75.47  | (74.91,76.03)   |
|     | 45-54 | 81.24  | (80.51,81.96)   | 78.41  | (77.79,79.03)   |
|     | 55-64 | 82.50  | (81.67,83.33)   | 79.87  | (79.15,80.60)   |
|     | 65-74 | 81.56  | (80.72,82.40)   | 79.13  | (78.35,79.91)   |
|     | 75+   | 80.38  | (79.61,81.15)   | 79.26  | (78.41,80.11)   |
|     |       |        |                 |        |                 |

CI: confidence interval

30.38 (79.61,81.15) 79.26 (78.41,80.11)

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## STROBE Statement-checklist of items that should be included in reports of observational studies

|  | Item<br>No          | Recommendation   |   |
|--|---------------------|--|---|
| Title and abstract   | 1                   | ( <i>a</i> ) Indicate the study's design with a commonly used term in the title or t   | he abstrac<br>P1-   |
|  |                     | (b) Provide in the abstract an informative and balanced summary of what w  | as done   |
|  |                     | and what was found   | P2  |
| Introduction   |                     |  |   |
| Background/rationale   | 2                   | Explain the scientific background and rationale for the investigation being  | ng reporte  |
|  |                     |  | F   |
| Objectives   | 3                   | State specific objectives, including any prespecified hypotheses   | P4  |
| Methods  |                     | ,  |   |
| Study design   | 4                   | Present key elements of study design early in the paper  | P4-5  |
| Setting  | 5                   | Describe the setting, locations, and relevant dates, including periods of recipient  | uitment,  |
|  |                     | exposure, follow-up, and data collection   | P4-5  |
| Participants   | 6                   | (a) Cohort study—Give the eligibility criteria, and the sources and method   | s of  |
|  |                     | selection of participants. Describe methods of follow-up   |   |
|  |                     | Case-control study-Give the eligibility criteria, and the sources and method   | ods of  |
|  |                     | case ascertainment and control selection. Give the rationale for the choice  | of cases  |
|  |                     | and controls   |   |
|  |                     | Cross-sectional study-Give the eligibility criteria, and the sources and me  | thods of  |
|  |                     | selection of participants  | P4  |
|  |                     | (b) Cohort study-For matched studies, give matching criteria and number  | of  |
|  |                     | exposed and unexposed  |   |
|  |                     | Case-control study-For matched studies, give matching criteria and the n   | umber of  |
|  |                     | controls per case  |   |
|  |                     |  |   |
| Variables  | 7                   | Clearly define all outcomes, exposures, predictors, potential confounders, a   | nd effec  |
| Variables  | 7                   | Clearly define all outcomes, exposures, predictors, potential confounders, a modifiers. Give diagnostic criteria, if applicable  |   |
| Variables Data sources/  | 7 8*                |  | Р   |
|  |                     | modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods o   | Pe<br>f   |
| Data sources/  |                     | modifiers. Give diagnostic criteria, if applicable   | Po<br>f<br>if there   |
| Data sources/  |                     | modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods o<br>assessment (measurement). Describe comparability of assessment methods   | Pe<br>f<br>if there i<br>F  |
| Data sources/<br>measurement   | 8*                  | modifiers. Give diagnostic criteria, if applicable<br>For each variable of interest, give sources of data and details of methods of<br>assessment (measurement). Describe comparability of assessment methods<br>more than one group   | Pe<br>f<br>if there i<br>F<br>F   |
| Data sources/<br>measurement<br>Bias<br>Study size                           | 8*<br>9<br>10       | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at  | Pe<br>f<br>if there i<br>F<br>F<br>F  |
| Data sources/<br>measurement<br>Bias   | 8*                  | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If application  | Pe<br>f<br>if there i<br>F<br>F<br>ble,   |
| Data sources/<br>measurement<br>Bias<br>Study size                           | 8*<br>9<br>10       | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at  | Pe<br>f<br>if there<br>F<br>F<br>ble,<br>P5-<br>onfoundin                                 |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation.   | Performance<br>f<br>if there if<br>F<br>F<br>ble,<br>P5-<br>onfoundin                     |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation (b) Describe any methods used to examine subgroups and interactions  | Pe<br>f<br>if there i<br>F<br>F<br>ble,<br>P5-<br>onfoundin<br>I<br>F                     |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation (c) Explain how missing data were addressed  | Pe<br>f<br>if there i<br>F<br>Ble,<br>P5-<br>onfoundin<br>I<br>P<br>F                     |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicate describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for control | Pe<br>f<br>if there if<br>P<br>F<br>ble,<br>P5-<br>onfoundin<br>I<br>P<br>F<br>Sed        |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation (b) Describe any methods used to examine subgroups and interactions         (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address         Case-control study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching of cases and comparation (c) study—If applicable, explain how matching (c) study (c  | Pe<br>f<br>if there if<br>P<br>F<br>ble,<br>P5-<br>onfoundin<br>I<br>P<br>F<br>Sed        |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address Case-control study—If applicable, explain how matching of cases and comparation addressed  | Pe<br>f<br>if there i<br>F<br>B<br>ble,<br>P5-<br>onfoundin<br>I<br>F<br>Sed<br>rrols was |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for study—If applicable, explain how matching of cases and control addressed         (d) Cohort study—If applicable, explain how matching of cases and control addressed         (a) Coss-sectional study—If applicable, describe analytical methods taking addressed  | Pe<br>f<br>if there i<br>F<br>F<br>ble,<br>P5-<br>onfoundin<br>I<br>F<br>sed<br>crols was |
| Data sources/<br>measurement<br>Bias<br>Study size<br>Quantitative variables | 8*<br>9<br>10<br>11 | modifiers. Give diagnostic criteria, if applicable         For each variable of interest, give sources of data and details of methods or assessment (measurement). Describe comparability of assessment methods more than one group         Describe any efforts to address potential sources of bias         Explain how the study size was arrived at         Explain how quantitative variables were handled in the analyses. If applicat describe which groupings were chosen and why         (a) Describe all statistical methods, including those used to control for comparation (c) Explain how missing data were addressed         (d) Cohort study—If applicable, explain how loss to follow-up was address Case-control study—If applicable, explain how matching of cases and comparation addressed  | Pe<br>f<br>if there i<br>F<br>B<br>ble,<br>P5-<br>onfoundin<br>I<br>F<br>Sed<br>rrols was |

For peer review only - http://bmjopen!bmj.com/site/about/guidelines.xhtml

| Participants   | 13*                                       | (a) Report numbers of individuals at each stage of study-eg numbers potentially elig  | gible,   |
|--|---|---|--|
|  |   | examined for eligibility, confirmed eligible, included in the study, completing follow  |  |
|  |   | analysed  | P7   |
|  |   | (b) Give reasons for non-participation at each stage  | P7   |
|  |   | (c) Consider use of a flow diagram  | N/A  |
| Descriptive  | 14*                                       | (a) Give characteristics of study participants (eg demographic, clinical, social) and in  |  |
| data   |   | on exposures and potential confounders  | P7   |
|  |   | (b) Indicate number of participants with missing data for each variable of interest   | N/A  |
|  |   | (c) Cohort study—Summarise follow-up time (eg, average and total amount)  | N/A  |
| Outcome data   | 15*                                       | Cohort study-Report numbers of outcome events or summary measures over time   |  |
|  |   | Case-control study-Report numbers in each exposure category, or summary measur  | es of  |
|  |   | exposure  |  |
|  |   | Cross-sectional study—Report numbers of outcome events or summary measures  | P7   |
| Main results   | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and t   | heir   |
|  |   | precision (eg, 95% confidence interval). Make clear which confounders were adjuste  | d for and  |
|  |   | precision (eg, 95% confidence interval). Make clear which comounders were adjuste   | u ioi allu   |
|  |   | why they were included  | P8   |
|  |   |   |  |
|  |   | why they were included  | P8<br>P6   |
|  |   | why they were included         (b) Report category boundaries when continuous variables were categorized  | P8<br>P6   |
| Other analyses   | 17  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a material structure risk into absolute risk fo | P8<br>P6<br>heaningful<br>N/A  |
| Other analyses   | 17  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period  | P8<br>P6<br>heaningful<br>N/A  |
| Other analyses<br>Discussion   | 17  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivity  | P8<br>P6<br>heaningful<br>N/A<br>ty  |
|  | 17  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivity  | P8<br>P6<br>heaningful<br>N/A<br>ty  |
| Discussion   |   | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses   | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10   |
| <b>Discussion</b><br>Key results   | 18  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives  | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10   |
| <b>Discussion</b><br>Key results   | 18  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives         Discuss limitations of the study, taking into account sources of potential bias or impr         Discuss both direction and magnitude of any potential bias   | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15                                  |
| Discussion<br>Key results<br>Limitations                                       | 18<br>19                                  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives         Discuss limitations of the study, taking into account sources of potential bias or impression  | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15                                  |
| Discussion<br>Key results<br>Limitations<br>Interpretation                     | 18<br>19                                  | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives         Discuss limitations of the study, taking into account sources of potential bias or impr         Discuss both direction and magnitude of any potential bias         Give a cautious overall interpretation of results considering objectives, limitations, m of analyses, results from similar studies, and other relevant evidence   | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15<br>nultiplicity<br>P10-14        |
| Discussion<br>Key results<br>Limitations<br>Interpretation<br>Generalisability | 18           19           20           21 | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives         Discuss limitations of the study, taking into account sources of potential bias or impr         Discuss both direction and magnitude of any potential bias         Give a cautious overall interpretation of results considering objectives, limitations, m  | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15<br>nultiplicity<br>P10-14        |
| Discussion<br>Key results<br>Limitations<br>Interpretation                     | 18           19           20           21 | why they were included         (b) Report category boundaries when continuous variables were categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a m time period         Report other analyses done—eg analyses of subgroups and interactions, and sensitivi analyses         Summarise key results with reference to study objectives         Discuss limitations of the study, taking into account sources of potential bias or impr         Discuss both direction and magnitude of any potential bias         Give a cautious overall interpretation of results considering objectives, limitations, m of analyses, results from similar studies, and other relevant evidence   | P8<br>P6<br>heaningful<br>N/A<br>ty<br>P8-9<br>P10<br>ecision.<br>P15<br>nultiplicity<br>P10-14<br>P15 |

BMJ Open: first published as 10.1136/bmjopen-2017-020126 on 28 March 2018. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen?bmj.com/site/about/guidelines.xhtml